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SUMMARY
The proposal of Vane (1971) that aspirin-like drugs exert 
their pharmacological actions via inhibition of prostaglandin (PG) 
biosynthesis is now widely accepted. It was the object of the present 
work to prepare PG synthetase from human rheumatoid synovial tissue 
in order to study its basic biochemical properties, and to study the 
interaction(s) between the enzyme and some of the aspirin-like drugs 
commonly used in the therapy of the rheumatic diseases.
Using a radiometric technique PG synthetase activity was 
measured in vitro in the microsomal fraction of 31 synovial tissues 
taken from 27 patients with rheumatoid arthritis. Its biochemical 
properties and inhibition in vitro by low concentrations of aspirin­
like drugs suggested that it did not differ radically from the well- 
studied enzymes prepared from animal tissues.
While the enzyme preparation from patients receiving indo- 
methacin, naproxen or ibuprofen therapy possessed considerable 
activity in vitro, preparations from patients receiving aspirin, even 
in low doses, were incapable of PG synthesis. Aspirin may therefore 
be unique in being an irreversible inhibitor of the enzyme,
A correlation was found to exist between the potency of the 
aspirin-like drugs as inhibitors of synovial PG synthetase in vitro 
and their known therapeutic potencies. The significance of 
interesting anomalies such as salicylic acid is discussed.
Studies of the effects of copper and copper aspirin showed 
interesting quantitative and qualitative effects in vitro which may 
have therapeutic potential.
Studies with human peripheral leucocytes showed that platelets 
contain a high level of synthetase activity and a comparison of the 
effects of aspirin and indomethacin, both in vitro and in vivo, 
confirmed the results obtained with synovial preparations.
The use of /_ acetyl-^H_/ aspirin of high specific activity 
showed the drug to be capable of acetylating a particulate fraction 
protein from both platelet and synovial preparations. The possibility 
that this protein is the cyclo-oxygenase component of the enzyme 
complex is discussed.
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"It is now apparent that prostaglandins are implicated in many 
biological mechanisms, both physiological and pathological."
Horton, 1976.
"Perhaps prostaglandins are just a way of removing lipids 
capable of forming damaging peroxides : they would then be 
seen as metabolic waste, of only slightly more value to the 
animal than is morphine to the poppy or digitalis to the 
foxglove."
Brocklehurst & Dawson, 1974,
"The prostaglandins have the ability to stimulate as well as 
to sow confusion; privately, we are convinced that the role 
of prostaglandins is to make people go back to school and learn 
their subjects a little better."





Studies by Goldblatt (1933) and von Euler (1935) showed that 
human seminal plasma and extracts of the vesicular gland of sheep 
contained a substance possessing vasodepressor and smooth muscle 
stimulating activity which, owing to its occurence in extracts of the 
prostate and vesicular gland was called prostaglandin. Preliminary 
characterisation showed that prostaglandin had the properties of a 
fatty acid,being readily extracted into lipid solvents from an 
acidified aqueous solution, and freely soluble in aqueous alkali.
It was further established that prostaglandin was a nitrogen-free 
compound, and that it probably possessed hydrophilic groups and some 
degree of unsaturation. The formation of a stable, water-soluble 
barium salt permitted some purification of the crude extract, but 
analytical techniques available at the time were inadequate for further 
elucidation of the structure of prostaglandin.
The development of chromatographic techniques during the 
1950's provided a powerful new tool for the purification and separation 
of crude biological extracts, and in 1960 Bergstrttm and Sjftvall 
succeeded in isolating an active compound from sheep glands in 
crystalline form. Furthermore, it soon became apparent that 
'prostaglandin' was not a single substance, but consisted of a family 
of closely related chemical structures. In the space of the next 
four years Bergstrttm's group were able to separate 13 distinct 
compounds, all derivatives of a parent substance given the trivial 
name prostanoic acid.
Elegant work involving micro-analytical degradations and 
transformations elucidated the various structures of the prostaglandins.
final confirmation being achieved by X-ray crystallography (Abrahamsson, 
Bergstrttm and Samuelsson, 1962) and mass-spectrometry (Bergstrbm and 
others, 1962). Although the early work on prostaglandins established 
that high concentrations existed in seminal vesicular glands and in 
the seminal fluid of man and some animals, later work showed virtually 
all tissues and cell types studied to be capable of prostaglandin 
biosynthesis, thus raising the possibility that prostaglandins might 
have a more general significance than at first anticipated.
1.2 Chemistry
All prostaglandins (PC's) are derivatives of a C 20 mono- 
carboxylic acid, which has been given the trivial name prostanoic 
acid (Fig 1.1). It is not a naturally occuring compound. The main 
families or series of prostaglandins are denoted by a letter e.g. 
prostaglandin F (universally abbreviated to PCF). Eight series 
have been recognised to date, extending alphabetically from PGA to 
PGH inclusive. • Each series is distinguished by the type and position 
of various functional groups in the molecule, usually within the 
cyclopentane ring, i.e. on carbon atoms 8-12. PGG is unique in 
possessing a hydroperoxy group at C-15, all others having a hydroxyl 
group in this position.
Chemical conversion between some of the different series is 
readily achieved. Thus, treatment of F-type prostaglandins with 
acid or base yields A or B-type prostaglandins respectively and this 
can be used to assay PGE, as both PGA and PGB are chromophores 
exhibiting characteristic UV absorption maxima at 217nm and 278nra 
respectively. Chemically, the A-type prostaglandins are dehydration 
products of the E series, in which the 11-hydroxyl group has been 
lost and a double bond formed between C-10 and C-11. The B-type
Fig. l.'l Numbering scheme for prostanoic acid and 
























prostaglandins and isomers of PGA in which the double bond is shifted 
from to A® via the relatively unstable A^^ ^^ compound
PGC. Clearly, extremes of pH must be avoided during the extraction 
and separation of prostaglandins in order to prevent the formation 
of PGA or PGB artefacts from PGE compounds.
Treatment of PGE (or its isomer PGD in which the 9-oxo and 
11-OH groups are reversed) with a reducing agent such as sodium 
borohydride yields a mixture of PGF^ and PGFg, the and 3 referring 
to whether the hydroxyl substituent at C-9 is below (<=) or above (3) 
the plane of the cyclopentane ring. Conversion of the relatively 
unstable PGG and PGH (the so-called "cyclic endoperoxides") to PGF is 
readily achieved with a reducing agent such as stannous chloride.
Within each prostaglandin family or series several members 
are possible, differing only in the number of double bonds present 
in their side chains, and these are designated by subscript numbers 
e.g. PGEi, PGE2 etc. Members of the "1" series have a single A^® 
trans double bond. Members of the "2" series have an additional A® ® 
cis double bond, while members of the "3" series have a further A^^  ^® 
cis double bond. The degree of unsaturation of a PG is determined by 
the number of double bonds present in the fatty acid precursor of 
each series; thus the fatty acid precursors of the 1 , 2 and 3 series 
are all-cis-8 , 11, 14-eicosatrienoic acid (dihomo-y-linolenic acid), 
all-cis-5 , 8 , 11, 14-eicosatetraenoic acid (arachidonic acid) and 
all-cis-5, 8 , 11, 14, 17-eicosapentaenoic acid respectively.* There 
is no evidence that interconversion between prostaglandins with 
differing degrees of unsaturation occurs either in vivo or in vitro.
*Pace-Asciak (1976) has recently described the formation of 
6-keto-PGFi^ from arachidonic acid by homogenates of rat stomach.
e.g. PGEI to PGE2 or vice versa.
In most tissues prostaglandins of the 2 series predominate 
due to the relative abundance of arachidonic acid compared with 
dihomo- Y -linolenic acid. Prostaglandins of the 3 series, though 
found in human and sheep semen and sheep vesicular gland, (PGE3 and 
PGFge) are difficult to isolate and are susceptible to auto-oxidation. 
Their biological properties have not been extensively investigated, 
though reports so far indicate that their properties are similar to 
the corresponding 2 series compounds.
1.3 Biosynthesis
The biosynthesis of prostaglandins from a C 20 polyunsaturated 
("essential") fatty acid was demonstrated simultaneously by two groups . 
of workers (van Dorp and others, 1964; Bergstrftm, Danielsson and 
Samuelsson, 1964). Aerobic incubation of homogenised sheep vesicular 
glands with tritium labelled 5, 8 , 11, 14-eicosatetraenoic acid 
(arachidonic acid) gave a 20% yield of a compound having identical 
chemical, spectral and chromatographic properties to those of an 
authentic sample of PGE2. The enzymatic conversion of 8 , 11, 14- 
eicosatrienoic acid (dihomo-Y -linolenic acid) and 5, 8, 11, 14, 
17-eicosapentaenoic acid to PGEi and PGE3 respectively was subsequent­
ly achieved (BergstrBm and others, 1964; van Dorp and others, 1964b) 
using the same enzyme source.
The multi-enzyme complex, prostaglandin synthetase (E.G. 1.14.99.1) 
is found in the high-speed particulate ("microsomal") fraction of cells 
but may be solubilised with the use of suitable non-ionic detergents 
(Sih and Takeguchi, 1973). A preliminary resolution of the enzyme 
complex into its separate oxygenase and isomerase components has been 
achieved using DEAE-cellulose column chromatography of solubilised
bovine vesicular gland microsomes (Miamoto, Yamamoto and Hayaishi,
1974). The oxygenase component (Fraction I) itself exhibited two 
distinct enzyme activities; firstly, in the presence of appropriate 
co-factors such as haemoglobin and tryptophan, it was able to 
catalyse the formation of PGGi from dihomo-y -linolenic acid and 
secondly to transform PGG, into PGH, (i.e. 15-hydroperoxy ->• 15-hydroxy). 
The isomerase component (Fraction II), in the presence of reduced 
glutathione was able to transform the cyclic endoperoxide PGHj into 
PGEi. Recently Fraction I has been further purified by isoelectric 
focussing (Miyamoto and others, 1976) and provisionally named 
prostaglandin endoperoxide synthetase. A preliminary estimation of 
the molecular weight of the purified enzyme, by gel filtration on 
Sephadex G — 200 in the presence of 0.2% Tween 20, gave a value of 
300,000-350,000.
Many workers have used the microsomal fraction from tissues 
as an enzyme source for incubation studies as this gives a preparation 
of high specific activity and also effectively removes the prostaglandin 
metabolising enzymes present in the cytoplasmic fraction of cells.
Mechanism of PG biosynthesis
The separate steps involved in the biosynthesis of prostaglandins 
from polyunsaturated fatty acids have been reasonably well elucidated 
(Nugteren, Beerthuis and van Dorp, 1966; Hamberg and Samuelsson, 1967), 
though doubt still exists as to whether some of the transformations 
are achieved by enzymatic or non-enzymatic means. Although much of 
this early work was done with the PG synthetase system derived from 
sheep seminal vesicular glands, there is no reason to believe that 
biosynthesis takes place in other tissues by radically different pathways,
The initial step in the reaction is the stereospecific removal
of the hydrogen atom at C-13, followed by isomérisation of the 11-cis
double bond to 12-trans with the simultaneous attachment of molecular
oxygen at C-11. A concerted reaction then follows, with the addition
of molecular oxygen at C-15, ring closure between C-8 and C-12, and
formation of a "cyclic endoperoxide" between C-9 and C-11. In agreement
with this mechanism, 2 moles of oxygen are consumed for each mole of
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product formed, and elegant studies using O 2 - O 2 mixtures have 
shown that the oxygen atoms at C-9 and C-11 in prostaglandins derive 
from the same oxygen molecule (Ryhage and Samuelsson, 1965). The 
mechanism thus explains why only prostaglandins with a cis relation­
ship between the hydroxyl groups at C-9 and C-11 are naturally occuring 
i.e. PGF and not PGF„. Studies by Wlodawer and Samuelsson (1973)
Œ p
of the action of PG synthetase from sheep seminal vesicle microsomes ' 
on octa-deutero arachidonic acid also indicate that a common synthetase 
provides the t.adoperoxide precursor for both PGE2 and PGF2=\
The observation that prostaglandin biosynthesis in bovine
seminal vesicle microsomes is inhibited by catalase suggests that
synthesis proceeds via a free-radical mechanism and that hydrogen
peroxide may play a role as the source of the initial radical,
possibly a hydroxyl radical. (Panganamala, 1974). It is well known
that compounds such as hydroquinone stimulate PG Diosynthesis and
these compounds generate hydrogen peroxide through a quinone-
hydroquinone cycle (Deamer and others, 1971). Furthermore, the
++
possible participation of an Fe -enzyme complex in the decomposition 
of hydrogen peroxide to yield hydroxyl radicals may explain the 
observed enhancement of PG biosynthesis by some heme compounds 
(Yoshiraoto, Ito and Tomita, 1970).
The cyclic endoperoxide PGH is the key intermediate in prosta­
glandin, biosynthesis, and may be modified in a number of ways by the 
'isomerase' component(s) of the enzyme complex. Isomérisation may 
yield PGE or PGD, and reductive cleavage leads to the formation of 
PGF^. Cleavage of carbon-carbon bonds may also occur to yield a Ci? 
hydroxyacid (12-hydroxy-5, 8 , 10-heptadecatrienoic acid, HHT) and a 
C 3 fragment (malondialdehyde). Recent studies (Hamberg, Svensson 
and Samuelsson, 1975; Needleman and others, 1976) have identified an 
enzyme in platelet microsomes which is able to convert the cyclic 
endoperoxides PGG2 or PGH2 into an extremely unstable (tj^  at 37^C 
approx. 30 sec.) and biologically active non-prostanoid, oxane compound 
named thromboxane A 2 (TXA2). This highly active compound decomposes 
to the stable and biologically inactive thromboxane B 2 (TXB2, formerly 
named PHD). Finally, polyunsaturated fatty acids such as arachidonic - 
acid may be metabolised by enzyme systems other than the well-documented 
fatty acid cyclo-oxygenase responsible for prostaglandin and throm­
boxane biosynthesis. Lipoxygenases may convert arachidonic acid to 
compounds such as 12-hydroperoxy-5, 8 , 10, 14-eicosatetraenoic acid 
(HPETE) and 12-hydroxy-5, 8 , 10, 14-eicosatetraenoic acid (HETE) 
though these are only produced in small amounts and their biological 
properties have not been extensively investigated.
Key stages in the biosynthesis of prostaglandins, thromboxanes 
and certain hydroxy acids are shown in Fig 1.2. The E and F series 
are the primary products of prostaglandin biosynthesis (Hinman, 1972). 
PGA and PGB are dehydration products of PGE and may be easily formed 
from PGE by treatment with acid or base respectively. A PGA isomerase 
has been demonstrated in rabbit plasma (Jones, 1974) but there has 
been no conclusive evidence for a 'PGE-dehydratase' which could convert 


















































































PGA could be biosynthesised other than through PGE. This is of interest 
to the renal physiologist as the occurrence of PGA2 in renal tissue and 
its actions on renal and cardiovascular tissue have provided evidence 
for its involvement in the physiology of natriuresis and blood pressure 
regulation (Lee, 1973). However, doubt has recently been cast on the 
significance of PGA2 in renal haemostasis (Frftlich and others, 1975).
Using an elegant GC/MS technique these authors showed that rabbit renal 
medulla homogenates contained no detectable PGA2 and were incapable of 
biosynthesising it in vitro, raising the somewhat disturbing 
possibility that PGA2 found in renal tissue by other workers may have 
been an artefact formed from PGE2 during extraction and isolation 
procedures.
The conversion of PGE to PGF has been demonstrated using the 
cytoplasmic fraction from guinea pig liver (Hamberg and Israelsson
1970) i.e. PG-9-ketoreductase activity, and this can also be brought about 
by an enzyme from sheep blood (Hensby, 1974a). The significance of. these 
observations at the present time is not known. A similar conversion of 
PGD2 to PGF2°^ i.e. PG-ll-ketoreductase activity, has also been reported 
(Hensby, 1974b). Conversion of PGF2^ to PGE2 i.e. PG-9-hydroxydehydro- 
genase activity, has been reported in rat kidney (Pace-asciak, 1975).
Cofactor requirements
Although PG synthetase activity is found in the microsomal 
fraction of cells, heat-stable cofactors from the cytoplasmic fraction 
are necessary for appreciable activity to be demonstrated in vitro.
As the cytoplasmic fraction also contains prostaglandin metabolising 
enzymes, it is usual to supply these cofactors in the form of reduced 
glutathione (GSH) and a phenolic compound such as hydroquinone (HQ) 
or adrenaline, which act as a supply of reducing equivalents to 
recycle the GSH in its reduced form. The exact role of GSH is not known.
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though its function may be a specific one as several other thiol 
compounds, are inactive in this respect (van Dorp, 1967). Lands, Lee 
and Smith (1971) have postulated that GSH stimulates the internal 
1,2-hydride shift in the cyclic endoperoxide intermediate and hence 
explains the commonly observed enhancement of PGE production by GSH 
at the expense of PGF. Cupric ions and dihydrolipoamide acted in the 
opposite way (Lee and Lands, 1972), and the role of copper in 
prostaglandin biosynthesis will be fully discussed later (section 4,4). 
These results thus lend further support to the conclusion that the 
cyclic endoperoxide is a common precursor of both PGE and PGF.
Yoshimoto, Ito and Tomita (1970) showed that in addition to 
GSH and HQ, the synthetase system from bovine seminal vesicles was 
stimulated by haemoglobin, myoglobin or haemin and concluded that haera 
compounds and HQ were involved in the step in which molecular oxygen 
became attached to the substrate. GSH, however, was involved in the 
reduction of the cyclic endoperoxide, as shown by the close relation­
ship between PGE2 formation and GSH utilisation. Whether or not this 
reduction is catalysed by glutathione peroxidase remains unanswered.
L-tryptophan may act as a cofactor for the biosynthesis of the 
cyclic endoperoxide (Miyamoto, Yamamoto and Haishi, 1974), but is unable 
to convert PGG or PGH to PGE or PGF. It is interesting to note that 
substantial quantities of L-tryptophan may be isolated from the super­
natant fraction of bovine vesicular gland homogenates (Chan and others,
1975), raising the possibility that L-tryptophan may be the natural 
cofactor for the prostaglandin endoperoxide synthetase component, at 
least in bovine vesicular gland.
Substrate specificity ^
Only fatty acids containing at least three conjugated cis
13
double bonds in the 6, 9 and 12 positions from the terminal methyl 
group are substrates for PG synthetase. Of these, good conversion 
is only achieved with a chain length of 19, 20 or 21 carbon atoms 
(van Dorp, 1967). Furthermore a free carboxyl group is essential for 
conversion to occur, the corresponding fatty acid methyl esters being 
very poor substrates (Struijk and others, 1966). Similarly poly­
unsaturated alcohols such as dihomo-y -linolenyl alcohol and 
arachidonyl alcohol are not converted to the corresponding (hypothetical) 
prostanols (van Dorp, 1967).
Lands and Samuelsson (1968) showed that l-palmitoyl-2-/_ 2 
eicosatrienoyl g lycero-3-phosphoryl choline was not a substrate for PG 
synthetase and that the ^^C-eicosatrienoic acid had to be cleaved from 
the phospholipid before conversion to ^^C-PGEi could occur. Similarly, 
Vonkeman and van Dorp (1968) showed that incubation of sheep seminal 
vesicle microsomes with l-stearoyl-2-/^  _/ arachidonyl-lecithin 
produced no ^H-PGEz and that prostaglandin synthesis took place only 
after addition of lecithinase A to the incubate.
Control of PG biosynthesis
The above findings are of prime importance to an understanding 
of the factors controlling prostaglandin biosynthesis and release as, 
with tlie exception of seminal fluid in man and some animals, prosta­
glandins do not exist in the body as pre-formed 'stores' but are rapidly 
synthesised and released in situ in response to a variety of neuronal, 
hormonal or even mechanical stimuli. In tissues processed to prevent 
biosynthesis during homogenisation and extraction, prostaglandin levels 
are virtually undetectable (Jouvenaz and others, 1970) and reports in 
the early literature of prostaglandin levels in tissues are probably 
only a measure of biosynthetic potential.
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In most tissues, levels of free i.e. non-esterified, poly­
unsaturated fatty acids are extremely low; for example seminal vesicles 
contain only 10-50ng arachidonic acid per gram of wet weight tissue.
As most tissues are able to rapidly produce amounts of prostaglandins 
which are orders of magnitude greater than this level of free substrate, 
in response to suitable stimuli, it is clear that a control mechanism 
must exist in cells which is capable of making appropriately high 
concentrations of substrate available for PG biosynthesis.
In most tissues, the polyunsaturated fatty acids form part of 
the phospholipid membrane structure and thus constitute a ubiquitous 
source of substrate for an apparently ubiquitous enzyme. Samuelsson 
(1972) has postulated that the hydrolytic release of the precursor acids, 
catalysed by phospholipase A, could be the rate-limiting step in the 
production of prostaglandins, and that the control of prostaglandins 
by humoral and neural mechanisms could be exerted at this site.
Recently, Flower and Blackwell (1976) have shown directly that 
phospholipase A 2 is indeed an important regulatory enzyme for the bio­
synthesis of prostaglandins. Slices of guinea pig spleen were incubated 
in buffer containing /__ 1-^^C / arachidonic acid, the label being partially 
incorporated into cellular phospholipid and neutral lipid pools. When 
the tissues were mechanically vibrated, or subjected to anaphylactic 
shock, there was a significant release of labelled arachidonic acid from 
the phospholipid pools only, and an appropriate increase in the synthesis 
of labelled PGE2. The release of arachidonic acid from the phospholipid 
pool was blocked by mepacrine, a known phospholipase inhibitor, though 
the effect on subsequent PG synthesis was difficult to estimate as 
mepacrine is an inhibitor of PG synthetase at the concentrations used 
to block phospholipase activity (10 ^M).
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These results thus confirm that phospholipase A 2 is a key 
enzyme involved in the release of non-esterified fatty acid from 
phospholipid precursors prior to PG biosynthesis. However, it was 
also found that when spleen slices were vibrated in the presence of 
labelled arachidonic acid without prior incorporation into phospholipid 
pools, PG synthesis was increased several-fold over control (i.e. non­
vibrated) incubations. This suggests that damage to the cell membrane 
may change its permeability in such a way as to allow increased access 
of non-esterified substrate to the PG synthetase 'compartment', and 
hence increased PG synthesis. Availability of substrate, therefore, may 
not be the only factor involved in the control of PG production.
1.4 Prostaglandin metabolism
Most prostaglandins are rapidly metabolised when introduced into 
the circulation or when incubated with broken-cell homogenates in vitro. 
Metabolism is initiated by oxidation at C-15 to form a 15-oxo derivative, 
the enzyme responsible being prostaglandin 15-hydroxydehydrogenase (PGDH). 
Reduction of the  ^ double bond by prostaglandin reductase is followed 
by both 3 and 0) oxidation.
The metabolising enzyme which has been studied in most detail is 
PGDH; it is MAD dependent and is found in the cytoplasm of cells, as 
are the other metabolising enzymes. The distribution of PGDH was studied 
in swine tissues by Anggard, Larsen and Samuelsson (1971) who found the 
highest concentrations in lung, spleen and renal cortex; smaller amounts 
were present in testicle, stomach, small intestine, heart and adipose 
tissue. The enzyme is also found in most tissues of rat, guinea pig 
and man, a particularly high level of activity being present in human 
placenta (Anggard and Samuelsson, 1966). PGEj and PGE2 are the best 
substrates for PGDH; F and A-type prostaglandins are less readily oxidised 
and 3 prostaglandins are not oxidised at all.
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Important species differences exist in the metabolism of 
administered prostaglandins. Thus ^H-PGE2 administered intravenously 
to human subjects is rapidly converted to ll«:-hydroxy-9,15-diketo- 
prost-5-enoic acid (by oxidation of C-15 hydroxyl and reduction of
Further degradation yields several metabolites which are mainly 
excreted in the urine, the principal one being 7=-hydroxy-5,ll-diketo- 
tetranor-prostane-1,16-dioic acid (Hamberg and Samuelsson, 1969).
PGFi« and PGF2= are metabolised to the corresponding 7°:-dihydroxy- 
11-keto-tetranor-prostane-l,16-dioic acid (Granstrttm and Samuelsson,
1971). In the guinea pig, however, the major urinary metabolite of 
^H-PGE2 , given intravenously is 53, 7=-dihydroxy-ll-keto-tetranor- 
prostanoic acid (Hamberg and Samuelsson, 1969), and in the rat 
administration of ^H-PGFi^ produces dinor-PGFi# as the major urinary 
metabolite (Granstr5m, Inger and Samuelsson, 1965).
A systematic study of PG metabolism in lung tissue homogenates 
was made by Anggard and Samuelsson (1964; 1966) using both guinea pig 
and pig lung. Incubation of PGEi, PGE2 or PGE3 with a homogenate of 
guinea pig lung produced a mixture of the corresponding 13,14-dihydro 
and 13,14-dihydr0-15-0X0 prostaglandins whereas pig lung homogenates 
incubated with PGEj produced only the 15-oxo derivative. Incubation 
of ^H-PGEj with the 3-oxidation system of rat liver mitochondria showed 
PGEi to be converted to dinor-PGEj; 13,14-dihydro-PGEi produced both 
dinor and tetranor metabolites and PGF2# was transformed into a C 15 
derivative. Studies with the microsomal fraction of human liver 
(Hamberg and Samuelsson, 1968) demonstrated the transformation of PGAj, 
but not PGEi, into the 19-hydroxy prostaglandin. This is consistent 
with the presence of 19-hydroxy-PGA, in human seminal plasma.
1.5 General pharmacology
The original findings of large amounts of prostaglandins in
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the male accessory genital glands and their secretions, and subsequent 
discovery in menstrual and amniotic fluids showed that these substances 
were intimately linked with several aspects of reproduction. The 
recent avalanche of research into all aspects of prostaglandin pharma­
cology and physiology which has followed these early observations has 
provided much evidence for the involvement of prostaglandins in the 
physiology of many bodily functions, and the pathological disorders 
of these functions. Disturbed prostaglandin production might contribute 
to the symptomology associated with some pathological conditions, and 
administration of prostaglandins or inhibitors of prostaglandin 
synthesis or action may limit the symptoms. This is of particular 
interest in the iatrogenic pathology associated with the ingestion of 
many of the commonly used anti-inflammatory drugs (see section 1 .12).
The pharmacological effect of prostaglandins.on the respiratory 
system has been studied as the lungs are the principal site of 
metabolism of circulating prostaglandins in the body, both inactive 
and biologically active metabolites being formed. Interest has centred 
around the possible involvement of prostaglandins in the pathogenesis 
of asthma. Prostaglandins of the E series will inhibit, and prosta­
glandins of the F series will increase bronchial tone in man (Smith 
and Cuthbert, 1973) leading to speculation of a possible imbalance 
between PGE and PGF production in asthmatic patients. Furthermore, 
such patients show increased airway resistance when they inhale an 
aerosol of PGF2=, in quantities thousands of times smaller than those 
producing a comparable effect in normal subjects (Smith, 1972). The 
bronchodilator effect of E prostaglandins in man suggests a possible 
use of these compounds in the treatment of asthmatic symptoms.
Prostaglandins also have varied actions on the cardiovascular 
system. Thus, E and A series prostaglandins decrease total peripheral
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resistance whereas the F prostaglandins are vasoconstrictor. PGE2 
possesses antiarrhythmic activity in experimental animal models and 
also increases coronary blood flow (Wennmalm and Hedquvist, 1970).
The effect of prostaglandins upon regional blood flow can be variable 
and important species differences exist.
The occurrence of prostaglandins in renal tissue and their 
actions on renal and cardiovascular tissue have provided evidence 
for their involvement in the physiology of natriuresis and blood 
pressure regulation (Lee, 1973). In normal subjects infusion of PGE2 
or PGA2 causes increased cortical blood flow and a concomitant 
decrease in medullary flow. Infusion in hypertensive patients results 
in a fall in blood pressure accompanied by natriuresis, diuresis and 
increased GFR.
Secretions and motility of the gastrointestinal tract can be 
radically modified by prostaglandins. Both E and F prostaglandins 
cause the longitudinal muscle of the gut to contract, but the circular 
layer is relaxed by PGE2 and contracted by PGF2°^. Prostaglandins are 
also potent inhibitors of gastric acid and pepsin secretion, the 
newer synthetic PG analogues being particularly active in this respect. 
Not surprisingly such compounds have undergone clinical trials for the 
treatment of gastric ulcers.
The role of prostaglandins in inflammation is discussed in 
greater detail in section 1.8 of this chapter. Similarly the role of 
prostaglandins, their cyclic endoperoxides and the newly discovered 
thromboxanes, in platelet aggregation is to be found in section 5,1,
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B. INFLAMMATION, ASPIRIN-LIKE DRUGS AND PROSTAGLANDINS
1.6 The Inflammatory Process
The physiological and biochemical changes which occur during 
inflammation have been the subject of inumerable books, reviews and 
papers; notable amongst these is the 'standard' text of Zweifach,
Grant and McCluskey (1974).
Inflammation has been defined by Ebert and Grant (1974) as 
'a process which begins following sublethal injury to tissue and ends 
with permanent destruction of tissue or with complete healing'.
Even such a general definition may fail to take account of the apparent 
'stalemate' often seen clinically with the chronic inflammatory 
diseases such as rheumatoid arthritis. The four cardinal signs of 
inflammation, redness, swelling, heat and pain were described by 
Celcus (30B.C. - 38A.D.) and the fifth, loss of function, added by 
Galen (130-200A.D.) Regardless of the initial inflammatory stimulus 
or the location of the injured tissue the immediate effect is that 
cells are adversely affected by the insult and an inflammatory reaction 
is initiated.
This response is usually brought about by the release of intra­
cellular contents into the extracellular space with a subsequent response 
in the surrounding capillaries. Vasoactive mediators such as histamine and 
5-hydroxytryptamine are liberated, primarily from mast cells. These 
increase the permeability of the venules and capillaries to circulat­
ing macromolecules and cells, resulting in the accumulation at the 
injured site of fluid containing, initially, a predominantly poly- 
morponuclear (PMN) cell population, due to the greater ease with 
which the PMN leucocyte is able to penetrate the vascular endo­
thelium (Paz and Spector, 1962),
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The accumulation of leucocytes at an inflammatory focus may be 
explained by the phenomenon of chemotaxis, i.e. the liberation or 
formation at the inflammatory site of substances which produce an 
attraction for leucocytes which over-rides their normal random 
migration. Numerous such chemotactic attractants have been demon­
strated in vitro, notably the production of chemotactic factors 
from complement activation (Cochrane, 1968). Products of the 
inflammatory reaction may themselves account for cell specific chemo­
taxis, as kallikrein formation, due to activation of the kinin 
system, releases chemotactic factors specific for neutrophils (Kaplan, 
Kay and Austen, 1972). Other mediators such as cyclic nucleotides 
and prostaglandins are also released, their relatively short action 
being terminated either by catabolism or dilution within the extra­
cellular space. Synthesis and/or release of these mediators may 
occur either from the locally damaged tissue, or from the invading 
leucocytes; thus histamine is transported by the basophil and 
eosinophil (Graham and others, 1955), 5-hydroxytryptamine by the 
platelet (Humphrey and Jacques, 1954), while prostaglandins are 
synthesised and released by platelets (Smith and Willis, 1971) and 
PMN's (Higgs and Youlten, 1972).
Fibrin deposition and platelet aggregation occur late in the 
inflammatory response causing micro-thrombi formation. Prosta­
glandins were shown to be only weakly pro-aggregatory or even, in 
the case of PGEi, an inhibitor of platelet aggregation (Kloeze,
1967). Recently however, platelets have been shown to be capable of 
producing prostaglandin endoperoxides and thromboxanes of the '2 ' 
series possessing potent pro-aggregatory properties (Hamberg,
Svensson and Samuelsson, 1975). Such localised thrombi formation 
may be important, resulting in stasis, ischaemia and anoxia, leading
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to possible tissue necrosis. As discussed later (section 1.11) the 
aspirin-.like drugs have been shown to be potent inhibitors of 
prostaglandin production.
Inflammatory exudates also contain a number of proteases, 
esterases, cathepsins and lytic enzymes, including collagenases 
and nucleases, capable of degrading protein-polysaccharide complexes 
within surrounding connective tissue. These enzymes are derived from 
lysosomal granules of the invading PMN's or from phagocytic cells 
within the tissue. Inevitable destruction of the epithelial base­
ment membrane by these enzymes facilitates the entry of further leuco­
cytes. The final cell scavengers in an acute inflammatory reaction 
are the monocytes, which phagocytose any remaining debris before 
returning to the circulation. This is in contrast to the typical 
chronic inflammation exemplified by rheumatoid arthritis, where there 
is colonization of the inflammatory focus by the monocytes.
One of the most important, though least well understood aspects 
of inflammation is the transition from the initial beneficial, acute 
inflammation to a degenerative, chronic inflammation. It is now 
thought that the chronic response is a result of the generation and 
release of 'autoantigens' from the injured tissue, possibly involving 
a modification of normal tissue components by lysosomal enzymes 
(Weissman, 1964).
The inflammatory stimulus is thus self-perpetuating and able 
to continue the process long after the original initiator has been 
removed. Such an explanation would account for the fact that experi­
ments designed to isolate and identify the antigen responsible for 
initiating the events leading to chronic degenerative inflammation in 
man have been uniformly unsuccessful.
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Investigations into the mode of action of a drug in a patho­
logical process need to be based on an intimate knowledge of the 
physiological and biochemical changes which have occurred in the 
tissue and which the drug is, hopefully, to reverse or correct. It 
is possible that an understanding of the mode of action of thera­
peutically useful drugs might also lead to the rational design of 
more effective drugs, and provide some insight into the pathogenesis 
of the disease itself.
1.7 Rheumatoid Arthritis (R.A.)
Rheumatoid arthritis is a chronic, systemic, degenerative 
disease, principally affecting the distal joints of the limbs. The 
disease is found only in man, its etiology is unknown and there is no 
known cure.
The joint inflammation is characterised by a proliferating, 
hyperaemic synovium with cellular infiltration, and exudation into 
the synovial space. Lymphocytes are the predominant cell type found 
within the synovium and have a tendency to aggregate around small blood 
vessels. That the lymphocyte plays a key role in the pathogenesis 
of R.A. is shown by the finding that prolonged thoracic-duct drainage, 
leading to lymphocyte depletion, ameliorates the activity of the 
disease (Wegelius and others, 1970). Much evidence now exists suggest­
ing that cell-mediated immunity may play a role in the pathogenesis 
of R.A. This is beyond the scope of the present brief description of 
the disease and is comprehensively reviewed by Glynn (1972), Earland
(1973) and Yu and Peter (1974).
As discussed above, a critical event, or series of events in 
the development of the disease is the transition from an initial 
reversible synovitis to one in which the synovium hypertrophies to
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form a granulocytic tissue called "pannus". Cartilage is undermined 
and eroded at its margins, leading to erosion and digestion of the 
underlying bone matrix, with the pannus occupying the space normally 
taken by cartilage and thus preventing re-growth of normal cartilage. 
This erosion is thought to be due to proteolytic and other enzymes 
released in the main from lysosomes of the infiltrating cells; the - 
presence of such enzymes may be readily demonstrated in both rheuma­
toid synovium and in synovial fluid (Hamerman, Stephens and Barland, 
1961). Though most of the common tissue proteases have optimum 
activity at acid pH's unlikely to be found in vivo, it has been 
shown that collagenase is present in inflamed synovial tissue (Evanson, 
Jeffrey and Krane, 1968), an enzyme capable of digesting native 
collagen at or near to neutral pH.
Most R.A. synovial fluids possess considerable chemotactic 
activity for leucocytes in vitro, and this activity may be due to 
products of the complement system (Cochrane, 1968), fibrin and its 
degradation products (Riddle, Bluhm and Barnhart, 1965), kinins 
(Melraon and others, 1967) and prostaglandins (Higgs, McCall and 
Youlten, 1975).
Prostaglandins are found in raised levels in rheumatoid 
synovial fluids (Levine, 1973; Higgs and others, 1974) though the 
levels do not correlate with either the clinical index of inflamm­
ation in the joint or the leucocyte count in the fluid (Swinson,
Bennett and Hamilton, 1976). It is not possible however to conclude 
from these results either that prostaglandins do not contribute 
significantly to the inflammation or that leucocytes are not the 
source of synovial fluid prostaglandins, as prostaglandins may be 
rapidly cleared from the joint (Ferreira, 1976). The role of 
prostaglandins in inflammation and their possible involvement in R.A.
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are discussed in detail in the following two sections.
1.8 The role of prostaglandins in inflammation
Prostaglandins are generated in many forms of tissue damage 
in both animals and man including carrageenin inflammation (Willis, 
1969), thermal injury to the skin (Jonsson, 1971) , anaphylaxis 
(Piper and Vane, 1969), monoarticular arthritis (Blackham and others, 
1973), experimental uveitis (Eakins and others, 1973) , allergic 
contact eczema (Greaves, S^ndergaard and McDonald-Gibson, 1971), 
ultraviolet-induced inflammation (Greaves and S^ndergaard, 1970) and 
rheumatoid arthritis (Levine, 1973; Higgs and others, 1974).
Much evidence now exists which shows the prostaglandins to be 
capable of either producing the classical signs and symptoms of 
inflammation, or of augmenting the inflammatory effects of other 
mediators such as histamine, 5-hydroxytryptamine and bradykinin. 
Current thinking places more emphasis on the latter possibility, 
namely that prostaglandins act in many inflammatory processes as 
modulators rather than mediators of inflammation. Paradoxically it 
is also possible to demonstrate some anti-inflammatory properties of 
certain prostaglandins, leading to speculation that the involvement 
of prostaglandins at an inflammatory focus may be a function of a 
qualitative rather than a quantitative change in prostaglandin 
production (Stone, Mather and Gibson, 1975).
In different types of inflammation some mediators may have 
a more prominent role than others and the involvement of each one 
may follow a very different time course in terms of release and 
maintenance of effect. It would thus be a gross oversight to focus 
ones attention solely on the prostaglandins as mediators or modu­
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lators of inflammation without taking into account the participation 
of the other mediators involved. Recognition of this fact may go some 
way towards explaining the inability of the aspirin-like drugs to 
arrest the disease process in a chronic condition such as rheumatoid 
arthritis, and has given rise to suggestions that the ideal anti­
inflammatory therapy might consist of a 'cocktail' mixture of drugs 
with each component directed at one particular mediator or modulator 
of the inflammation.
(a) Inflammatory properties of prostaglandins
(i) Erythema
Prostaglandins of the E and F series cause erythema in man and 
animals, the E series being considerably more potent than the F series. 
Bergstrfim and others (1959) demonstrated a dull erythema after the 
infusion of PGEi into the forearm and Ambache (1962) showed a similar 
effect with an extact of iris ('irin'), later shown to contain high 
concentrations of PGE2 and PGF2=. Notable features of the vascular 
effects of prostaglandins are the long-lasting action in producing 
erythema and the ability to counteract the vasoconstriction caused by 
such substances as noradrenaline and angiotensin. It should be noted 
however that the long-lasting effect applies only to cutaneous vessels 
and superficial veins, the vasodilator effect on other vascular beds 
vanishing within a few minutes. The long-lasting erythema induced 
by PGEi, measured thermographically, is also seen in rat paw (&erg, 
1973) .
(ii) Oedema
In the rat and in man prostaglandins cause increased 
vascular permeability by inducing leakage at the postcapillary and 
collecting venules (Kaley and Weiner, 1971). The vascular permea-
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bility of guinea pig skin is little affected by the application of 
prostaglandins alone, but they cause a marked potentiation of the 
response to either histamine or bradykinin (Williams and Morley,
1973). Prostaglandins Ei, E 2 and A 2, though not F2*, cause oedema 
when injected into.rat paws (Glenn, Bowman and Rohloff, 1972) though 
the effect is not dose-related as is the case with bradykinin. The 
use of.PGEi together with either histamine or bradykinin showed a 
synergistic potentiation of the oedema response rather than a simple 
additive effect, though there was no addition of effect between 
histamine and bradykinin (Moncada, Ferreira and Vane, 1973). Lewis, 
Nelson and Sugrue, (1974) have shown a potentiated oedema response to 
carrageenin and kaolin by arachidonic acid.
Thomas and West (1973) made the interesting observation that 
whilst PGEi selectively potentiated the increased permeability 
induced in rat skin by bradykinin, PGE2 was without effect and PGF2“ 
actually inhibited the effects of other mediators. PGEi however had 
no effect on dextran-induced oedema. The inhibitory effect of PGF2“ 
may be peculiar to rat skin as bradykinin-induced oedema in the rabbit 
is not inhibited by PGF2^.
In general the oedema-inducing effects of the prostaglandins 
are not as marked as their erythema-inducing, i.e. vasodilator, 
effects and the effect is not long-lasting compared with the erythema,
(iii) Pain
In man high doses of prostaglandins administered intra- 
dermally or intramuscularly cause long-lasting overt pain, and intra­
venous prostaglandins cause headache and pain along the veins into 
which they are infused (Bergstr5m and others, 1959). However, in 
'realistic' concentrations likely to be found at inflamed sites
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prostaglandins induce a state of hyperalgesia i.e. a state of hyper­
sensitivity to normally painless stimuli. This sensitising action 
at the pain receptors is cumulative and long lasting and has been 
observed in man when PGEj was given intradermally or infused sub- 
dermally (Ferreira,. 1972). The observation has been confirmed in 
dog spleen, dog knee joint and rat paw. As:with the oedema response, 
the effect of PGEi v/as to potentiate the pain-producing effects of 
bradykinin and/or histamine, as separate infusions of PGEi, brady­
kinin or histamine produced no overt pain. Similarly, none of these 
three substances cause pruritus when infused separately, but when 
PGEi was infused together with histamine, itch was always recorded.
Prostaglandins applied topically to a blister base do not 
cause pain, possibly because the site is already 'saturated' with 
prostaglandins (Horton, 1963).
A lipoxygenase system is present in many tissues together with 
the prostaglandin forming cyclo-oxygenase system, and the fatty acid 
hydroperoxides generated by the action of lipoxygenase on arachidonic, 
linoleic or linolenic acids, have been shown to cause pain in man 
when injected intradermally (Ferreira, 1972). Due consideration 
therefore must be given to the pharmacological effects of non­
prostanoid products of fatty acid metabolism; in some tissues prosta­
glandins may represent only a small percentage of the total products 
of arachidonic acid metabolism (Hamberg and Samuelsson, 1974a, 1974b).
(ivj Fever
Prostaglandin Ei is the most potent pyrogen known when 
injected into the third cerebral ventricle of rabbits, rats and cats 
or directly into the anterior hypothalamus (Milton and Wendlandt,
1971; Feldberg and Saxana, 1971). The effect is dose-dependent.
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almost immediate and lasts for about three hours. During fever there 
is an increase in the level of a prostaglandin E-like substance in 
the central nervous system, and concentrations in the CSF rise 
severalfold after intravenous pyrogen (Feldberg and Gupta, 1973).
(v) Loss of function
Injections of PGEi and PGE2 into the dog knee joint induce a 
long-lasting inflammatory effect, causing incapacitation within 
fifteen minutes; PGF2= produces a more gradual incapacitation over 
several hours. (Rosenthale and others, 1972). As with oedema and 
pain the action of bradykinin in this model has been reported to be 
potentiated by prostaglandins (Ferreira, Moncada and Vane, 1973).
(vi) Leucocyte migration
Studies of the effect of prostaglandins on the migration of 
leucocytes, both in vitro and in vivo, have produced conflicting data, 
Kaley and Weiner (1971) reported PGEi, but not A i , E2, or F 2=, to be 
chemotactic for rabbit peritoneal polymorphonuclear leucocytes 
in vitro, though the concentration used was high (l]jg/ml) . Further­
more the PMN's were shown to be the main source of prostaglandins in 
immunogenic uveitis in rabbits (Eakins and others, 1972). More 
recently it has been reported that PGEi is chemotactic in concen­
trations as low as lOng/ml i.e. a concentration less than that 
typically found in inflammatory exudates (Higgs, McCall and Youlten,
1975). It has thus been suggested that prostaglandins produced 
during phagocytic activity could act as chemotactic stimuli for 
further phagocyte infiltration of the inflamed area.
Other observations however cast doubt upon the importance of 
PGEi as a leucotactic agent. Thus intradermal injection of PGEi in 
the skin of both rat and man failed to cause increased leucocyte
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migration (Arora, Lahiri and Sanyal, 1970). Another finding of great 
interest is that freshly prepared solutions of PGEi do not exhibit 
chemotactic activity against either human or rat peripheral leuco­
cytes in vitro, even at a concentration of lyg/ml (Turner, Campbell 
and Lynn, 1975; Ford-Hutchinson, Smith and Walker, 1976), though 
such activity can be detected in aged solutions. The latter authors 
have recently shown that although PGE i does exhibit chemotactic 
activity against rabbit peritoneal PMN's it is devoid of such activity 
against similar cells obtained from the rat or against peripheral 
PMN's from rabbit, rat or man (Walker, Smith and Ford-Hutchinson,
1976).
(vii) Granuloma formation
An important aspect of the inflammatory reaction is the 
granuloma formation associated with increased collagen production.
PGEi enhances the granuloma formation by implanted cotton pellets 
(Arora, Lahiri and Sanyal, 1970) and increases collagen synthesis in 
check embryo tibia (Blumenkrantz and S^ndergaard, 1972) . However 
in rats PGEi did not elicit a granulomatous reaction when injected 
into air blebs at high doses (50-100 yg) (Glenn, Bohman and Rohloff,
1972). The administration of aspirin-like drugs diminished cotton 
pellet granuloma (Winter, Risley and Nuss, 1963).
(viii) Cartilage metabolism
Preliminary results have been presented which suggest that 
prostaglandins produced by rheumatoid synovial cultures reduced the 
incorporation of glycine, leucine and sulphate into normal rabbit 
articular cartilage in vitro and may therefore be inhibiting 
protein-polysaccharide synthesis (Robinson and McGuire, ]975).
Another report has described inhibition of chondroraucoprotein synthesis
30
of chicken and rat cartilage by high concentrations of PGAi, though 
not by PGEi or PGE2 (Eisenbarth, Beuttel and Lebovitz, 1974).
(ix) Bone resorption
One of the most interesting aspects of the role .of prosta­
glandins in chronic inflammatory conditions such as rheumatoid 
arthritis is that they may be capable of promoting bone resorption, 
and erosion, thus being fundamentally implicated in the destructive 
disease process as opposed to merely contributing to the signs and 
symptoms of the inflammation. Klein and Raisz (1970) reported that 
PGEi and PGE2 caused resorption of foetal rat bone in vitro and 
Tashjian and others (1972) showed that the ability of a mouse 
fibrosarcoma to cause hypercalcaemia in mice and promote bone resorp­
tion in mouse calvaria organ cultures was attributable to the 
production of large amounts of PGE2 by the tumour cells. Robinson, 
Tashjian and Levine (1975) have implicated PGE^ directly in the 
pathogenesis of rheumatoid arthritis by demonstrating a high level 
of bone resorption-stimulating activity in culture media from frag­
ments of rheumatoid synovia, and have presented convincing evidence 
that this activity is due to the production of PGE2 by the culture.
(b) Anti-inflammatory properties of prostaglandins
In spite of all the inflammatory properties of the prosta­
glandins described above, several reports have shown them to exhibit 
certain anti-inflammatory and anti-arthritic properties. (Zurier 
and Quagliata, 1971; Glenn and Rohloff, 1972). In general the E 
series are the most potent in suppressing various models of 
inflammation, though anti-inflammatory activity has been demonstrated 
for PGF2= in both carageenin oedema and adjuvant arthritis (Dipasquale 
and others, 1973). It must be emphasised however that very large 
doses of prostaglandins are necessary to demonstrate these effects.
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and that such doses may be producing pronounced pharmacological 
effects not found with physiological concentrations of prosta­
glandins.
Kalinder and Austen (1974) have postulated that the anti­
inflammatory effects of prostaglandins may be mediated via the 
nucleotide levels of target cells. Treatment of phagocytosing PMN's 
with PGEi brought about a rise in cellular cyclic 3 , 5  -adenosine 
monophosphate (cAMP) and a corresponding fall in the release of 
lysosomal enzymes; PGF2“ however produced the reverse effect. E 
series prostaglandins suppress antigen-induced release of histamine 
and slow reacing substance of anaphylaxis from human lung tissue 
(Tauber and others, 1973) and allergic histamine release from human 
leucocytes (Bourne, Lichtenstein and Melmon, 1972). Suppression of 
mediator release is associated with an increase in cellular cAMP, 
factors which decrease cAMP levels, such as phosphodiesterase 
activity, leading to greater mediator release. A finding of great 
interest is that although PGF2= has little effect on cAMP levels it 
is capable of elevating cyclic guanosine monophosphate (cGMP) levels. 
These two cyclic nucleotides usually have opposing roles in control­
ling cellular functions (Goldberg and others, 1973), so it is 
possible that the E and F series prostaglandins oppose each others 
actions by altering cellular levels of the two cyclic nucleotides.
1.9 Prostaglandins in rheumatoid arthritis
Using a radioimmunoassay technique to measure PGB levels in 
human synovial fluids, Levine (1973) showed that in a group of patients 
with inflammatory effusions (arbitrarily defined as those containing 
more than 10^ PMN's per cubuc millimetre) the mean concentration was 
significantly higher than that in a group with non-inflamraatory
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lesions. A group with inflammatory lesions who had received sali­
cylate or indomethacin therapy, however, had the same mean PGB level 
as the non-inflammatory group. A similar study by Higgs and others
(1974), using a bioassay technique to measure prostaglandins in R.A. 
synovial fluid, showed the average concentration in fluids from 
untreated patients to be seven times higher than that in fluids from 
patients receiving aspirin-like drugs. The hypothesis that aspirin- 
like drugs inhibit prostaglandin biosynthesis is fully discussed in 
section 1.11.
Studies of rheumatoid synovial fragments in culture have 
shown the tissue to be capable of producing both PGE2 and PGF2°^; the 
addition of indomethacin (5yg/ml) reduced prostaglandin levels to less 
than 2% of those found in both control and colchicine-stimulated 
cultures (Robinson and McGuire, 1975),
Synovial cultures from normal joints or from patients with 
degenerative or traumatic arthritis produced less PGE2 than was found 
with active rheumatoid specimens. Furthermore an area of a rheumatoid 
synovium with active synovitis (as shown histologically) produced 
greater concentrations of PGE2 and PGF2= than did an area with less 
active inflammation, as compared on the basis of equal wet weights.
The cell(s) in which prostaglandin synthesis originates in 
rheumatoid synovium are unknown; however, fibroblast cell lines 
cultured from rheumatoid synovia retain the ability to produce 
large amounts of PGE2. A comparison of synovial and skin fibro­
blasts showed that, in general, rheumatoid synovial cells produce 
higher levels of prostaglandins and cAMP than do normal skin cells 
from the same patients (Robinson and McGuire, 1975).
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One of the most exciting findings to emerge from these studies 
is that- a high level of bone resorption stimulating activity is 
present in culture media from fragments of rheumatoid synovia and that 
this activity is due to production of PGE2 by the tissue (Robinson, 
Tashjian and Levine, 1975). This is the first piece of evidence 
that prostaglandins may be actively involved in the disease process- 
rather than merely contributing to the symptomology. This is 
supported by the finding that isolated adherent rheumatoid synovial 
cells in culture vessels produce large quantities of both collagenase 
and PGE2 (Dayer and others, 1976).
1.10 Anti-rheumatic therapy
The large number of drugs available for the treatment of a 
chronic inflammatory condition such as rheumatoid arthritis testifies 
to their individual inadequacy, and few clinicians would champion any 
as the 'drug of choice'. No treatment to date has been shown to 
significantly alter the course of the disease process in rheumatoid 
arthritis (Famaey, Brooks and Dick, 1975) though clearly much human 
suffering is alleviated by the use of such therapy.
(a) Aspirin-like drugs
Salicylates
Salicylates have occupied a key position in the treatment of 
rheumatoid arthritis for over 100 years. The use of willow bark for 
the treatment of various agues, fevers and abscesses was first 
described in 1763. By 1876 an extract of willow bark, 'salicin', was 
being used for the treatment of acute rheumatism and was shown to 
contain salicylic acid as the active constituent. Acetylsalicylic 
acid, under the trade name 'Aspirin' was first produced by the Bayer 
Company of Germany in 1899.
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Aspirin exhibits analgesic and antipyretic properties with 
small doses (GOOmg) though much higher doses (2-5g. per day) are 
necessary to produce anti-inflammatory effects. At this dose many 
patients are unable to tolerate the side effects of the drug, the 
principal ones being gastric irritation and CNS disturbances. Gastric 
problems have been minimised by the use of new pharmaceutical prepar­
ations of aspirin involving buffered, microencapsulated or esterified
forms of the drug.
/
Pyrazoles
Phenazone and amidopyrine were two of the earliest drugs in 
this group to be used in the treatment of rheumatic diseases, though 
neither are prescribed now due to their toxicity and tendency to 
cause agranulocytosis.
Phenylbutazone, (Butazolidin,) is the most commonly used 
member of this group of compounds, possessing potent antirheumatic 
effects and also being a weak analgesic. It is long acting and slowly 
metabolised, being firmly bound to plasma proteins, mainly albumin and 
oc-globulin. Toxic effects, usually dose-related, are common and 
include the expected gastro-intestinal irritation and potentially 
dangerous effects on the bone marrow.
Indomethacin
Indomethacin, (Indocid), was first synthesised in 1963 (Shen 
and others, 1963) and first reported as a useful drug in the treat­
ment of R.A. two years later (Norcross, 1965) . Numerous reports since 
have confirmed its potent anti-inflammatory and analgesic properties, 
both in man and in animal models. In man it has a short duration of 
action, roughly 4 to 12 hours depending on the dose given, being 
rapidly absorbed and quickly eliminated in the urine as the glucuronide,
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Side effects include gastric irritation, cerebral sensations, skin 
rashes and occasional ocular complications,
Proprionic acid derivatives
This group of compounds includes naproxen, (Naprosyn), 
ibuprofen, (Brufen), fenoprofen, (Fenopron), ketoprofen, (Orudis; 
Alrheumat) and flurbiprofen (Froben). All have been shown to possess 
anti-inflammatory and analgesic properties and to share the common 
unwanted side effects of gastric irritation, CNS disturbances and 
skin rashes. Numerous clinical trials have been carried out to 
compare their relative efficacy in the treatment of R.A. and to 
assess their undesirable side effects, often with conflicting results, 
A recent trial advocates naproxen as the drug combining the greatest 
effectiveness with the lowest incidence of side-effects (Huskisson 
and others, 1976) though doubtless many dissenting views could be 
found in the literature.
Anthranilic acid derivatives
Mefenamic acid, (Ponstan) and flufenamic acid, (Arlef) have 
been shown to be effective in the treatment of R.A. (Barnado and 
others, 1966; Rajan and others, 1967). They share the side effects 
common to all the drugs described above, together with a tendency to 
cause diarrhoea, and are not widely used in clinical practice.
(b) Anti-inflammatory steroids
Great excitement was aroused by the finding that the adreno­
cortical hormone, cortisone, had considerable activity in the treat­
ment of rheumatoid arthritis (Hench and others, 1949). Not surprising­
ly, at the doses used initially (300mg/day) the results obtained 
were dramatic, but this initial euphoria quickly gave way to 
disillusionment when the highly undesirable side effects of cortico­
steroid overdosage began to appear. These included fluid and
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electrolyte disturbances, hyperglycaemia and glycosuria,osteoporosis, 
poor wound healing and increased susceptibility to infection - 
nothing less than an iatrogenic Cushing's syndrome. Patent synthetic 
analogues of cortisone, such as prednisolone were later produced which 
caused fewer disturbances of fluid and electrolyte balance, and these 
remain highly effective drugs in the treatment of the disease when 
used at conservative dose levels. They are especially useful when 
given as an intra-articular injection to control a sudden 'flare-up' 
in a joint, and new pharmaceutical preparations have been devised 
which aim to provide a sustained action at the inflammatory focus 
with minimum systemic effects due to leakage from the joint.
The efficacy of corticosteroid therapy in the treatment of 
R.A. gave rise to the hypothesis that the supply of cortisol to the
nuclei of cells susceptible to, or involved in R.A. might be
abnormal i.e. deficient (Bailey and West, 1967) though this has 
apparently not been pursued.
(c) Other antirheumatic drugs
Gold
Gold salts were first introduced into medicine because they 
were thought to be effective in tuberculous disease. On the 
assumption that R.A. might be a disease of infective origin gold 
was tried as a treatment and found to be effective, thereby intro­
ducing a valid therapy on what is now thought to be a false
theoretical basis. Several clinical trials have testified to the 
effectiveness of gold injections in the treatment of R.A., though 
the active joint disease is not arrested. The toxic effects of 
chrysotherapy, such as leucopenia, are formidable; these effects are 
not dose-related, often arise without prior warning and can be fatal.
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Gold is one of the major causes of reported deaths from drug therapy 
(Girdwood, 1974).
Penicillamine
Penicillamine (Distamine), a powerful chelating agent, was 
first used in 1956 for the treatment of Wilson's disease. More 
recently a Multicentre Trial Group (1973) suggested that although slow 
in onset, penicillamine may actually slow the progression of 
rheumatoid arthritis. The drug dissociates macromolecules, decreases 
collagen synthesis (Nimmi and Bavelta, 1965) and reduces tlie titre 
of rheumatoid factor in the serum of patients with R.A. (Dresner and 
Trombly, 1960). Serious side effects of penicillamine therapy 
include gastro-intestinal upsets, skin rashes, albuminuria and 
agranulocytosis. Its use is therefore limited to situations where 
careful patient monitoring and supervision is possible.
Immunosuppressive drugs
As the pathogenesis of R.A. is now thought to have an immuno­
logical basis it was a logical step to test the efficacy of the known 
immunosuppressive drugs in the treatment of the disease. Cyclophos­
phamide and azathioprine have both been reported to be effective 
(Fosdick, Parsons and Hill, 1969; Fricke and Deicher, 1969) though 
fearsome side effects, including leucopenia, myelosuppression, 
hepatotoxicity and nephrotoxicity place severe limitations upon their 
usage in all but the most intractable of cases.
1.11 Inhibition of PG biosynthesis - the Vane hypothesis
The elucidation of the mode of action of the aspirin-like drugs, 
whereby they exert their anti-inflammatory, anti-pyretic and analgesic 
properties has been a topic of intense pharmacological interest for 
many years. Clearly the understanding of the mode of action of a
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group of compounds widely used therapeutically is a highly desirable 
goal if future, more effective and less toxic drugs are to be 
designed on a rational basis. Furthermore, an understanding of the way 
in which a drug influences a pathological process may shed some light 
on the aetiology and progress of the disease itself, and possibly 
suggest new approaches to its treatment or even prevention.
Many hypotheses have been advanced to explain the pharmaco­
logical properties of the aspirin-like drugs; these have included 
uncoupling of oxidative phosphorylation (Adams and Cobb, 1958), 
inhibition of leucocyte phagocytosis (Chang, 1972), stabilisation of 
lysosomal membranes (Weissmann, 1972), displacement of anti­
inflammatory peptides from serum proteins (Smith, Dawkins and McArthur,
1971) or interference with migration of leucocytes (Di Rosa, Giroud 
and Willoughby, 1971). These and other possibilities are presented 
in an excellent review by Famey , Brooks and Dick (1975) and will 
not be discussed here in detail. Suffice it to say that although each 
particular hypothesis has had its ardent supporters, all have been 
subject to telling criticism and none has achieved wide support. The 
most common objection raised to all of these hypotheses has been that 
very high concentrations of aspirin-like drugs are necessary to 
demonstrate the appropriate anti-inflammatory properties in vitro, 
concentrations usually far in excess of those which are achieved 
therapeutically in vivo. Aspirin-like drugs at high concentrations 
also inhibit protein biosynthesis and many cellular enzymes, but 
these effects are more likely to be observed in cases of drug 
overdose and intoxication than in normal therapeutic usage. A 
further objection to some of the hypotheses has been that no 
correlation can be demonstrated between the proposed mode of action 
of the aspirin-like drugs in vitro and their known anti-inflammatory
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potency both in animal models and in the treatment of disease in man - 
with the lysosome theory, for example, there is an inverse correlation 
between the potency of the aspirin-like drugs as anti-inflammatory 
agents and their ability to stabilise lysosomal membranes.
In 1971, Vane and his colleagues at the Royal College of 
Surgeons, London, proposed inhibition of prostaglandin biosynthesis 
as a mechanism of action for the aspirin-like drugs. In the first 
paper Vane (1971) showed that aspirin, indomethacin and sodium 
salicylate inhibited the synthesis of PGE2 and PGF2= from arachi- 
donic acid in a guinea pig lung cell-free homogenate, in a dose- 
dependent manner. Secondly, Smith and Willis (1971) showed that 
the same three drugs inhibited prostaglandin release from human 
platelets induced by thrombin, without affecting the release of 
5-hydroxytryptamine, adenine nucleotide or lysosomal enzymes; further­
more platelets obtained from volunteers who had taken either aspirin 
or indomethacin were also shown to be capable of very little prosta­
glandin synthesis when challenged with thrombin. In a third paper, 
Ferreira, Moncada and Vane (1971) added further weight to the hypo­
thesis by showing that aspirin and indomethacin, though not sodium 
salicylate, reduced the output of prostaglandins in the perfusate 
of a dog spleen stimulated with adrenalin.
Those pioneering papers triggered off a great surge in 
prostaglandin research, for here was a group of cheap, readily 
available^welürstudied drugs which were capable of specifically 
inhibiting PG synthesis in cell-free homogenates, isolated cells 
and intact organs. Furthermore, the fact that this group of 
drugs is used extensively in the treatment of chronic human inflam­
matory disease makes the topic an extremely relevant one to both
pharmacologists and clinicians.
(i) Inhibition by aspirin-like drugs
Within a short space of time Vane's hypothesis had achieved 
wide acclaim and had been investigated and confirmed in a wide 
variety of species and preparations (see Flower, 1974 for a compre­
hensive list). Almost all of the aspirin-like drugs tested have 
been shown to be potent inhibitors of prostaglandin synthetase, 
regardless of the source of the enzyme or the analytical technique 
employed. That inhibition of prostaglandin synthesis is a property 
solely of the aspirin-like drugs is shown by the fact that many 
other pharmacologically active compounds are inactive against the 
enzyme in concentrations of 1.0-5.0mM (Gryglewski and others, 1972).
Salicylic acid is of interest, as it possesses little anti^ 
synthetase activity in vitro, yet is as potent as aspirin as an 
anti-inflammatory drug, both in animal models and when used thera­
peutically in man. A possible explanation for this anomaly arises 
from the observation (Flower and Vane, 1974) that metabolites of 
salicylic acid are more potent inhibitors of the synthetase system 
than salicylic acid itself. This point is discussed in detail in 
section 4.6. Two salicylic acid isomers, m- and p-hydroxybenzoic 
acid, which possess'no anti-inflammatory properties, are both 
devoid of anti-synthetase activity.
Paracetamol (4-acetamidophenol) was found to be inactive 
against prostaglandin synthetase prepared from peripheral tissues, 
but showed good activity against the enzyme prepared from dog, 
rabbit, mouse or gerbil brain (Flower and Vane, 1972). This is 
a highly significant finding and raises the possibility that 
prostaglandin synthetase may exist as iso-enzymes within an organism.
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the enzyme from each tissue having its own pharmaco.lological 'profile' 
of sensitivity to various aspirin-like drugs. It would thus explain 
paracetamol's anti-pyretic activity and lack of anti-inflammatory 
activity. As discussed in section 1.12. the undesirable side-effects 
of the aspirin-like drugs may be due, at least in part, to the inhi­
bition of gastric and renal prostaglandin synthesis. The design of 
a drug directed specifically at the synthetase system of the inflam­
matory 'target' tissue, yet possessing little activity against the 
enz^nne from other tissues may therefore go some way towards solving 
the major toxicity problems of this group of drugs. Marked discrep­
ancies exist in the literature however on this point. Thus whilst 
Bhattacherjee and Eakins (1974) found orders of magnitude differences 
in the potency of indomethacin against the synthetase from various 
rabbit tissues. Pong and Levine (1976) found virtually identical 
potencies for seven different rabbit tissues studied, and suggested 
that previously reported differential sensitivities to indomethacin 
probably reflected different substrate concentrations in the relative­
ly crude enzyme preparations used. Clearly clarification of this 
point is highly desirable if the search for an 'ideal' aspirin-like 
drug is not to be an illusory one.
As the aspirin-like drugs are thought to be competitive 
inhibitors of prostaglandin synthetase (Ku and Wasvary, 1973), it is 
perhaps not surprising that the absolute potencies of the drugs 
reported by different workers vary widely, as a wide range of 
substrate concentrations have been employed. Even relative potencies 
reported for the same tissue show great variation (Ferreira and Vane,
1974), so that comparisons between different laboratories can only 
be made with great caution.
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Another factor which influences the activity of the aspirin­
like drugs is the way in which the enzyme is prepared. Thus, whilst 
fluorindomethacin and indomethacin competitively inhibit fresh micro­
somal preparations from ovine and bovine seminal vesicular glands 
(Hamberg, 1972), the effect on an acetone powder preparation from 
sheep vesicular glands was irreversible and increased by pre-incubation 
(Smith and Lands, 1971).
Evidence in support of Vane's hypothesis was provided by the 
finding that the rank order of potency of the aspirin-like drugs in 
the carrageenin rat paw oedema test was the same as the order of 
potencies as inhibitors of dog spleen synthetase (Flower and others,
1972). An even more striking correlation is shown by studying optical 
isomers of naproxen, indomethacin and ibuprofen; in each case the 
isomer with the anti-inflammatory activity shows good anti-synthetase 
activity and the one with weak anti-inflammatory potency shows little 
anti-synthetase activity (Ham and others, 1972; Tomlinson and others, 
1972; Adams, Bresloff and Mason, 1975). This is a remarkable 
correlation between an in vitro property and known in vivo potency 
which no other hypothesis has been able to demonstrate. Clearly 
one should not expect perfect correlation between in vitro and 
in vivo properties of a series of drugs, as an orally administered 
drug faces many hazards of absorption, protein binding, distribution 
metabolism and excretion before reaching its target in the form of 
a microsomal enzyme.
In addition to inhibiting PG synthesis in Isolated calls and 
tissues the aspirin-like drugs are capable of reducing whole body 
PG synthesis. Hamberg (1972), measuring a principal urinary 
metabolite of PGEj and PGE2 as an index of whole body PG synthesis.
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showed that the daily excretion of this compound was greatly reduced 
in volunteers taking therapeutic doses of aspirin,indomethacin or 
salicylate. The same experiment was carried out in guinea pigs though 
in this species the dose required to abolish output of the urinary 
metabolite was much higher than in man.
(ii) Inhibition by other anti-rheumatic drugs
Greaves and McDonald-Gibson (1972) reported inhibition of PG 
synthesis in rat skin homogenates by some steroidal anti-inflammatory 
drugs, though later work using a microsomal preparation showed this 
group of compounds to be inactive, and it is now generally agreed 
that steroidal anti-inflammatory drugs do not inhibit prostaglandin 
synthetase. Recent work however suggests that these drugs may block 
an earlier stage of prostaglandin production, namely the release of 
substrate (arachidonate) from cellular phospholipids (Hong and 
Levine, 1976; Nijkamp and others 1976). Studies of the effects of 
steroidal anti-inflammatory drugs on PG production by rheumatoid 
synovial cultures and cultured mouse fibrosarcoma cells also support 
this conclusion. In the former study (Kantrowitz, Robinson and 
McGuire, 1975) it was shown that cortisol, dexamethazone and pred­
nisolone, when present in culture fluid at concentrations of 10 ®M to 
10 **M inhibited the production of prostaglandins in a dose-related 
manner. This inhibition of PG production was not due to inhibition 
of PG release, as has been suggested by others (Lewis and Piper,
1975), nor was it due to enhanced PG metabolism in the tissue or 
degradation in the culture medium. In the latter report (Tashjian, 
Voel.kel and McDonough, 1975) cortisol was shown to be a potent 
(ID5o~10 ®M) inhibitor of PG formation by a clonal strain of cells 
in culture, and the effect was not the result of an action on PG 
release or transport mechanisms.
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Chloroquine has been reported to inhibit prostaglandin 
synthetase, though only at high doses (Gryglewski and others, 1972). 
Nugteren and others (1966) and Deby, Bacq and Simon (1973) have 
proposed that the therapeutic activity of some gold salts could be 
due to their action on the prostaglandin synthetase system. 
Penicillamine has proved to be inactive as a PG synthetase inhibitor.
(iii) Inhibition by substrate analogues and fatty acids
Ahern and Downing (1970) reported a time-dependent inhibition 
of sheep vesicular gland synthetase by an acetylenic analogue of arach- 
idonic acid, eicosa-5, 8, 11, 14-tetraynoic acid, TYA. The 
inhibition was irreversible and the acid was not a substrate for the 
enzyme. Nugteren (1970) showed that a 12-trans analogue of dihomo- 
y-linolenic acid and a 12-trans analogue of arachidonic acid were 
unusually potent inhibitors of PG synthesis; both were competitive 
inhibitors and were unchanged by the enzyme. Robak, Dembinska-Kiec 
and Gryglewski (1975) showed that a series of saturated fatty acids, 
ranging from Cio to Cia were capable of inhibiting the microsomal 
synthetase system of bovine seminal vesicles in vitro, the most 
potent being lauric and myristic acid. Capric acid had previously 
been reported to be a weak inhibitor (Wallach and Daniels, 1971).
All these compounds, though useful in the elucidation of, 
enzyme mechanisms, are of little therapeutic interest and have 
rarely been used in vivo, owing to incomplete knowledge of their 
absorption, excretion, distribution and metabolism. Certain 
prostaglandin analogues have been shown to competitively inhibit 
PG synthesis (McDonald-Gibson, Flack and Ramwell, 1973), suggesting 
that a product binding site, as well as a substrate site, exists 
on the enzyme, as postulated by others (I.ands and others, 1973) .
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(iv) Inhibition by miscellaneous agents
In common with many other enzymes, PG synthetase may be 
inhibited by excessive amounts of cofactors or substrate. Nugteren 
and others (1966) showed that PGEi production could be inhibited 
by excess amounts of reduced glutathione and other anti-oxidants 
and Flower, Cheung and Cushman (1973) demonstrated substrate 
inhibition for PGE2 production above a concentration of 0.5mM.
Some metal ions, including Zn^^, Cd^- and Cu^^ have been shown to 
be inhibitory (Nugteren and others,1966) though many others were 
without effect at the concentration used (5 x 10 ^M). Lee and 
Lands (1972) showed that the inhibition of PGE synthesis by Cu^^ 
was accompanied by a simultaneous increase in PGF synthesis. This 
finding has possible therapeutic implications and will be 
discussed in detail in section 4.4. Many other entities are able 
to influence PG synthesis and have been comprehensively reviewed 
by Flower (1974).
1.12 Side effects of aspirin-like drugs
The aspirin-like drugs share the common unwanted side 
effects of causing gastrointestinal irritation which may lead to 
ulceration, and varying degrees of nephrotoxicity with some 
incidence of papillary necrosis. As this group of drugs is used 
for the alleviation of chronic inflammatory conditions these side 
effects often impose a serious limitation on their therapeutic 
usefulness. It is possible that these toxic effects may be caused 
by the inhibition of PG synthesis in tissues which depend upon 
prostaglandins for the control and maintenance of normal 
physiological function.
PGEi inhibits gastric acid secretion (Shaw and Ramwell, 1968)
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and may therefore play a part in the control of acidity in the 
stomach; inhibition of this locally released PG by the ingestion 
of aspirin-like drugs could therefore lead to hyperacidity and 
possible ulceration. Several of the synthetic PG analogues have 
been shown to be potent inhibitors of gastric acid secretion and 
may have clinical potential as anti-ulcer compounds (Gallus and 
Hirsh, 1976). Locally released prostaglandins in the stomach may 
also exert a protective effect on the mucosa by increasing its 
blood supply, the removal of this function by aspirin-like drugs 
leading to ischaemia and necrosis. A further possibility is that 
ingestion of aspirin-like drugs can lead to a local accumulation 
of arachidonic acid and this, or possibly a peroxide derivative, 
could cause gastric irritation; in this context prostaglandins 
may be viewed as mere metabolic waste, consequent upon the removal 
of potentially damaging lipids as suggested provocatively by 
Brocklehurst and Dawson (1974).
In the kidney prostaglandins are natriuretic (Lee, 1972), 
prostaglandin synthetase being located in the cells forming the 
collecting tubules (Janszen and Nugteren, 1971). Prostaglandin 
synthesis and release in the kidney may be important for the local 
control of both blood and urine flow; infusion of angiotensin 
into the kidney releases a prostaglandin which moderates the vaso­
constriction and indomethacin, by inhibiting PG synthesis, 
effectively potentiates the vasoconstrictor effects of angiotensin, 
producing a much larger decrease in renal blood flow (Vane, 1972).
1.13 Objects of the study
The work described in this thesis revolves around the 
possible involvement of prostaglandins in the pathogenesis of
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rheumatoid arthritis, and the hypothesis that aspirin-like drugs 
exert their therapeutic effects via inhibition of prostaglandin 
biosynthesis.
On the basis of studies of the interaction between aspirin­
like drugs and prostaglandin synthetase prepared from various 
animal tissues, many authors have gone on to discuss the anti­
inflammatory actions of these drugs in the treatment of rheumatoid 
disease. This is a little surprising in view of the fact that the 
same authors apparently accept the hypothesis that isoenzymes of 
prostaglandin synthetase exist, and that even within the same 
species the enzymes from different tissues may have widely differing 
susceptibilities to inhibition by aspirin-like drugs. When the 
present study was initiated there was no evidence in the literature 
to suggest that results obtained using animal preparations of 
prostaglandin synthetase could be extrapolated to human inflammatory 
tissue. The logical conclusion to be drawn, therefore, was that if 
meaningful results were to be obtained on the interaction between 
aspirin-like drugs and prostaglandin biosynthesis in rheumatoid 
disease, the enzyme used in the studies should be derived from tissue 
involved in the inflammatory reaction.
In a preliminary study in this laboratory, Rose (1975) was 
unable to demonstrate any prostaglandin synthetase activity in a 
cell-free homogenate of rheumatoid synovium, though initial results 
obtained by the present author suggested that this was an unsuitable 
preparation to use in combination with the assay system employed.
The work described in this thesis was therefore carried out in order 
to answer or clarify as many as possible of the following points
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1. Is rheumatoid synovium capable of prostaglandin biosynthesis?
2. Do its fundamental biochemical properties show it to be 
radically different from the well-studied enzymes prepared 
from animal tissues?
3. Does the level of enzyme activity found in rheumatoid 
synovium correlate with other parameters of disease activity, 
either clinical or biochemical?
4. How does the enzyme activity in rheumatoid synovium compare 
with levels found in other tissues?
5. Does R.A. synovium contain raised levels of enzyme activity 
compared with normal synovial tissue?
6. Is the enzyme susceptible to inhibition in vitro by the 
aspirin-like drugs used therapeutically?
7. If so, is this inhibition achieved at therapeutically 
'realistic' concentrations?
8. Does the potency of the aspirin-like drugs as inhibitors 
of rheumatoid synovial prostaglandin synthetase correlate 
with their known therapeutic potencies, i.e. would this 
assay form the basis of a good in vitro screening test for 
new anti-inflammatory drugs?
9. Do other antirheumatic drugs, e.g. steroids, penicillamine, 
have any effect on prostaglandin biosynthesis in this 
system?
10. Which cells are capable of contributing to PG production 
at the inflammatory site?
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11. Do all the aspirin-like drugs inhibit the enzyme in the
same manner?
12. At which point in the synthesis of prostaglandins from
arachidonic acid do the aspirin-like drugs act?
13. Do any of the aspirin-like drugs show 'selective'
inhibition of any one product of arachidonic acid metabolism?
14. Can any information concerning the structure or 
organisation of the enzyme complex be gained from studying 
the interaction between the enzyme and aspirin-like drugs?
15. In summary, do the results of the study as a whole support
or detract from the hypothesis that aspirin-like drugs 







. A multitude of techniques are now available for the separa­
tion, purification, identification and quantitation of prostaglandins
Chromatographic techniques have been described for prelim­
inary purification and separation of prostaglandins including thin 
layer chromatography (Green and Samuelsson, 1964), paper chroma­
tography (Egan, 1975), silica gel microcolumns (Hillier and Dilley, 
1974), sephadex LH-20 columns (Zia and Horton, 1973), ion-exchange 
liquid chromatography (Morozowich, 1974) and high pressure liquid 
chromatography (Andersen and Lepvey, 1974).
Identification and quantitation may be achieved using bio­
assay (Ferreira and Vane, 1967), radioimmunoassay (Levine, 1973), 
competitive protein binding (FrBlich and others, 1974), viroimmuno- 
assay (Andrieu, Mamas and Dray, 1974), radioisotope dilution 
(Aizawa and Yamada, 1974), enzymatic assay (Matschinsky, Shanahan 
and Ellerman, 1974), spectrophotometry (Takeguchi and Sih, 1972), 
isotope derivative assay (Flower and McClure, 1975), gas-liquid 
chromatography (Pugsley and Beilin, 1974) or combined gas-liquid 
chromatography/;mass-spectrometry (FrOlich and others, 1975). As 
these are only representative publications for each technique it 
is clear that many combinations of these procedures are possible, 
and that no particular one is a 'method of choice'.
The initial work involved in adopting and validating a 
technique can represent a considerable outlay in terms of time 
and effort before any experiments can be undertaken and results 
obtained with any confidence. At the start of this work, therefore, 
careful consideration was given to the many techniques available 
in order to decide which would be most suitable for the planned
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experiments in terms of accuracy, specificity, sensitivity, conven­
ience and cost. It is always recognised that such a choice must 
inevitably represent a compromise - the most accurate, sensitive 
and specific technique available is rarely the most convenient.
Bioassay of prostaglandins, using cascade superfusion 
systems, has been widely used as it is capable of good sensitivity 
without the need for time-consuming purification of the sample or 
expensive equipment. Specificity may be increased by the use of 
antagonists and the use of several tissues in parallel (usually 
rat stomach strip, rat colon and chick rectum). The disadvantages 
of the technique are that metabolites cannot usually be measured, 
and the precision of the assay is variable.
Radioimmunoassay has been increasingly used by many workers 
due to its excellent sensitivity, potential ability to measure any 
prostaglandin or metabolite, and the feasibility of assaying large 
numbers of samples. Elegant studies by Levine (1973) have shown 
that the combined use of several antibodies of different specifities 
may yield much information concerning the kinetics of prostaglandin 
metabolism. The fundamental objection to radioimmunoassay has 
always been its inherent lack of specificity - however exhaustive 
the cross-reactivity studies performed to validate the specificity, 
the possibility always exists that a new, as yet unknown prosta­
glandin or prostaglandin metabolite (or even a non-prostanoid 
compound) may bind to the antibody. That this is not merely a 
hypothetical objection has been shown in work by Samuelsson (1973) 
and Frttlich and others (1975). In the former study the assay of 
PGFz^ levels in peripheral venous blood, using both a radio­
immunoassay and a GC/MS method, has shown that much of the material
binding to PGFz* antibodies is not in fact PGF2®.
In the latter work, also employing a GC/MS method, 
much doubt has been cast on previously obtained values for PGA2 
levels in human plasma - the values obtained by GC/MS were only 
about 10% of those previously reported using a radioimmunoassay 
technique. A further drawback of adopting a radioimmunoassay 
technique is the time (and a certain element of luck) involved in 
producing the appropriate antibodies - often several months 
before a good titre of high specificity antibody is obtained.
Gas-chromatography / mass spectrometry is seen by many as 
the method of choice for the identification and quantitation of 
prostaglandins in tissue extracts and biological fluids. It is 
an accurate, sensitive technique and the presence of interfering 
compounds is easily detected. The technique is also applicable 
to metabolites, and the use of deuterated internal standards and 
single-ion monitoring allows accurate quantitation in the low na no­
gram range. This technique would thus be widely used, were it not 
for the high cost of the equipment and the extremely time-consuming 
preparatative and technical procedures involved in its operation.
Spectrophotometrie techniques for the measurement of 
prostaglandins have the attraction of simplicity. Their sensitivity, 
however, '3 not good and at low levels specificity may be doubtful. 
Furthermore, this method can only be used for prostaglandins which 
are natural chromophores e.g. PGA, PGB or those which can be easily 
converted to a chromophore e.g. PGE. Spectrophotometric methods 
have been successfully used to measure relatively high concentrations 
of incubation products where high substrate concentrations were 
employed with very active prostaglandin synthetase preparations
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from ovine or bovine seminal vesicular glands (Takeguchi and Sih,
1972). However, as discussed later, it was considered of prime 
importance in this work to use 'realistic' substrate concentrations 
approximating to those which exist in vivo i.e. very low concen­
trations of substrate (~lyM) producing only nanogram amounts of 
products.
As the purpose of this work was primarily to study prosta­
glandin synthetase activity in rheumatoid tissue, rather than to 
measure concentrations of endogenous prostaglandins in synovial 
fluid or synovial tissue, consideration was given to the possibility 
of employing a radiometric assay to measure the enzyme activity. 
Previous experience with a radiometric assay for serum lecithin- 
cholesterol acyl transferase (LCAT) activity (Misra and others, 1974) 
had convinced the author that such a technique was reliable and 
convenient, possessing good accuracy, precision and sensitivity, 
even using  ^**C labelled substrate of relatively low specific activity.
The proposed method for use in this study would thus involve 
incubation of prostaglandin synthetase, from synovial tissue, with 
radioactively labelled substrate (either or ^H) , followed by
extraction and separation of unchanged substrate and formed prosta­
glandins (and possibly other, non-prostanoid, products). Accurate 
and sensitive measurement of the labelled prostaglandins formed, 
and hence quantitation of the enzyme activity, would be achieved 
by liquid scintillation counting.
At the time this work was undertaken, ^H-labelled substrate 
(arachidonic acid) of high specific activity was not commercially 
available. However, calculation showed that the '^^ C arachidonic 
acid available (Radiochemical Centre, Amersham) was of sufficiently high
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specific activity to achieve good sensitivity, and would have the 
further 'advantage of greater radiochemical stability (^H labelled 
compounds can be troublesome due to tritium exchange in solution). 
Of the commonly used methods available for separation of unchanged 
substrate and formed prostaglandins, thin-layer chromatography was 
chosen rather than paper or column chromatography due to its speed, 
ease of handling and ease of radioscanning to locate active zones 
prior to liquid scintillation counting,
2.2 Materials
The reagents used in these studies were purchased from 
British Drug Houses Ltd., Poole or the Sigma Chemical Company Ltd., 
London. Whenever possible they were of 'Analar' grade or its 
equivalent. Solvents to be used for storage purposes (benzene or 
ethanol) were redistilled through a 60cm packed fractionation 
column. Pyridine used in the synthesis of {^H-acetyl} aspirin was 
redistilled immediately before use.
Silica gel G was purchased from Merck, Darmstadt, Germany 
and scintillation chemicals from Koch-Light Laboratories, Colnbrook, 
Disposable polythene liquid scintillation counting vials were 
supplied by Hos-Tek Ltd., Canterbury.
The following radiochemicals were obtained from the 
Radiochemical Centre, Amersham :-
^H-Acetic anhydride Specific activity 3,SOOmCi/mmol 
{l-^^c} Arachidonic acid " " 56mCi/mmol
{5,6,8,11,12,14,15(n)-^h} Prostaglandin E 2 " " 140,000mCi/mmol
{5 ,6,8,11,12,14,15(n)-^h} Prostaglandin F 2°^ " " 150,000mCi/mmol
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The prostaglandin standards used in this work were the 
generous gift of Dr. J.E. Pike, Upjohn Co., Kalamazoo, U.S.A.



























Merck, Sharp & Dohme
Boots Pure Drug Co.
Syntex
A. H. Robins
Parke, Davis & Co.
Geigy Pharmaceuticals 
May & Baker 
Winthrop Laboratories 
Reckitt & Colman
1-^^C-Arachidonic acid was diluted to a concentration of 
lyCi / ml with re-distilled benzene and stored under nitrogen at 
4°C in dark, sealed ampoules. Stock solutions of non-radioactive 
arachidonic acid were prepared in redistilled benzene at concen­
trations of lOmg/ml and 0.1 mg/ml and stored under nitrogen at 
-20^C in dark, sealed ampoules. When used for enzyme studies, the 
benzene was evaporated under nitrogen at 37°C, and the residue 
dissolved in a small volume of redistilled absolute ethanol 
(20-50yl). This ethanolic arachidonic acid solution was diluted 
to the desired concentration with tris-acetate buffer, pH8.0 to 
give an ethanol concentration which did not exceed 1%.
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All glassware which had been in contact with radioactive 
extracts was soaked in chromic acid overnight, washed thoroughly 
and rinsed with distilled water and acetone.
2.3 Preparation of microsomal PG synthetase
(i) Bovine seminal vesicles
A freeze-dried microsomal powder of bovine seminal vesicles 
was prepared according to the method of Takeguchi, Kohno and Sih 
(1971) and was the generous gift of Dr. P. Bresloff, Boots Pure 
Drug Co., Nottingham.
(ii) Rabbit renal medulla
Albino Californian rabbits of both sexes, 2-3kg. body 
weight, were killed by cervical dislocation. The kidneys were 
immediately excised, and after removal of the adhering fat and 
connective tissue were placed on ice. Each kidney was cut into 
lateral slices 2-4mm thick with a scalpel blade, and the medullary 
tissue dissected from the cortex with scissors. The medullae from 
both kidneys, 2-6 gm, were coarsely chopped before homogenisation 
(20% w/v) in O.IM tris-acetate buffer, pH 8.0 containing sucrose 
(0.25M), EDTA (ImM), hydroquinone (O.5mî4), cysteine hydrochloride 
(ImM) and reduced glutathione(2mM)., using a Potter-Elvehjm 
homogeniser. The homogenate was centrifuged for 10 min. at 
4000g, filtered through cheesecloth and centrifuged for a further 
10 min. Centrifugation of the supernatant at lO^g for Ih. 
produced a microsomal pellet which was used as the enzyme source.
(iii) Human rheumatoid synovium
Synovial tissue, obtained at surgical synovectomy of the 
knee or elbow, or at total knee replacement, was kept on ice and 
used within one hour. (No attempt was made during this work to
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utilise tissue which had been either deep frozen or stored at 
4°c. due to the intrinsic instability of the enzyme). The synovium 
was dissected free of fat and chopped into small pieces with scissors, 
In preliminary studies, the tissue was finely minced and a 20%
(w/v) homogenate prepared in O.IM tris-acetate buffer, pH 8.0, 
containing sucrose (0.25M), EDTA (lmf4) , hydroquinone (O.SmM), 
cysteine hydrochloride (ImM), and reduced glutathione (2mM), using 
a combination of a Waring blender and a Potter-Elvehjm homogeniser. 
Subsequently a shaft-type homogeniser was acquired (IL Model X--1020, 
Scientific Instrument Centre Ltd., London) and this was found to 
give a more efficient homogenisation and hence greater yield of 
microsomes. Using this instrument, tissue was homogenised at full 
speed for 1 minute, while cooled in ice. The homogenate was 
centrifuged for 10 min. at 4000g and the supernatant filtered 
through a double layer of cheesecloth. This process was repeated, 
and a microsomal pellet obtained by centrifugation at lO^g for one 
hour. The average yield of microsomes was l.Omg protein/g .tissue.
(iv) Human peripheral leucocytes
(a) 'Total* white cell preparation
Venous blood was taken into heparin (20 units/ml) and 
centrifuged at 500g for 10 min., at room temperature. The 
plasma and buffy white cell layer were then pipetted into a 20ml 
plastic syringe. After incubation at 37°c for 1 hour, the turbid 
plasma layer was transferred to plastic tubes and centrifuged at 
600g for 10 min. The pellet was washed twice in phosphate- 
buffered saline (P.B.S.), then resuspended in P.B.S. (5.0ml) and 
a cell count performed. After obtaining a cell pellet again by 
centrifugation, ice-cold tris-acetate buffer (as used in (iii) 
above) was added (5.0ml) and the suspension sonicated (Rapidis
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300, Ultrasonics Ltd) by three 30 second impulse of 200 watts. Cell 
debris and any intact cells were removed by centrifugation (2000g 
for 10 min), after which a microsomal pellet was obtained by 
centrifugation at 10^g for one hour.
(b) Platelets
Platelet-rich plasma was obtained by centrifugation of 
heparinised blood at 50g for 10 min., then at lOOg for 10 min.
A platelet count was performed and a pellet obtained by centrifu­
gation of the plasma at 2000g for 5 min. The platelets were 
sonicated and a microsomal pellet obtained as described above 
for the 'total' white cell preparation.
(c) Polymorphonuclear cells
The method used was based on that of Dioguardi and others, 
(1963). Heparinised blood (15 ml) was added to 0.83% NHi+Cl (70ml), 
gently mixed and allowed to stand at room temperature for 10 rain. 
After centrifugation at 120g. for 10 min. the supernatant was 
discarded and the washing process with NH^Cl repeated. After this 
stage the preparation was free of erythrocytes. Residual lympho­
cytes were removed by suspending the pellet in Hank's solution 
(50ml) and centrifuging at 55g for 10 min. Lymphocytes, suspended 
in the supernatant, were discarded and the washing repeated twice. 
Typically, the final PMN preparation contained 92% PMN, 6% lympho­
cytes and 2% monocytes. The yield was approximately 65-70% of the 
original cell number and PMN viability > 98% as judged by trypan 
blue exclusion. (Phillips, 1973). The PMN cells were sonicated 




The method used was essentially as described by Boyum (1968). 
Heparinised blood (10ml) was added to a solution of 1% methyl 
cellulose in 0.9% saline (2.5ml), 30mg carbonyl iron added and the 
mixture gently shaken at 37°c for 30 min. The blood bottle was then 
stood on a strong magnet for 30 min. in a 37°c incubator, during 
which time the erythrocytes, together with the iron-loaded PMN's 
and large mononuclear cells, sedimented out.
Triosil (Nyegaard & Co., Oslo; 20 ml) was diluted with 
water (24ml), mixed well and added to 9% ficoll (100ml). The 
lymphocyte-rich supernatant was carefully removed after the 37°c 
incubation, layered onto the ficoll-triosil solution and centrifuged 
at 220g for 30 min. The lymphocytes, appearing as a white band 
at the interface between the upper plasma layer and the lower ficoll- 
triosil, were carefully removed and washed twice in Hank's physio­
logical saline. Contamination of this preparation by PMN's rarely 
exceeded 2% and cell viability, as above, was >98%.
(v) Synovial fluid leucocytes
Fresh samples of synovial fluid, obtained from R.A. patients, 
were incubated with hyaluronidase (1.5% of a 0.02% solution) 
at 37° for 30 minutes. A white cell pellet was obtained by centri­
fugation at 4000g for 10 minutes, after which a microsomal fraction 
was prepared as described above in (iv), (a) for peripheral 
leucocytes.
2.4 Production of prostaglandins from ^^C arachidonic acid
substrate
Microsomal PG synthetase, prepared as described in section
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2.3 above was resuspended in fresh tris-acetate. buffer, pH 8.0 (see 
section 2,3 (iii) above), by a brief period of sonication (The use of 
a 'Whirlimixer' did not give an efficient re-suspension of the micro­
somal pellet). Aliquots of the microsomal suspension were incu­
bated with arachidonic acid (lOOnCi/0.1ml; final concentration
0.85yM) at 37°c, for one hour, with shaking, in a volume of 2.0ml,
The reaction was terminated by the addition of 2M citric acid 
solution (0.25ml), reducing the pH to 2.5-3.0,
2.5 Extraction, separation and quantitation of prostaglandins
The formed prostaglandins • and unconverted  ^ arachidonic acid 
were extracted from the acidified incubate with diethyl ether (2x3.0ml). 
After evaporation of the combined extracts under nitrogen at 37°c the resi­
due was immediately dissolved in 20yl chloroform :methanol, 2:1, and 5]il 
applied to a thin-layer chromatographic plate (silica gel G, O.25mm 
thickness, containing 2.5% silver nitrate). Authentic arachidonic 
acid, PGE2 and PGF2°: (lOyg of each) were applied in a marker lane 
and the plate developed in the solvent system benzene-dioxan-acetic 
acid, 20:20:1 (system AI) to a height of 15 cm. After locating the 
markers with phosphomolybdic acid, and scanning the plate for 
radioactivity (Berthold thin-layer scanner. Model LB 2723, Camlab, 
Cambridge), the zones in the extract lanes which corresponded to the 
markers were scraped from the plate, transferred to counting vials 
and methanol (1.0ml) added. After shaking briefly, 8ml of liquid 
scintillant was added (0.5% PPO and 0.03% dimethyl POPOP in toluene) 
and the samples counted in a liquid scintillation system (Phillips 
Liquid Scintillation Analyser, Model 01). Samples were counted at 
their 'balance point' to a present level of 10** c.p.m’. (error ± 2%), 
at an efficiency of approx. 85%. The absolute activity (d.p.m.) was
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calculated by the counter, using a preprogrammed 'quench correction 
curve' based on a channels ratio (see appendix 1). From the counts 
obtained in the substrate and prostaglandin regions of the chroma­
togram (which represent approx. 95% of the total activity on a 
typical separation), the percentage conversion of the substrate 
can be calculated, and hence the activity of the microsonal PG 
synthetase preparation derived :-
% substrate conversion x substrate concentration 
Activity 100 X microsomal protein concentration
Throughout this study, the PG synthetase activity has been 
expressed in terms of 'pmol PG produced per mg. microsomal protein 
per hour'.
2.6 Characterisation of formed prostaglandins
The foirmed prostaglandins were characterised by running in 
various chromatographic systems, with authentic prostaglandin 
standards, by chemical conversion to other prostaglandins followed 
by further chromatographic identification, and by bioassay of TLG 
eluates.
(i) Chromatography
The chromatographic systems used were :-
1. Benzene-dioxan-acetic acid, (20:20:1), with and without silver 
nitrate.
2. Ethyl acetate-methanol-acetic acid-water-2,2,4 trimethyl pentane, 
(110:35:30:100:10), upper phase used.
3. Chloroform-methanol-acetic acid-water, (90:6:1:0.75).
System 1 was used routinely in this project, systems2 and 
3 being used for confirmation whenever a new tissue or cell preparation
6*3
was being characterised. An aliquot of the incubation extract was 
always added to the authentic marker spot before chromatography, as 
it was observed that pure markers running in a lane which contained 
no extract did not run exactly parallel with markers superimposed 
on an extract lane. This was confirmed by the addition of authentic 
radioactive prostaglandins to extract and marker lanes, followed by 
chromatography and radioscanning.
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(ii) Chemical conversion of C-PGEa
The radioactive zone in the extract lane which corresponded 
to authentic PGE2 was scraped from the thin-layer plate into a small 
glass sinter column and eluted with redistilled methanol (2.0ml), solid 
NaCl (lOmg) was added,and the precipitated AgCl removed by centri­
fugation at 2000g for 5 min. The clear supernatant was removed, 
divided into two portions and evaporated under nitrogen at 37°c. To 
one portion was added 0,5M NaOH (2,0ml), the tube mixed well and 
incubated at 37°c for Ih. To the second was added water (2.0ml), 
the pH adjusted to 8.0 with 0.05M NaOH, solid NaBH^ added (lOmg) and 
the tube also incubated at 37° for Ih. Both mixtures were then 
brought to pH 2,5 with 2M citric acid, extracted with diethyl ether 
(3 X 2.0ml) and the residues, after evaporation of the extracts, 
re-chromatographed in the solvent system benzene-dioxan-acetic acid, 
(20:20:1),
(iii) Bioassay of TLC eluates
A portion of the chloroform/methanol extract was applied to 
a thin layer plate (silica gel G, 0.25mm thickness) and developed 
to a height of 15 cm in the AI solvent system, 1 cm bands were 
transferred to small glass sinter columns and eluted with redistilled 
methanol (1.2 ml), an aliquot of which (0.2 ml) was used to measure
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the radioactivity present in each extract. The remainder was 
evaporated under nitrogen at 40°, redissolved in Tyrode's solution 
(1.0ml) and aliquots (0.1ml) used for bioassay.
A rat stomach strip was superfused with Tyrode's solution 
containing a mixture of antagonists (Gilmore, Vane and Wyllie,,
1968) at a flow rate of 4.5ml/min. Standard solutions of PGE2 and 
PGF2= were used for calibration purposes. The use of a rat colon 
strip in series with the stomach strip, in order to preferentially 
detect any PGFa® present, was not successful.
(iv) Detection of PG-metabolising activity in microsomal 
preparations
Although the principal prostaglandin metabolising enzymes 
are known to be found in the cytoplasmic fraction of cells, the 
possibility exists that a microsomal preparation might contain, or 
be contaminated with, a small but significant amount of prosta­
glandin-metabolising activity. This would clearly be a potential 
source of error in microsomal incubations, particularly when the 
effect of PG synthetase inhibitors was being studied. (Indo- 
methacin and aspirin are both inhibitors of 15-hydroxyprostaglandin 
dehydrogenase (Hansen, 1974).
The possibility that the microsomal preparation might contain 
PG metabolising activity was therefore investigated by adding 
authentic ^H-PGE2 and ^H-PGF/^ as substrate, in place of  ^ arachi- 
donic acid, to separate microsomal incubates. These were then taken 
through exactly the same incubation, extraction and separation 
procedures as for the usual arachidonate incubates. Using the AI 
solvent system, possible PG metabolites such as the 15-oxo or the 
13,14-dihydro-15~oxo metabolites would be readily detectable.
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2.7 Protein estimation
Microsomal protein concentrations throughout this thesis 
were measured by the method of Lowry and others (1951), using 
bovine serum albumin as standard. Concentrations varied between 
experiments, but were in the range 0.4-2.0 mg/ml for the synovial 
studies, and 50-200]jg/ml for the white cell studies.
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2.8 Preliminary results
Initial studies were carried out in order to check the 
validity of the method in terms of accuracy and precision and to 
determine the optimum conditions for extraction, chromatography 
and liquid scintillation counting.
(i) Extraction
In order to check the completeness of extraction of formed 
prostaglandins and unchanged substrate from incubates, lOOnCi of 
either ^^C-arachidonic acid, ^H-PGEa or ^H-PGF2“ was added in 
duplicate to suspensions of R.A. synovial microsomes (2.0ml) exactly 
as used for incubation studies (section 2.4), the mixture acidified 
with 2M citric acid (0.25ml) and extracted with three portions of 
diethyl ether (3.0ml each). Each separate ether extract was 
evaporated to dryness in a counting vial, methanol (1.0ml) then 
liquid scintillant (7.0ml) added and the amount of activity present 
determined by liquid scintillation counting, from which percentage 
recoveries were calculated (Table 2.1).
Table 2.1 Percentage recoveries of authentic ^^C-arachidonic 






extraction ::: --3 86:1 86.4
2nd ether 
extraction ::: =•> 1:3 6.3 ::: 30.7
3rd ether 
extraction 0.1 0-9 i:i 3.1
As can be seen, all three compounds are readily extracted
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from the incubation mixture by diethylether, two extractions being 
sufficient to extract greater than 97% of each of the three compounds, 
As would be expected the least polar compound (arachidonic acid) is 
extracted with slightly greater efficiency than the other two, and 
vice versa for PGF2®=.
The experiment was repeated, except this time the combined 
ether extracts were evaporated to dryness under nitrogen in small 
conical tubes, and the residues assayed for radioactively labelled 
arachidonic acid, PGE2 and PGF2= exactly as for a normal incubate 
(section 2.5). Overall recoveries for the entire procedure for 
arachidonic acid, PGE2 and PGF2= were 92.1%, 90.7% and 88.6% 
respectively. This was considered to be satisfactory both in terms 
of absolute recovery of each compound, and of comparative recoveries 
for the three compounds, permitting calculations of prostaglandin 
synthetase activity to be made on the basis of the percentage conver­
sion of the substrate to prostaglandins.
(ii) Chromatography
An inspection of the solvent systems available for thin 
layer chromatography of prostaglandins (Green and Samuelsson, 1964) 
showed that the AI system (benzene-dioxan-acetic acid, 20:20:1) 
should give a good separation of arachidonic acid and the anticipated 
products PGE2 and PGF2=. Silver nitrate (2.5%) was included in the 
plates as this was found to give a larger separation between the two 
prostaglandins than when silica gel alone was used. It was also 
found that an unlagged, unequilibrated tank gave a much better 
separation than if the system was equilibrated, as is the usual 











The running time for the system was about hours, though 
this was somewhat temperature-dependant and could be as long as 
3 hours when the room temperature was low. The solvent itself is 
stable and can be re-used many times without any adverse effects on 
either the separation or the chemical stability of the extracts.
(iii) Liquid scintillation counting
Quench corrections were made with the use of a channels-ratio 
method, owing to the heterogeneous nature of the samples to be 
counted. A series of standard vials were prepared using hexadecane-1 
(5,170d.p.m.), silica gel (scraped from an area 2.0cm x 1.5cm 
of a 0.25mm thick plate), methanol (1.0ml), toluene scintillant 
(7.0ml) and varying amounts of carbon tetrachloride (0-150yl) as the 
quenching agent. With one channel of the counter set for balance 
point counting, a second channel's attentuation was varied and the 
counts for each sample determined simultaneously in both channels.
The ratio of the count in each channel was plotted against the 
efficiency of counting in the channel set for balance point counting. 
The attenuation setting was selected which gave the nearest to 
a straight line calibration, and the parameters of this line set on
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the computer calculator boards of the instrument. Typical efficiencies 
found for incubate extracts were in the range 85-91%.
(iv) Precision of the assay
During these initial experiments all assays were carried out 
in duplicate in order to obtain a measure of the precision of the 
method. The index of precision, (s), for duplicate determinations 
was calculated from the formula :-
Æ 5 ,
V  2ns = V  
where d is the difference between duplicates and n the number of 
duplicates.
For prostaglandin synthetase activities in the range 
146 - 395 pmol/mg/hr. it was 19 pmol/mg/hr., (n = 17) , a surprisingly 
good value in view of the relative complexity of the method. In 
many of the later studies (especially the druj inhibition dose- 
response curves) duplicate assays could not be performed owing to 
shortage of the microsomal enzyme preparation, though from the 
figures above a reasonable estimate of the error on a single 
determination would be 5-10%.
(v) Supernatant 'inhibition'
Previous studies in this laboratory (Rose, 1975) had 
demonstrated an apparent pH-dependent inhibition of prostaglandin 
synthesis when the high-speed supernatant fraction of rabbit renal 
medulla was added back to the microsomal fraction derived from 
this tissue. In view of the subsequent failure to demonstrate 
any PG synthetase activity in a cell-free homogenate of human R.A. 
synovium in the above studies, this phenomenon was briefly re­
investigated in order to determine whether a cell-free homogenate 
of R.A. synovium would be a suitable preparation to use.
70
To microsomal preparations from bovine seminal vesicles and 
rabbit renal medullae (section 2.3) was added the high-speed super­
natant fraction from rabbit renal medullae (2.8 mg protein/ml) and 
the mixtures incubated with ^^C-arachidonic acid over a pH range. 
Control incubations were also made over the same pH range, but with 
the addition of O.IM tris-acetate buffer, pH 8.0 instead of the 
rabbit medulla supernatant fraction. The results (Fig 2.1) show 
that the supernatant fraction produces a significant inhibition of 
prostaglandin synthetase from both bovine seminal vesicles and 
rabbit renal medullae, and that the maximum inhibition, in absolute 
terms, is produced at pH 8.0 in both preparations as shown by the 
'difference' curves obtained by subtracting the 'inhibited' value 
from the supernatant-free value at each pH. It is of interest to 
note that phospholipase from rat liver has a pH optimum at pH
8.0 (Bj^rnstad, 1966) and pancreatic phospholipase A 2 has a pH 
optimum in the region 7.9 - 8.4 (de Haas and others, 1968).
A possible explanation of these results is that phospholipase 
A 2 present in the supernatant fraction releases arachidonic acid 
(or other polyunsaturated fatty acids) from phospholipids and that 
this non-radioactive substrate effectively dilutes the radioactive 
substrate, producing an apparent inhibition of PG synthesis, as only 
the labelled fraction of the product is measured; this could 
presumably be verified by measuring the 'total' i.e. labelled plus 
unlabelled, PG produced over the pH range using bioassay or radio­
immunoassay. Although not pursued further these results showed that 
a cell-free homogenate is not a suitable tissue preparation of the 
enzyme to use in conjunction with the radiometric assay technique and 
that the proposed studies of R.A. synovial PG synthetase should be 
carried out using a microsomal preparation.
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Fig. 2.1 The effect of rabbit renal medulla supernatant
on PG synthesis by rabbit renal medulla microsomes 
and bovine seminal vesicle microsomes
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ddition of rabbit renal medulla high-speed supernatant (2.8 mg protein/ml) 
to either rabbit renal medulla microsomes (0 .5ml supernatant added per 
incubation) or bovine seminal vesicles (0.1 ml added) over a pH range 
produced curves ( B ) having maxima at pH 9.0. Subtraction from 
control incubations ( ©  Q  ) containing no supernatant gave curves




BIOCHEMICAL STUDIES OF 
RHEUMATOID SYNOVIAL PG SYT'ITHETASE
73
3.1 Introduction
Much evidence now exists which suggests that prostaglandins 
have an important role as mediators or modulators of many aspects of 
the inflammatory process. Their ability to initiate or augment all 
the cardinal signs of inflammation together with their seemingly 
inevitable presence at any site of tissue injury is readily demon­
strated in many types of acute inflammation, though their role in the 
transition from such acute states to the type of chronic, degenerative 
inflammation typified by rheumatoid arthritis is less obvious. The 
possible influence of prostaglandins on fundamental aspects of the 
pathogenesis of chronic inflammatory disease such as granuloma 
formation, cartilage metabolism and bone resorption is clearly of 
great interest, though further work will be necesary to relate these 
initial in vitro findings to the situation in vivo.
Aspirin-like drugs form the backbone of antirheumatic therapy, 
and it was therefore of great interest to pharmacologists and clinicians 
alike when Vane (1971) proposed that this group of drugs exert their 
pharmacological effects by inhibiting prostaglandin biosynthesis.
This hypothesis acted as a great stimulus for further research into 
the interaction between aspirin-like drugs and prostaglandin bio­
synthesis, and many reports of both in vivo and in vitro studies 
soon substantiated the initial findings. As emphasised by Whitehouse 
(1965) there are great advantages in employing an in vitro technique 
as a screen for anti-inflammatory activity, and it soon became 
de rigeuerto test potential new anti-inflammatory drugs for their 
ability to inhibit prostaglandin biosynthesis in vitro. Such studies 
have invariably been carried out using the enzyme derived from ovine 
or bovine serainial vesicular glands as these (microsomal) preparations 
are convenient to use in lyophilised form and are highly active.
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Systematic studies of existing aspirin-like drugs have been carried 
out using such assay systems (Ham and others, 1972; Tomlinson and 
others, 1972) and the correlation found between in vitro enzyme 
inhibition and known in vivo therapeutic activity cited as evidence 
in support of Vane's hypothesis. However, as discussed in section 
1.11 an integral part of the hypothesis is that prostaglandin 
synthetase exists within an organism in multiple forms or isoenzymes, 
each having its own characteristic biochemical parameters and 
possessing a distinct pharmacological 'profile' with respect to 
inhibition by the aspirin-like drugs.
The inescapable conclusion to be drawn from this hypothesis 
is that if meaningful results are to be obtained from studies of the 
interaction between aspirin-like drugs and prostaglandin synthetase, 
the enzyme used must be derived from human tissue involved in the 
inflammatory reaction ("target" tissue). If such tissue is not 
readily available then at the very least it should be shown that the 
enzyme prepared from human inflammatory tissue does not differ 
radically in any respect from the well-studied animal preparations 
commonly used. When this study was initiated no such reports existed 
in the literature and this, in essence, forms the basis of the work 
presented in this chapter,
3.2 Metabolism of arachidonic acid by R.A. synovial microsomes
A microsomal fraction was prepared from human R.A. synovial 
tissue as described in section 2.3, incubated with ^^C-arachidonic 
acid and an ether extract of the acidified incubate separated by thin- 
layer chromatography (sections 2.4 and 2.5). Fig. 3.1 shows the scan 
obtained when 0.5 cm bands were scraped from the plate and the 
radioactivity in each band measured using liquid scintillation
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Chromatographic separation of an incubation of R.A. synovial 
microsomes with 1 4
to an identical incubate, 
below the scans.
C-arachidonic acid. The formation of ^"'C-PGEz
n (10“
Positions of authentic markers are shown
and ^^C-PGF2^ was abolished by the addition of indomethaci  ^M)
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counting. As can be seen the microsomal fraction from Human R.A. 
synovial tissue is capable of producing significant metabolism of 
added ^C-arachidonic acid; on the basis of their chromatographic 
mobilities the two products were tentatively identified as PGE2 
and PGF^ocf constituting 21.0% and 1.4% respectively of the total 
radioactivity on the plate. The combined radioactivity from the 
areas of the plate corresponding to authentic PGE2 , PGF2“ and 
arachidonic acid made up 95% of the total activity present and no 
other radioactive peaks were detected. When an identical 
incubate, to which had been added indomethacin (10 ^M), was 
assayed for arachidonic acid metabolism, the radioactive peaks 
seen in the first incubation were abolished, showing that the peaks 
produced during the incubation were unlikely to be chemical arte­
facts caused by auto-oxidation of the substrate. Furthermore as 
other enzyme systems likely to metabolise arachidonic acid (e.g. 
lipoxygenases) are not inhibited by indomethacin at this concen­
tration this provided further tentative evidence that the radio­
active peaks seen were products of the cyclo-oxygenase (i.e. 
prostaglandin-producing) system.
3.3 Chemical conversion of PGE 2
Further evidence for the identification of the major product 
of arachidonic acid metabolism as PGE 2 was sought by chemical 
conversion of the product to other prostaglandins, followed by 
chromatographic identification, as described in section 2.6. Treat­
ment of formed ’ ^ t-PGE 2 with sodium hydroxide followed by further 
chromatography showed that 83% of the original activity was now 
coincident with a standard PGB2 marker (Fig. 3.2). Similarly 
treatment with sodium borohydride gave two peaks which were
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Fig. 3.2 Chemical conversion of formed ^**C-PGE2





















^**C-PGE2 formed from the incubation of R.A. synovial microsomes with 
^^C-arachidonic acid was isolated by thin-layer chromatography and 
treated with either sodium borohydride or sodium hydroxide. Re­
chromatography of the extract showed conversion to an equal mixture 
of PGF2^ and PGF20 upon borohydride treatment (upper scan), and 
conversion to PGB2 with sodium hydroxide (lower scan).
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coincident with standard PGF^oc and PGF23/ containing 39% and 37% of 
the original activity respectively (figures not corrected for 
procedural losses). No other significant peaks of radioactivity 
were found in either extract and no material remained, running in 
the position of PGEg , which was resistant to chemical conversion. 
Both of these chemical conversions are characteristic of PGEg 
and it is highly unlikely that any compound other than PGE2 would 
behave in this manner upon treatment with sodium hydroxide or sodium 
borohydride. Further identification might have been achieved by 
measuring the increase in optical density at 278nm when a solution 
of PGE is treated with sodium hydroxide, though the sensitivity of 
this assay would probably not be adequate (A 20% conversion of the 
 ^ C-arachidonic acid substrate produces ca. lOOng I'^C-PGE^).
3.4 Bioassay of extracts after T.L.C.
Further confirmation of the identities of the products of 
arachidonic acid metabolism was sought by subjecting the ether 
extract of an incubate of R.A. synovial microsomes and arachidonic 
acid to thin-layer chromatography, followed by bioassay of 1 cm 
band eluates from the plate, as described in section 2.6 ,
When fifteen 1 cm band eluates were each bioassayed for 
their prostaglandin content a single major peak of activity was 
found (Fig. 3.3) which corresponded to the radioactive peak desig­
nated PGE2 , and was coincident with authentic PGE2 run in parallel 
Calculation showed that the amount of PGEg present as measured by 
bioassay was in reasonably good agreement with that found from 
the radioactivity present, no attempt being made to correct for 
procedural losses, A small amount of activity was seen in the 
PGFg^ region and this would presumably have been more readily
79
Fig. 3.3 Bioassay of an extract of R.A. synovial
microsomes incubated with  ^^ C-arachidonic 






















1 cm. bands from the thin-layer separation of an extract of R.A. 
synovial microsomes, incubated with ^^C-arachidonic acid, were 
eluted and subjected to bioassay on a superfused rat stomach strip.
The major peak of biological activity (O  O ) corresponded to the
peak of radioactivity running in the position of authentic PGE2, 
shown below the scan.
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and selectively detected on the rat colon strip preparation.
Final confirmation of the identities of the products of 
arachidonic acid metabolism would depend upon identification by 
combined gas chromatography - mass spectrometry but facilities 
were not available to attempt this. However combined chromatographic, 
chemical and bioassay results strongly support the original tentative 
designations of the products as PGE2 and PGF2«.
3.5 Location of PG synthetase activity
The relative amounts of PG synthetase activity present in 
the microsomal and high-speed supernatant fractions of R.A. synovial 
tissue are shown in Fig. 3.4 and confirm that, as found in other 
tissues studied, the activity resides in the microsomal fraction.
No activity was present in the supernatant fraction as the tiny 
amount of activity present can also be demonstrated in a prepara­
tion of boiled microsomes. This residual 'blank' value (usually 
representing less than 1% substrate conversion) is probably caused 
by very slight streaking of the arachidonic acid region on the 
TLC plate and was subtracted from all subsequent values, a boiled 
control being assayed in each experiment for this purpose.
As found in the preliminary studies (section 2.8), using 
rabbit renal medulla and bovine seminal vesicle preparations, the 
PG synthetase activity of R.A. synovial microsomes was 'inhibited' 
when the high-speed supernatant fraction of the homogenate was 
added back to the active microsomal fraction.
It is well known that high-speed supernatant fractions from 
many tissues contain prostaglandin metabolising enzymes, such as 
15-hydroxyprostaglandin dehydrogenase, which could explain this
Fig. 3.4 Conversion of ^^C-arachidonic acid to ^"^C-PGEz













Microsomal supernatant, 1.0 ml (5.2 mg protein) 
Boiled microsomes 1.0 ml (1,8 mg protein) 
Microsomes, 1.0 ml (1.8 mg protein).
Microsomes, 1.0 ml with added supernatant (1.0 ml).
I I PGE; PGF2<
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finding. However no chromatographic evidence for the production of 
such metabolites was found in any incubation which contained an 
aliquot of the supernatant fraction and the author remains convinced 
that the phenomenon is due to liberation of unlabelled substrate by 
phospholipase activity present in the supernatant. Attempts were 
made to confirm this explanation by the use of mepacrine, a known 
phospholipase inhibitor,but these were unsuccessful as at the concen- 
trations necessary to inhibit phospholipase activity (3 x 10 M) , 
mepacrine also largely abolishes prostaglandin synthetase activity; 
perhaps a more 'selective' inhibitor could have resolved the issue.
Clearly it is desirable to use the microsomal fraction of 
the tissue as the source of PG synthetase and the findings explain the 
failure of attempts to demonstrate PG synthetase activity in a cell- 
free homogenate of rheumatoid synovial tissue.
3.6 PG metabolising activity
The possibility that the microsomal fraction might contain 
prostaglandin metabolising activity was investigated by adding 
^H-PGE^ and ^H-PGF^a: as substrate, in place of ^'*C-arachidonic acid, 
to separate microsomal incubates. These were then taken through 
exactly the same incubation, extraction and incubation procedures 
as for the arachidonate incubates. Chromatography showed that 94% 
and 97% of the radioactivity present corresponded to authentic 
PGE^ and PGFg cc respectively; no other peaks of radioactivity were 
detected through likely metabolites (15-oxo or 13,14-dihydro-15-oxo) 
would have been readily detected in the chromatographic system used. 
This suggests that under the incubation conditions described the 
microsomal preparation from R.A. synovial tissue contains no 
prostaglandin metabolising activity. It is necessary to demonstrate
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this lack of metabolising activity as the aspirin-like drugs are known 
to inhibit 15-hydroxyprostaglandin dehydrogenase (Hansen, 1972); 
erroneous results would be obtained if the effect of aspirin-like 
drugs was studied in a system in which both PG synthetase and PG 
metabolising activity v;as present.
3.7 Level of PG synthetase in R.A. synovial microsomes
There is no internationally agreed unit for prostaglandin 
synthetase activity so that it is difficult to report absolute 
levels of the enzyme present in a tissue or tissue preparation. As 
shown by Christ and van Dorp (1972) the level of PG synthetase 
activity varies considerably between different tissues; when incu­
bated with all-cis-8 ,11,14-eicosatrienoic acid most tissue homogen- 
ates produced only a low yield of PGE^ (at most only a few percent 
conversion of substrate) though moderate yields (5-10%) were found 
for homogenates of lung and renal medullary tissue and high yields 
( > 20%) only for sheep vesicular glands, rabbit renal medulla and 
the urinary bladder of the frog.
Fig. 3.5A shows the comparative production of prostaglandins 
by microsomal preparations of rabbit renal medulla and R.A. synovial 
microsomes, assayed under identical conditions. Using the above 
criteria it must be concluded that R.A. synovial tissue is a good 
source of prostaglandin synthetase.
Fig. 3.5B shows that under identical incubation conditions 
microsomal preparations from rabbit renal medulla, R.A. synovia and 
bovine seminal vesicles produce different ratios of PGE2 to 
PGF20C , the values being ca. 3:1, 10:1 and 20:1 respectively. The 
predominance of PGE2 production over PGF2°c in all three preparations
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Fig, 3,5 Production of prostaglandins by human rheumatoid 
synovial (HRS) and rabbit renal medulla (RRM) 
microsomes, and relative proportions of ^^C-PGEa 
and i^C-PGF;= produced by HRS, RRM and bovine 













RRM HRS RRM HRS BSV
(A) (B)
(A) PGE2 [  I and PGF2# were formed by incubation
of microsomes in 0.25M sucrose/0.IM tris-acetate, at pH 8.0 
with C-arachidonic acid (lOOnCi) for 1 hr. at 37°c. Mean 
amounts of PG's produced are shown with the standard error of 
the mean for each (RRM : 3 preparations; HRS : 8 preparations)
formed(B) Relative proportions of PGE2 CZl and PGF2= 2
by rabbit renal medulla (RRM), human rheumatoid synovial (HRS) 
and bovine seminal vesicle (BSV) microsomes under identical 
incubation conditions. Production of PGE2 was taken as 100% 
for each preparation.
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is expected as the presence of reduced glutathione in the incubation 
mixture is known to favour PGE2 production at the expense of PGF2“ 
(Lands, Lee and Smith, 1971).
Throughout these studies yields of PGF/^ from R.A. synovial 
microsomes were generally low (<2% substrate conversion) under the 
incubation conditions employed and most of the values of PG synthetase 
activity presented have been calculated on the basis of PGE2 product­
ion. However in a few very active preparations the yields of PGF2® 
were somewhat greater (2-5% substrate conversion) and in these 
experiments reliable and accurate figures could be obtained for the 
production (and often inhibition by drugs) of both PGE2 and PGF2®.
In such cases good agreement was obtained between results calculated 
on the basis of either PGE2 or PGF2= production,
3.8 pH profiles
The pH at which an enzyme exhibits its optimum activity is a 
fundamental property of that enzyme. In view of the hypothesis 
discussed earlier that PG synthetase may exist as isoenzymes within 
different tissues it was of interest to compare the pH profile of 
the enzyme from R.A. synovium with that of rabbit renal medulla and 
bovine seminal vesicle. When incubations were carried out over the 
pH range 7.0 - 9.5 all three preparations produced a similar profile 
(Fig. 3.6) with pH optima in the region 8.0 - 8.5; it was not possible 
to distinguish between the three preparations on the basis of their 
pH profiles, through perhaps one might not expect isoenzymes to have 
markedly different pH optima.
3.9 Cofactor requirements
Although PG synthetase activity is found in the microsomal
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7.0 7.5 8.0 8.5
pH OF INCUBATION
9.0 9.5
Production of ^'^C-PGE2 from ^^C-arachidonic acid (100 nCi/ 
incubation) by human rheumatoid synovium (O  — O  ) , rabbit
renal medulla ( @ ----©) and bovine seminal vesicle ( B ■ )
microsomes over a pH range. Incubations were carried out in
0.25M sucrose/0.IM tris-acetate buffer for 1 hr. at 37°c in 
a volume of 2.0 ml.
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fraction of cells, heat-stable cofactors from the cytoplasmic fraction 
are necessary for appreciable activity to be demonstrated in vitro. 
Reduced glutathione (GSH) has been found to act as a suitable cofactor, 
together with a phenolic compound such as adrenaline or hydroquinone 
(HQ). In addition ethylenediamine tetracetic acid (EDTA) is often 
included in incubations, both to remove metal ions which might have 
an inhibitory effect on the enzyme (Nugteren, Beerthuis and van Dorp, 
1966) and also to inhibit any phospholipase activity which might 
give spurious results due to liberation of endogenous substrate(s), 
phospholipase being a calcium-dependant enzyme. The optimum concen­
trations of these three compounds to produce maximum PG synthetase 
activity were therefore investigated, the results being shown in 
Fig. 3.7. GSH and HQ both enhance PG synthesis at the lower concen­
trations studied, optimal values being 2mM and O.SmM respectively. 
Concentrations higher than these produce no further stimulation of 
enz^nne activity and may in fact be inhibitory to the enzyme. The 
addition of ImM EDTA enhances enzyme activity by approximately 50%, 
though higher concentrations are markedly inhibitory. As can be 
seen from Fig. 3.7 production of PGF2= tended to parallel production 
of PGE2 and there was no evidence that either GSH or HQ could enhance 
production of one prostaglandin at the expense of the other.
3.10 Kinetic studies
The time course of PG production was investigated in order 
to determine an optimum incubation time for the enzyme and also to 
measure the time over which the formation of products was linear. 
Incubations of R.A. synovial microsomes with  ^**C-arichidonic acid 
were carried out as described in section 2.4 and the reaction termin­
ated at various times by the addition of 2M citric acid solution 
(0.25ml). The amounts of PG's produced in each sample were then
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Fig. 3,7 Time course of PG production by R.A. synovial






































0.5 1.0 2.0 3.0O
GSH (mM) HQ (mM)
A. R.A. synovial microsomes were incubated with 
for varying times and the amounts of PGE2 ( ^  
( B  B ) measured as described in the text.
C-arachidonic acid
 A  ) and PGF2=
PG production was
linearly related to time for the first 30 minutes of the incubation,
B. C. and D,
Varying the co-factor concentrations showed the optimum enzyme 
activity was found with ImM EDTA, 2mM GSH and 0.5mM HQ.
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determined as described (section 2.5). The results (Fig. 3.7a) show 
that production of both PGE2 and PGF2= is linear with respect to 
time for the first 30 minutes of the incubation, the initial rates 
being 35pmol/mg/min and 4.4pmol/mg/min respectively in the prepara­
tion shown. A further increase in PG production occurs over the 
next 30 minutes through this is no longer linearly related to the 
time of incubation, representing an additional 21% production over 
the 30 minute value. For determination of the Michaelis constant 
(Km), described below, an incubation time of 30 minutes was therefore 
chosen, though one hour was used in all other experiments.
Another fundamental property of an enzyme is its Km value,
i.e. the substrate concentration producing half maximum velocity.
This was determined for R.A. synovial PG synthetase by varying the 
substrate concentration over the range 0.4-40yM. As the amount of 
 ^^ C-arachidonic acid needed to achieve this concentration would have 
been excessive the amount of labelled arachidonic acid in each 
incubation was kept constant (100 nCi) and the total concentration 
desired achieved by the addition of unlabelled arachidonic acid; 
multiplication of the percentage conversion of the labelled substrate 
to PGE2 by the total' substrate concentration in each incubation 
gave the velocity of the reaction at each substrate concentration.
When this was done the enzyme exhibited typical saturation 
kinetics and the results are shown in Fig. 3.8. In the upper plot 
the results are in the form of a 'direct linear plot' (Eisenthal 
and Cornish-Bowden, 1974) and yield values for the Km of 12yM and 
llyM, calculated on the basis of PGE2 and PGF2= production respectively. 
This finding is in agreement v/ith the generally accepted belief that 
synthesis of PGE2 and PGF2= proceeds via a common intermediate 
(Samuelsson, 1972).
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Fig. 3.8 Effect of varying substrate concentration 














PG production by R.A. synovial microsomes was measured 
at substrate concentration from 0.4-40yM. The results 
are presented as a direct linear plot (Eisenthal and 
Cornish-Bowden, 1974) and as a conventional double­




In the lower plot of Fig. 3.8 the results of varying the 
substrate concentration are shown as a conventional double-reciprocal 
(Lineweaver-Burke) plot; as can be seen the lines obtained for PGE2 
and PGF2= production have a common intercept on the -x axis, yielding 
a Km of 12.5yM.
3.11 ■ Discussion
Prostaglandin synthetase activity has been found in virtually 
every mammalian tissue studied, as well as in tissues from other 
vertebrate and invertebrate species (Christ and van Dorp, 1972). 
Numerous experiments using tissue homogenates, isolated organs or 
whole animals have confirmed that prostaglandin synthetase may indeed 
be considered a ubiquitous enzyme (see Flower, 1974). Using tissue 
culture techniques it has been conclusively shown (Levine, 1973; 
Robinson and McGuire, 1975) that fragments of R.A. synovium are capa­
ble of significant production of prostaglandins in vitro. Further­
more, human R.A. synovial fluid contains readily measured amounts of 
prostaglandins, and the levels are several-fold higher than those 
found in normal fluids (Levine 1973; Higgs and others, 1974),
In view of the above results it is perhaps not surprising 
therefore to find that R.A. synovium is capable of prostaglandin 
biosynthesis in vitro. As in all other tissues studied, the enzyme 
activity is associated with the high-speed particulate , 'microsomal', 
fraction. The term 'microsomal fraction' however tells us nothing 
about the cellular location of the enzyme, and the use of such a term 
has been criticised (De Duve, 1971). No attempt was made in the 
present work to fractionate the crude microsomal preparation in order 
to locate the site of PG biosynthesis within the cell, though this 
has been achieved by others (Bohman and Larsson, 1975) studying
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membrane fractions from rabbit renal medulla. Using sucrose gradients 
3 membrane fractions were isolated from a 'microsomal' preparation, 
and the subcellular origin of the membranes determined by electron 
microscopy and marker enzyme content; PG synthetase activity was also 
measured in each fraction using a radiometric technique similar to 
that used in the present work. Fraction II, the cytomembrane 
fraction, (consisting of closed vesicles of both smooth-surfaced and 
ribosome-studded membranes) contained the majority of the PG synthetase 
activity, though some activity was detectable in fraction I (a plasma 
membrane fraction) and fraction III (mitochondrial fraction). The 
authors concluded that PG synthetase is located in the endoplasmic 
reticulum of renal medullary cells.
Having demonstrated that R.A. synovial microsomes were capable 
of producing significant metabolism of added  ^^ C-afachidonic acid it 
was essential to characterise the products before proceeding with 
further studies as enzyme systems other than PG synthetase are able 
to metabolise polyunsaturated fatty acids (e.g. lipoxygenases) and 
identification of products on the basis of mobilities in a single 
solvent system, when compared with authentic marker compounds, would 
be most unsafe. The combined use of three different chromatographic 
solvent systems, chemical conversions of the principal product to 
other products followed by further chromatography, and bioassay of 
TLC eluates demonstrated beyond reasonable doubt that the original 
tentative identifications of the products of arachidonic acid 
metabolism as PGE2 and PGF2^ were justified. Absolute confirmation 
would require the use of combined GC/MS facilities and these were 
not available to the author. However PGE2 and PGF^* are designated 
as such throughout this work on the basis of the above criteria 
in order to avoid the use of the cumbersome *PGE2-like' etc.
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When the high-speed supernatant of a homogenate of R.A. synovium 
was addëd back to an active microsomal fraction, an inhibition of the con­
version of ^^C-arachidonic acid to ^^C-PGE^ and ^^C-PGF2= was seen, con­
firming the preliminary studies with rabbit renal medulla and bovine seminal
vesicles reported in section 2.8U If this phenomenon was due to the
presence of a natural inhibitor of PG biosynthesis in the cyto­
plasmic fraction of the cell this would be of considerable importance, 
to an understanding of the cellular control of PG synthesis and would 
certainly warrant further study. However results from other studies 
suggest that this is unlikely to be the case; Pace-Asciak and Wolfe 
(1970) studying prostaglandin synthesis in rat stomach homogenates 
found that a considerable dilution of the added substrate by 
endogenous arachidonic acid took place during incubation and that 
prostaglandins were formed from both substrates. Had these authors 
measured only the tritium-labelled products without taking into 
account unlabelled products formed from endogenous precursor they 
would certainly have observed an apparent 'inhibition' of PG 
synthesis in a cell-free homogenate when compared with a microsomal 
fraction from the same preparation.
Results obtained by Samuelsson (1970) lend further support 
to these findings; when a microsomal fraction of sheep vesicular 
gland was incubated with a labelled phospholipid (containing 
^^C-dihomo-y-linolenic acid in the 2-position), ^^C-PGE} was produced 
in only trace amounts. Addition of a high-speed supernatant fraction 
from rat liver, however, resulted in the production of large amounts 
of ^^C-PGEi, showing that the supernatant fraction contained phos- 
pholipase activity capable of liberating polyunsaturated fatty acid(s) 
from phospholipid. As phospholipids are ubiquitous components of such 
sub-cellular fractions it is not unreasonable to suppose that any
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high-speed supernatant is capable of liberating prostaglandin precur­
sor (s) from phospholipid.
Since calcium ions are necessary for optimum phospholipase A 
activity (Newkirk and Waite, 1971) the inclusion of EDTA in the buffer 
used in the present studies might be expected to reduce, if not abolish 
this activity; perhaps at the concentration used (ImM) some residual 
phospholipase activity remains,sufficient to produce the effects 
described above. It is of interest to note that the pH optimum for 
PG synthesis at which the incubations were carried out (pH 8.0) is also 
the optimum for phospholipase A 2 activity (Bj^rnstad, 1966; de Haas 
and others, 1968). As shown in section 3.9, higher concentrations of 
EDTA markedly inhibited PG synthetase activity.
Confirmation that this 'inhibitory' effect of the cytoplasmic 
fraction of R.A. synovial tissue was due to release of endogenous 
substrate(s) was sought with the use of mepacrine, a known phospholi­
pase inhibitor (Kunze and Vogt, 1971); however at the concentration 
used (3 X 10 ^M) prostaglandin biosynthesis was virtually abolished 
and the values obtained were too low for accurate quantitation. A 
more specific phospholipase inhibitor would possibly have provided 
the answer.
The finding that R.A. synovial microsomes exhibit no prosta­
glandin-metabolising activity under the standard incubation conditions 
used was not surprising, as these metabolising enzymes have been 
shown in many other tissues to be located in the cytoplasmic fraction 
and to be NAD dependent. (Anggard and Samuelsson, 1966). Neverthe­
less it was necessary to demonstrate this lack of PG metabolism under 
the chosen incubation conditions as the later studies of the inhibition 
of PG synthesis by aspirin-like drugs could have led to erroneous results
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in the presence of PG metabolising activity, as some aspirin-like 
drugs are known to inhibit 15-hydroxyprostaglandin dehydrogenase 
(Hansen, 1972).
When assayed under identical conditions the microsomal frac­
tions from R.A. synovial tissue and rabbit renal medullae were 
found to contain similar levels of PG synthetase activity. As rabbit 
renal medulla is considered to be a good source of PG synthetase 
(Christ and Van Dorp, 1972), R.A. synovium must also be regarded as a 
tissue containing appreciable activity. Perhaps in the future an 
international unit' of PG synthetase activity will be defined in order 
to facilitate more objective comparisons between different tissues 
or between the findings of different workers.
When incubated over a pH range PG synthetase prepared from 
R.A. synovium was found to exhibit optimum activity at pH 8.0. Most 
other tissues studied have been found to exhibit optimum PG synthetase 
activity at pH 8.0-8.2, though the enzyme from rabbit renal medulla 
has been reported to be maximally active at pH 7.5 (Rose and Collins, 
1974; Blackwell, Flower and Vane, 1975). The latter authors also 
reported that the enzyme was very sensitive to small changes in pH, 
a pH change of only 0.2 from the optimum resulting in a decrease in 
product formation of 45-55%. This degree of sensitivity was not 
observed in the present work in any of the preparations studied and 
is possibly a reflection of the substrate concentrations used. In 
the present work a low (lyM), 'physiological' substrate concentration 
was used whereas in the work described above a concentration of 2mM 
was employed. At these extremely high substrate levels minor 
products of arachidonic acid metabolism in vitro may be exerting pH- 
dependent inhibitory effects on the enzyme which would be quite 
insignificant in vivo. Speculation that the high sensitivity of the
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kidney enzyme to changes in pH has a physiological significance must 
therefore be viewed with some scepticism.
Other studies of PG synthetase from rabbit renal medulla 
are at variance with the results of Blackwell, Flower and Vane (1975); 
using a substrate concentration of 60yM, Tai, Tai and Hollander (1976) 
found that the enzyme exhibited a virtually flat pH profile from pH 7.0 
to pH 8.5 similar to that reported in the present work. Similarly 
Schwartzman, Gafni and Raz (1976) reported a broad pH profile for 
both a homogenate and a microsomal preparation with optimum activity 
at pH 8.4, using a low (3.3yM) substrate concentration.
The cofactor requirements of bovine seminal vesicle PG 
synthetase are well documented (Yoshimoto, Ito and Tomita, 1970; Lands, 
Lee and Smith, 1971; Tomlinson and others, 1972). Reported optimum 
concentrations were in the range 1.0-2.OmM for GSH and 0.2-0.5mM for 
HQ. In the present work the optimum requirement of PG synthetase, 
prepared from R.A. synovium, for GSH and HQ was found to be 2mM and 
0.5mM respectively, in good agreement with the above. Similar findings 
have been reported for the enzyme prepared from rabbit renal medulla 
(Tai, Tai and Hollander, 1976), sheep seminal vesicular gland 
(Wallach and Daniels, 1971), rat skin (Kingston and Greaves, 1976), 
human skin (Ziboh, 1973) and even the reproductive tract of the male 
house cricket (Destbphano, Brady and Woodall, 1976).
In the present studies the inclusion of EDTA (ImM) in the 
incubation buffer was found to stimulate PG synthesis though higher 
concentrations were markedly inhibitory. Ziboh (1973) has shown 
that EDTA enhances PG synthesis by human skin subcellular fractions 
and suggested that this may be due, in part at least, to chelation 
of heavy metal ions known to be inhibitory to the enzyme (Nugteren,
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Beerthuis and van Dorp, 1966; Deby, Bacq and Simon, 1973). Hamberg 
(1969) has recommended the inclusion of EDTA at a concentration of 
20mM in incubations involving whole tissue extracts. Such a concen­
tration, using the microsomal preparations used in the present work, 
is markedly inhibitory (Fig. 3.7); as discussed previously part of 
the apparent stimulatory effect may be due to inhibition of endogen­
ous phospholipase activity.
When the time course of prostaglandin production by R.A. 
synovial microsomes was studied, synthesis was found to proceed 
linearly for the first 30 minutes of the incubation but to decrease 
proportionally thereafter. Values in the literature for the time 
at which PG production ceases to be linearly related to the time of 
incubation vary greatly, and probably reflect the very different con­
ditions, particularly the substrate concentrations used, under which 
the various experiments have been carried out. Using bovine seminal 
vesicle microsomes, Yoshimoto, Ito and Tomita (1970) found that 
synthesis proceeded linearly only for the first 90 seconds of incu­
bation, whereas Kingston and Greaves (1976), using rat skin micro­
somes, found PG production to be directly proportional to the time 
of incubation for the first 20 minutes. As discussed by Wallach and 
Daniels (1971), who reported a time of 6 minutes for sheep seminal 
vesicle microsomes, the enzyme may be inhibited by one or more 
products of the reaction and the effect is markedly substrate dependent; 
removal of the enzyme from the incubation mixture by centrifugation, 
followed by addition of fresh substrate, allowed the reaction to 
proceed at its original rate, showing that the postulated inhibitor 
produced a competitive inhibition of the enzyme rather than a 
destruction of the catalytic site.
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Incubation of R.A. synovial microsomes with varying concen­
trations of arachidonic acid over the range 0.4-40]iM showed that 
PG synthetase exhibited typical Michaelis-Menten kinetics; the use 
of either a direct linear plot or a conventional double-reciprocal 
plot gave a Km value of approximately 12yM, calculated on the basis 
of either PGE2 or PGF2= formation. The finding that the Km value is 
the same when calculated on the basis of either product of arachidonic 
acid metabolism is consistent with the belief that synthesis of 
PGE2 and PGF2= proceeds via the common intermediate, PGH2 (Samuelsson,
1972) .
Reported values in the literature for the Km's of various 
PG synthetase preparations vary greatly and large discrepancies exist 
between the values obtained using the same tissue for the preparation 
of the enzyme. Thus, whilst values of 8.3yM and lOyM have been 
reported for the Km of rabbit renal medulla PG synthetase (Tai, Tai 
and Hollander, 1976; Schwartzman, Grafni and Raz, 1976), Blackwell, 
Flower and Vane (1975) reported an optimum substrate concentration 
for the same enzyme of 2mM, implying a Km of approximately ImM. In 
view of such large variations in reported values it is clear that 
comparisons between different tissues studied in different labora­
tories are dubious and unlikely to yield meaningful results unless 
the conditions employed are standardised.
In most tissues the levels of free polyunsaturated fatty acids 
are very low, typically 10-50 ng/g. (Brocklehurst and Dawson, 1974). 
Control of PG biosynthesis is thought to be exerted by release of 
polyunsaturated fatty acid(s) from membrane phospholipid by phosphol­
ipase A 2 activity (Samuelsson, 1972; Flower and Blackwell, 1976), and 
there is no evidence to suggest that conversion of precursor to
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prostaglandins is the rate-limiting step in the sequence. The present 
author is unable to see the justification for the use of the high . 
substrate concentrations (l-2mM) used by some workers for in vitro 
studies as the enzyme could not possibly find itself working under 
such 'forced* conditions in vivo. Throughout the present work a 
'realistic' substrate concentration of approximately lyM was used 
for in vitro studies, well below the measured Km of 12yM.
In summary, a study of the basic biochemical properties of 
PG synthetase prepared from R.A. synovial tissue showed no note­
worthy differences between this enzyme and the well-studied enzymes 
prepared from several animal tissues. As one of the tenets of 
Vane's hypothesis is that each isoenzyme of PG synthetase exhibits 
a characteristic pharmacological 'profile' in respect of inhibition 
by aspirin-like drugs, the interaction between this group of drugs 
and R.A. synovial PG synthetase was studied in some detail. These 
results are presented in the following chapter.
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CHAPTER FOUR




The reports of Vane (1971), Smith and Willis (1971) and 
Ferreira, Moncada and Vane (1971) that aspirin-like drugs inhibited 
biosynthesis of prostaglandins provided for the first time a 
plausible hypothesis to explain the mode of action of this group, 
of compounds. These initial results were soon confirmed in many 
other systems, both in vivo and in vitro, and inhibition of PG 
biosynthesis shown to be a property peculiar to aspirin-like drugs 
since many other pharmacologically active compounds are inactive 
against PG synthetase, even in concentrations of up to 5mM 
(Flower, 1974).
Prostaglandins exhibit certain inflammatory properties which 
suggest they may be implicated in various aspects of the inflammatory 
process in general, and in rheumatoid arthritis in particular 
(sections 1.8 and 1.9 respectively). As the aspirin-like drugs form 
the basis of the clinical treatment of chronic inflammatory diseases 
such as rheumatoid arthritis it is clearly of relevance to study the 
interaction between this class of drugs and PG synthetase derived 
from tissue involved in the disease process.
The results presented in this chapter concern principally the 
in vitro inhibition of R.A. synovial PG synthetase by aspirin-like 
drugs, though the effect of other antirheumatic drugs such as 
penicillamine and the corticosteroids has also been studied. Copper 
is known to influence PG biosynthesis (Lee and Lands, 1972; Maddox
1973); the interaction between copper ions and synovial PG synthetase 
was studied, as copper chelates of the aspirin-like drugs have been 
proposed as potentially valuable anti-inflammatory agents (Sorenson, 
1976). Finally the therapy which patients were receiving at the time 
of operation was found to markedly influence subsequent microsomal
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PG synthetase activity and these results are discussed in relation to 
the in vitro studies.
4.2 In vitro inhibition by aspirin-like drugs
The aspirin-like drugs used in these studies were the generous 
gifts of the manufacturing companies and are listed, together with their 
trade names in section 2.2. Solutions of these drugs were always made 
up freshly and used within 30 minutes of preparation. Usually a stock 
solution of the drug (10 or 10 ^) was prepared in the O.lM tris 
acetate buffer, pH 8.0 with the aid of a small amount (0.5ml in 25ml) 
of absolute alcohol, such that the concentration of ethanol never 
exceeded 0.2% in any incubation. (Levels of ethanol up to 2.5% were 
shown to have no effect on the enzyme activity). Appropriate aliquots 
were added to suspensions of the microsomal PG synthetase preparation 
and the volume made up to 1.9ml. with the tris-acetate buffer used 
for the incubation (section 2.4). After a 5 minute incubation of the 
enzyme with the drug the radioactive substrate was added and the 
incubation carried out as described previously.
A comparison of the amounts of ^^C-prostaglandins produced in 
incubations containing various concentrations of a drug with the 
amounts produced in control incubations gave a dose-response curve 
from which IC50 values (the concentration of a drug necessary to 
reduce PG production to 50% of control values) could be calculated 
(graphically). In all these studies aspirin was assayed in each 
experiment as a 'standard' compound and relative potencies expressed 
on a molar basis, taking aspirin as unity.
Fig. 4.1 shows a composite dose-rcsponse curve obtained for 
aspirin for nine consecutive preparations of R.A. synovial PG 
synthetase. The mean IC50 value was 45pM and the range observed
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The composite dose-response curve represents the mean 
of nine consecutive synovial preparations. The mean 
IC50 value was 45^M. Vertical bars indicate the standard 
error of the mean.
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(26yM to 93pM) showed that it was essential to assay aspirin in each 
synovial preparation. Variations in the IC50 values were not due to 
the different concentrations of enzyme used between experiments as 
there was no correlation between the microsomal protein concentration 
used in an experiment and the IC50 value obtained from the dose- 
response curve.
A comparison of the effects of aspirin, paracetamol, indometha- 
cin and flurbiprofen, assayed on the same preparation, is shown in 
Fig 4.2. Aspirin produced a typical dose-response curve, giving an 
IC50 value of 51yM. However paracetamol (4-acetamidophenol), a drug 
possessing no anti-inflammatory activity was virtually inactive in 
this assay, a concentration of ImM producing only 19% inhibition of 
PGE2 production. Other authors have found paracetamol to be inactive 
against PG synthetase prepared from peripheral tissues such as dog 
spleen (Flower and Vane, 1972) or rat skin (Greaves and McDonald- 
Gibson, 1972), though active against the enzyme from dog, rabbit, 
mouse or gerbil brain (Flower and Vane, 1972; Willis and others, •
1972). Indomethacin was found to be considerably more potent than 
aspirin as an inhibitor of R.A. synovial PG synthetase; its IC50 
value of 0.24yM meant that on a molar basis it was 257 times more 
potent than aspirin. Flurbiprofen was found to be a remarkably 
potent inhibitor (IC50 10.9nM). On a molar basis it was 22 times 
more potent than indomethacin and no less than 5,600 times more 
potent than aspirin, the most potent inhibitor of synovial PG 
synthetase tested.
One drug of particular interest is sodium salicylate which 
is as effective as aspirin against experimental inflammation, and 
in the treatment of rheumatoid disease (Collier, 1969), and yet is 
virtually inactive as an inhibitor of PG synthetase in vitro (Vane,
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Fig. 4.2 Inhibition of R.A. synovial PG synthetase by

























Human rheumatoid synovial microsomes (3.1 mg protein/ 
incubation) were incubated in 0.25M sucrose (O.lM tris- 
acetate buffer, pH 8.0, with ^^C-arachidonic acid (lOOnCi) 
for 1 hour at 37 c. Production of ^^C-PGE2 was inhibited
by the addition of aspirin ( @---- 0  ) , indomethacin ( O ---
and flurbiprofen ( 8 B ) . Paracetamol ( □ □ ) was
virtually inactive in this respect.
-O )
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1971; Willis and others, 1972). This apparent discrepancy has led 
some authors to suggest that salicylic acid requires metabolic trans­
formation before it is fully active in vivo, and that gentisic acid, 
a metabolite of salicylic acid, possess high antisynthetase activity 
(Flower and Vane, 1974).
The dose-response curves obtained when aspirin, salicylic 
acid and various salicylate, metabolites were added to R.A. synovial 
PG synthetase incubations are shown in Fig 4.3. As found with other 
enzyme preparations salicylic acid was virtually inactive as an 
inhibitor of PG biosynthesis, producing only 20% inhibition at a 
concentration of ImM. (aspirin produced 93% inhibition at this concen­
tration) . However, no evidence was found that any of the di-hydroxy- 
benzoic acid compounds studied (including gentisic acid) was a potent
inhibitor; even the most potent of the four (2,6-dihydroxybenzoic
I
acid, y-resorcylic acid) had only '/20 the potency of aspirin as an 
inhibitor of PG biosynthesis. Other metabolites, such as the acyl 
or phenolic glucuronides, were not available for testing. The results 
obtained provide evidence against the possibility that R.A. synovial 
PG synthetase is sensitive to inhibition by salicylic acid, or its 
metabolite gentisic acid.
Benorylate, the ester of aspirin and paracetamol, may represent 
a compound which acquires antisynthetase activity in vivo after metabolic 
transformation, presumably hydrolysis to aspirin and paracetamol.
In vitro, benorylate was inactive as an inhibitor of synovial PG 
synthetase, though it could not be tested at concentrations greater 
than 10 '^ M due to its insolubility.
Table 4.1 shows the relative molar potencies obtained using 
the present assay for 14 of the commonly used aspirin-like drugs.
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Fig. 4.3 Inhibition of R.A. synovial PG synthetase in vitro

























Human rheumatoid synovial microsomes (1.1 mg protein/incubation) 
was incubated in 0.25M Sucrose/0.IM tris-acetate buffer, pHB.O, . 
with  ^**C-arachidonic acid (lOOnCi) for 1 hour at 37 c. Production
of ^^C-PGE2 was inhibited by the addition of aspirin ( @ -----© )
and, to a less extent, by 2,6-dihydroxybenzoic acid ( Q  O  ) .
2,3- ( ^  ) , 2,4- ( A ---------- A  ) and 2,5- ( ▼-----------V  ) dihydroxybenzoic
acid were virtually inactive in this respect, as was salicylic acid
( B sa ) .
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Table 4.1 Relative molar potencies of some aspirin-like
drugs for 50% inhibition o f PGE2 synthesis
DRUG
RELATIVE MOLAR 















k e t o p r o f e n 615
FLURBIPROFEN 5,600
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Fig. 4.4 A comparison of the potencies of aspirin-like drugs
as inhibitors of R.A. synovial PG synthetase in vitro 























1. PARACETAMOL 7. FLUFENAMIC ACID
2. ASPIRIN 8. MEFENAMIC ACID
3. AZOPROPAZONE 9. INDOMETHACIN
4. PHENYL BUTAZONE 10. KETOPROFEN
5. IBUPROFEN 11. FLURBIPROFEN
6. NAPROXEN
Values on both scales are expressed on a weight basis, relative 
to aspirin.
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arranged in rank order of potency. From these values Fig. 4.4 was 
constructed, showing the correlation obtained between the potencies 
of the aspirin-like drugs as inhibitors of R.A. synovial PG 
synthetase activity and their known therapeutic potencies in the 
treatment of rheumatoid disease. Aspirin was taken as unity for 
each parameter and the relative therapeutic potencies of the drugs 
assessed from their recommended doses to be found in the 'Monthly 
Index of Medical Specialities,' and from the typical doses of each 
drug which clinicians prescribe. Clearly such an assessment of 
therapeutic potency is inherently imprecise and serves only to 
illustrate that a relationship does exist between the two parameters.
The finding that mefenamic acid is more potent than flufenamic acid
/
as an inhibitor of PG synthetase, but is less potent therapeutically, 
has been observed by others using the enzyme from sheep seminal 
vesicles (Ham and others, 1972).
4.3 In vitro inhibition by other antirheumatic drugs
Penicillamine (g'g"-dimethylcysteine) has been increasingly 
used in the treatment of R.A. since a Multicentre Trial Group (1973) 
suggested that this drug may actually slow the progression of the 
disease. Penicillamine cannot be classed as an aspirin-like drug; 
its slow onset of action and lack of analgesic and antipyretic 
properties suggest that its mode of action is different from that of 
the aspirin-like drugs. The finding that this drug is inactive as 
an inhibitor of R.A. synovial PG synthetase (Fig 4.5) confirms that 
its anti-inflammatory action is unlikely to be related to inhibition 
of PG biosynthesis.
The initial reports of Vane (1971) and Ferreira, Moncada 
and Vane (1971) showed that cortisol was inactive as a PG synthetase 
inhibitor. Interest was aroused when Greaves and McDonald-Gibson
I l l
Fig. 4.5 The effect of penicillamine on R.A. synovial 
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Human rheumatoid synovial microsomes (2.4 mg protein/ 
incubation) were incubated in 0.25M sucrose/0.1 M tris- 
acetate buffer, gH 8.0, with ^^C-arachidonic acid (lOOnCi)
for 1 hour at 37 c. Both aspirin ( # -----@) and
ibuprofen ( A ▲ ) produced a dose-related inhibition of
^‘*C-PGE2 synthesis, whereas penicillamine ( O Cl ) was
inactive in this respect.
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(1972) reported inhibition of PG synthesis in rat skin homogenates 
by some steroidal anti-inflammatory drugs, though later work using 
a microsomal preparation of the enzyme showed the steroids to be 
inactive. Recent work (Hong and Levine, 1976; Nijkamp and others, 
1976) suggests that corticosteroids may indeed inhibit production 
of prostaglandins, but achieve this by blocking release of substrate 
from cellular phospholipid rather than by directly inhibiting PG 
synthetase. A study of PG production by rheumatoid synovial 
cultures (Kantrowitz, Robinson and McGuire, 1975) has shown that 
cortisol, prednisolone and dexamethazone are able to inhibit PG 
production in a dose-related manner in the concentration range 
10~®M - lo'^M.
Fig 4.6 shows that cortisol, prednisolone and dexamethazone 
•are all ineffective as inhibitors of synovial PG synthesis in vitro. 
Concentrations greater than 10 could not be achieved due to the 
limited solubility of the drugs, though such concentrations would 
be far greater than would be achieved therapeutically in vivo; for 
example, a single dose of prednisolone (15mg) given orally produces 
peak plasma levels of less than 10 (English, Chakraborty and 
Marks, 1974). The results are in agreement with findings in other 
tissues that corticosteroids do not inhibit PG synthetase and rule 
out the possibility that R.A. synovial PG synthetase is uniquely 
sensitive to inhibition by steroidal anti-inflammatory drugs.
4.4 In vitro inhibition by copper
The presence of copper ions in a homogenate or microsomal 
preparation of sheep vesicular tissue has been shown to influence 
PG biosynthesis, producing an increased conversion of substrate 
to PGF2“ and a parallel decrease in PGE2 synthesis (Lee and Lands,
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Fig. 4.6 The effect of anti-inflammatory steroids on R.A. 
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\
Human rheumatoid synovial microsomes (0.73 mg protein/ 
incubation) were incubated in 0.25M sucrose/0.IM tris-
C-arachidonic acid
Both aspirin ( ® ---- 9  ) and
fenclofenac ( □ B ) produced a dose-related inhibition
■O ),
— O ) were
acetate buffer, pH 8.0, with 
(lOOnCi) for 1 hour at 37°c.
of ^^C-PGE2 production, whereas cortisol ( O —
prednisolone ( A  A  ) and dexamethazone ( D-
virtually inactive in this respect.
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1972; Maddox, 1973). This observation may have therapeutic potential 
as the E series prostaglandins generally possess the most potent 
inflammatory properties (section 1.8), the F series being much less 
potent and in some cases antagonising the actions of the E compounds. 
The finding that copper acetate has an anti-inflammatory action in an 
experimental model of inflammation (Sorenson, 1976) provides some 
evidence that such a mechanism of action may exist in vivo and is 
not merely an in vitro phenomenon. This author has suggested that 
copper chelates may be the 'active' forms of several antiarthritic 
agents and has shown that these complexes are more potent anti­
inflammatory agents than their parent compounds. At the same time 
they are not only less ulcerogenic than the parent compounds but 
actually possess anti-ulcer activity,clearly an extremely attractive 
therapeutic goal. A study of the effects of copper aspirin and 
copper salicylate by Rainsford and Whitehouse (1976) however was less 
optimistic and suggests that further work is warranted.
The results of adding copper ions (as cupric acetate) to R.A. 
synovial microsomes, incubated with ^^C-arachidonic acid, are shown 
in Fig. 4.7. As can be seen copper produces a dose-related inhibition 
of PGE2 synthesis, giving an IC50 value of 4 x 10 However the
effect on PGF2°^ production is markedly different; a stimulation of 
PGF2^ synthesis is achieved over the range 10  ^ - 10 and inhibition 
is only seen at high concentrations (above 3 x 10 ^M). A plot of the 
ratio of PGE2 to PGF2^ produced shows that this value is a minimum 
(0 .8) at a copper concentration of 10 ^M, though maximum stimulation 
of PGE2= synthesis is achieved at 3 x 10
The effect of adding copper aspirin to synovial incubates is 
shown in Fig. 4.8, together with the dose-response curves obtained
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incubations were carried out as described previously, except 
that EDTA was omitted from the buffer.
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Human rheumatoid synovial microsomes (0.65 mg protein/ 
incubation were incubated in 0.25M sucrose/0.IM 
tris-acetate buffer (without EDTA), pH 8.0, with 
 ^**G-arachidonic acid (lOOnGi) for 1 hour at 37°c. 
Production of PGE2 (closed symbols) and PGF2= (open 
symbols) was inhibited by the addition of aspirin 
(@ - @  ,  O — O) and copper aspirin ( E l  B  , D — □  ) .
/
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by adding aspirin. Aspirin produced the expected dose-related inhibi­
tion of- both PGE2 and PGFz^ synthesis, giving an IC50 value calculated 
from either product of approximately 60yM. The effect of copper 
aspirin was quite different; while PGE2 production was inhibited in 
a dose-related manner, but to a greater extent than with aspirin 
(IC50 3yM), inhibition of PGF2= synthesis was not dose-related, being 
less than that produced by aspirin (at least over the range 
3 X 10 - 10 and having a minimum at 3 x 10 No stimulation
of PGF2= synthesis was observed, however, as was the case with copper 
ions alone (Fig. 4.7).
4.5 In vivo inhibition of PG synthetase
The results presented in this chapter were obtained using 31 
synovial tissue samples taken from 27 patients (23 female, 4 male) who 
had undergone surgical synovectomy of the knee or, in one case 
(patient 17), the elbow. All had classical R.A. with a positive latex 
test. Brief clinical details of these patients are shown in Table 4.2,
together with the weight of each tissue, trimmed of fat, and a
measure of the vascularity and degree of fibrosis, both scored on an 
arbitrary scale of O - +++.
It was of particular interest to study the influence of aspirin­
like drug therapy on subsequent PG synthetase activity in vitro, as 
both aspirin and indomethacin, for example, have been reported to be 
irreversible inhibitors of PG synthetase in other systems (Smith and 
Lands, 1971; Raz, Stern and Kenig-Wakshal, 1973).
Fig. 4.9 shows the amounts of PGE2 and PGF2# produced by the 
microsomal preparations from each of the 31 synovia studied. Tissues 
from seven patients receiving indomethacin therapy (patients 1-7) 
were all capable of PG synthesis in vitro (mean amount of PGE2 produced
118
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171 pmol/mg/hr, range 66-395 pmol/rag/hr). Similarly ten samples from 
patients receiving other aspirin-like drugs (patients 8-16) gave a 
mean PGE2 production of 256 pmol/mg/hr, range 32-569 pmol/mg/hr.
However, in six tissues from patients receiving aspirin, (patients 5(b) 
and 17-21) the amounts of PGE2 produced were virtually indistinguish­
able from zero (mean 6 pmol/mg/hr, range 2-9 pmol/mg/hr). Five 
samples from patients receiving no aspirin-like drugs (patients 24-27) 
produced about the same levels of PGE2 as did the groups being main­
tained on indomethacin and other aspirin-like drugs (mean value 238 
pmol/mg/hr, range 88-687 pmol/mg/hr). Three preparations from two 
patients taking benorylate (patients 22 and 23) produced small but 
measurable amounts of PGE2 (mean 41 pmol/mg/hr, range 35-53 pmol/mg/hr).
These findings may be explained if the inhibition of R.A. 
synovial PG synthetase by aspirin in vivo is considered to be of a non­
competitive (irreversible) type, while the in vivo inhibition caused 
by indomethacin and the other aspirin-like drugs studied here is 
considered to be competitive (reversible). In this latter case the 
manipulation of the tissue through the preparative stages described 
would be expected to remove the drug from the enzyme receptor site, 
reducing its concentration to a very low level and permitting virtually 
uninhibited enzyme activity in vitro. It may be that such a kinetic 
situation exists in vivo when the drugs are given therapeutically.
An opportunity arose to study the synovia obtained from the 
opposite knees of one patient, (patient 5) the first during indo­
methacin therapy and the second, two months later while the patient 
was receiving aspirin. As shown in Fig. 4.10 the amount of enzyme 
activity when the patient was receiving aspirin, even at the low 
dose of 600 mg/day, was only 2% of^that found in the opposite knee 
some 2 months previously when the patient was taking indomethacin
Fig. 4.10 PG synthetase activity of R.A. synovial
microsomes in vitro from opposite knees 












The production of PGE2 I I and PGF2= was measured 
in vitro using the standard technique described in 
sections 2.3 - 2,5.
1. Patient taking indomethacin, 75 mg/day.
2. Opposite knee of same patient two weeks later, 
indomethacin therapy replaced with aspirin,
600 mg/day.
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(75 mg/day). This marked different between the two synovia is most 
unlikely to be due solely to the difference in activity between one 
synovia and the next, for in three other patients (patients 11, 23 
and 27) who underwent simultaneous bilateral synovectomies the PG 
synthetase activities found in opposite knees were in reasonably good 
agreement (Fig 4.9).
No correlation was observed between the level of PG synthetase 
activity measured in the microsomal fraction of each tissue and other 
parameters such as the length of the patient’s history, the weight of 
the tissue or its degree of vascularity or fibrosis.
4.6 Discussion
The aspirin-like drugs have been shown to be potent inhibitors 
of PG biosynthesis, both in vitro and in vivo, in a wide range of 
human and animal tissues (Flower, 1974). It was not surprising there­
fore that PG synthetase prepared from R.A. synovial tissue was found 
to be susceptible to inhibition by low concentrations of the aspirin­
like drugs. However if the interaction between PG synthetase and the 
aspirin-like drugs in vitro is to be relevant to proposed in vivo 
effects, then it must be elicited at drug concentrations equivalent to 
those occurring in man during aspirin-like drug therapy.
Taking aspirin as an example, the maximum plasma salicylate 
concentration of a rheumatoid patient receiving 6g/day of aspirin in 
divided doses is of the order of l-2mM, the concentration of free 
salicylate, i.e. that fraction of the drug not bound to either circu­
lating or tissue proteins, being 0.1-0.6mM. (Smith and Dawkins, 1971) 
In the present study the IC50 values for aspirin, ranging from 26 to 
93yM, thus fall well within the range of concentration attainable in 
man during therapy. Similarly^ the maximum plasma concentrations of
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indomethacin achieved in man are approximately 5pM 'total' or O.SjiM . 
'free' (Hucker and others, 1965) whereas the IC50 values measured 
for indomethacin in the present work were in the range 0.1-0.37pM.
The IC50 values found in the present work are in marked 
contrast to some other values reported in the literature; using a 
bovine seminal vesicle preparation. Flower, Cheung and Cushman (1973) 
reported an IC50 value for .aspirin of 9mM for PGE2 formation, and 
>10mM for the formation of PGF2=, PGD2 and malondialdehyde. These 
concentrations would not be achieved in man even during acute aspirin 
poisoning , and in the present author's opinion are a reflection of 
the unrealistic substrate concentration employed (ImM). Similarly 
the reported IC50 values for indomethacin of 20-40yM are far above 
the concentration attainable in man during normal therapy. Tomlinson 
and others (1972), using a substrate concentration of 0.33mM with 
bovine seminal vesicles, reported an IC50 value for aspirin of 15mM 
and Smith and Lands (1971), using 60]iM substrate with sheep seminal 
vesicles, found an IC50 of 9mM for aspirin. That the enzyme from 
bovine seminal vesicular glands is not peculiarly insensitive to 
inhibition by aspirin or indomethacin has been shown by Cushman and 
Cheung (1976); using a substrate concentration of l]iM with bovine 
seminal vesicles these authors reported the much more realistic 
values of 400yM and 0.6yM for the IC50 of aspirin and indomethacin 
respectively. Such findings would appear to justify the low substrate 
concentration (lyM) used in the present studies.
The finding that paracetamol is virtually inactive as an 
inhibitor of R.A. synovial PG synthetase is in agreement with findings 
in other peripheral tissues (Flower and Vane, 1972; Greaves and 
McDonald-Gibson, 1972). As paracetamol possesses no anti-inflammatory 
activity this result is in accord with Vane's hypothesis.
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As discussed previously the susceptibility of brain PG synthetase to 
inhibition by paracetamol may explain the drug's anti-pyretic activity, 
as it is well established that paracetamol is a centrally-acting 
anti-pyretic. The analgesic action of paracetamol is less readily 
explained on this basis, however, as it is generally agreed that the 
aspirin-like drugs are peripherally-acting analgesics (Guzman, Braun 
and Lim, 1962; Lim and others, 1964), in contrast to the centrally- 
acting narcotic analgesics. As discussed shortly, it may be an 
indication that the aspirin-like drugs are able to exert their effects 
by mechanisms other than their well-documented inhibition of PG 
biosynthesis.
Salicylic acid was found to be virtually inactive as an 
inhibitor of R.A. synovial PG synthetase in vitro, in agreement with 
the findings in other systems (Vane, 1971; Willis and others, 1972). 
These results present a difficulty for the Vane hypothesis, for 
aspirin and sodium salicylate are known to be equally effective in 
the treatment of R.A. (Woodbury, 1965), and equipotent in a number 
of experimental models of inflammation in animals (Collier, 1969;
Willis and others, 1972; Smith, Ford-Hutchinson and Elliott, 1975).
Several suggestions have been advanced to explain this 
discrepancy. One is that different tissues contain isoenzymes of 
PG synthetase, each possessing a characteristic pharmacological 
'profile' in respect of inhibition by various aspirin-like drugs 
(Vane, 1971); salicylic acid could thus be a potent inhibitor 
of PG synthesis in inflammatory tissue yet be ineffective as an 
inhibitor in other tissues. The results obtained in the present work 
provide evidence against the possibility that human inflammatory 
tissue contains an isoenzyme of PG synthetase which is susceptible 
to inhibition by salicylic acid. i
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It has also been proposed (Vane, 1972; Willis and others, 1972) 
that salicylic acid requires metabolic transformation before it acquires 
anti-synthetase activity in vivo, and that gentisic acid, a metabolite 
of salicylic acid, possesses high anti-synthetase activity (Flower and 
Vane, 1974). The results obtained in the present study do not support 
this explanation; gentisic acid was virtually inactive as an inhibitor 
of synovial PG synthetase and even the most potent of the metabolites 
tested (y-resorcylic acid) was only as potent as aspirin. On 
purely hypothetical grounds this explanation would seem somewhat un­
likely. Firstly, gentisic acid and other dihydroxybenzoic acids rep­
resent only 1-5% of the metabolites of salicylic acid (Alpen and others, 
1951; Kapp and Coburn, 1942). As gentisic acid was reported to be 
only 1.5 times more potent than aspirin as an inhibitor of PG synthetase 
(Flower and Vane, 1974) this could hardly account for the equipotency 
of aspirin and salicylic acid as anti-inflammatory agents.
Secondly, gentisic acid itself possesses no anti-inflammatory 
activity in various experimental models of inflammation (Adams and 
Cobb, 1967) and is useless as a therapeutic agent in the treatment 
of rheumatoid disease (Bywaters, 1963). Finally, it is well known 
that in vivo aspirin is rapidly hydrolysed to salicylic acid and 
subsequently gives rise to the same pattern of metabolites as 
salicylic acid itself (Levy and Leonards, 1966). By implication . 
aspirin would also give rise to any salicylic acid metabolite possess­
ing anti-synthetase activity, making it difficult to envisage how 
salicylic acid could achieve the same therapeutic potency as aspirin.
Smith, Ford-Hutchinson and Elliott (1975) have presented 
evidence that an important component of the experimental anti­
inflammatory action of sodium salicylate and aspirin involves
interference with cellular infiltration. This action would not
/
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involve a primary effect on PG synthesis, in which case the in vivo 
effects of sodium salicylate on the PG content of inflammatory 
exudates (Willis and others, 1972) would be secondary to an initial 
effect on leucocyte migration. This secondary inhibition of PG 
production is quite possible, as leucocytes are known to release 
large amounts of phospholipase A and prostaglandins during phago­
cytosis (Higgs and Youlten, 1972).
A plot of the relative potencies of the aspirin-like drugs 
as inhibitors of R.A. synovial PG synthetase against their known 
therapeutic potencies in the treatment of rheumatoid disease showed 
that a relationship exists between the two parameters, albeit a 
somewhat imprecise one. As a drug has to overcome problems of absorp­
tion, distribution and metabolism before reaching its 'target' in 
vivo it is perhaps not to be expected that the correlation between 
an in vitro and in vivo property of a drug would be an exact one.
As exemplified by flurbiprofen, the in vitro assay may, with some 
drugs, give a grossly exaggerated indication of their in vivo potency. 
Clearly an in vitro assay is always subject to such limitations, 
particularly so in the case of PG synthetase as so little is known 
of the factors controlling the activity of the enzyme in its intra­
cellular environment in vivo. Furthermore, as discussed above, 
it may be an oversight to consider inhibition of PG biosynthesis as 
the sole mode of action of the aspirin-like drugs without taking 
into account their actions on other aspects of the inflammatory process,
The finding that cortisol, prednisolone and dexamethazone are 
inactive as inhibitors of R.A. synovial PG synthetase over the 
concentration range 10 ®-10 is in agreement with the original 
reports of Vane (1971) and Ferreira, Moncada and Vane (1971) that
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corticosteroids do not inhibit PG synthetase. A recent finding of 
great interest (Nijkamp and others, 1976) is that corticosteroids 
inhibit the activity of rabbit aorta contracting substance-releasing 
factor (RCS-RF) and that the relative activities of nine represent­
ative corticosteroids in blocking this RCS-RF activity closely 
parallel their known anti-inflammatory potencies. As it is thought 
that RCS-RF may act via phospholipase A 2 to release free arachidonic 
acid from cellular phospholipids and hence bring about increased 
synthesis of prostaglandin endoperoxides and thromboxanes, it is 
possible that corticosteroids may exert their anti-inflammatory actions, 
in part at least, through this indirect inhibition of PG biosynthesis.
The influence of copper on PG biosynthesis is of great 
interest, being able to bring about an inhibition of PGE2 synthesis 
and a simultaneous increase in PGF2* production. As discussed previous­
ly this may have therapeutic importance as the E type prostaglandins 
usually are the most potent in exerting inflammatory properties.
This 'selective' PGE inhibition is not usually seen with the aspirin- . 
like drugs, though phenylbutazone has been reported to be a selective 
PGE2 inhibitor in one in vitro system (Stone, Mather and Gibson,
1975) . A claim that phenylbutazone inhibited production of PGE2 and 
PGF2= but not PGD2 (Flower, Cheung and Cushman, 1973) was later 
retracted (Cushman and Cheung, 1976).
In the present studies the concentrations of copper necessary 
to produce these effects were higher than would be found in vivo; 
the IC50 for inhibition of PGE2 synthesis was 400yM, whereas in plasma 
the mean total copper concentrations in normals and R.A. patients 
are approximately 25 and 35yM respectively (Niedermeier, 1965). The 
corresponding concentrations of non-ceruloplasmin copper are 4yM and
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6yM respectively. Values for non-ceruloplasmin copper in synovial fluid 
are 6yM for normal volunteers and 4yM for R.A. patients. The high con­
centrations needed to elicit the effects shown in the present work may 
be due to the incubation conditions used, as GSH has been shown to 
partially reverse the inhibitory effects of Zn^^, Cd^^ and Cu^* ions 
(Nugteren, Beerthuis and van Dorp, 1966). The results emphasise the 
need for caution when extending in vitro findings to speculation of a 
possible action in vivo.
The finding that copper aspirin was able to bring about a 
greater degree of inhibition of PGE2 synthesis than aspirin itself, 
together with a markedly reduced inhibition of PGF2= synthesis is of 
interest as Sorenson (1976) has shown that copper coordination complexes 
of the aspirin-like drugs possess greater anti-inflammatory activity in 
animal models than the parent compounds, together with much lower 
toxicity. It has been suggested that copper complexes are possibly 
the 'active' forms of the aspirin-like drugs in vivo, and that unwan­
ted side effects such as gastric irritation may be due to depletion of 
copper in tissues such as the gastric mucosa which may require copper 
for their normal maintenance and function (Elmes, 1974).
It has also been suggested that copper complexes may protect 
synovial fluid from degradation, and leucocytes from premature death, 
by dismutation of superoxide anion, thereby preventing the formation 
of potentially damaging hydroxyl radicals (Richardson, 1976). The 
test of all the above hypotheses will be whether such in vitro effects 
can be observed in vivo and ultimately whether copper complexes are in 
fact potent, relatively non-toxic drugs in the treatment of rheumatoid 
disease in man.
A recent study (Boyle and others, 1976) has examined the ability 
of several aspirin-like drugs to cause ulceration when administered
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orally in the rat. The damage caused by clopirac, niflumic acid and 
aspirin was virtually abolished when they were given as copper complexes 
whereas the damage caused by indomethacin, ketoprofen and aspirin was 
unaltered. The lack of ulceration of the first three copper complexes 
was associated with a much reduced ability to inhibit PG synthesis in 
an in vitro system and suggests that inhibition of PG synthesis in vivo 
may be more relevant to ulcerogenicity than anti-inflammatory activity. 
All six copper complexes were found to be equipotent with their parent 
compounds in the carrageenan-induced oedema test, in contrast to the 
report of Sorenson (1976) that the copper complexes possessed greater 
anti-inflammatory activity. The difference may be due to the route of 
administration of the drug, for the former authors gave the drugs 
orally whereas the latter used subcutaneous administration.
It was of interest to find that microsomal preparations of 
synovial tissue from patients receiving indomethacin and other aspirin­
like drugs were capable of considerable PG synthesis in vivo as both 
aspirin and indomethacin have been reported to be irreversible inhibi­
tors of the enzyme prepared from sheep seminal vesicles (Smith and 
Lands, 1971; Ku and Wasvary, 1973; Raz, Stern and Kenig-Wakshal, 1973). 
In contrast, there appeared to be a fundamental difference in this 
respect after aspirin therapy; in vitro PG synthetase activity was 
virtually undetectable in the preaprations from six patients who were 
receiving aspirin therapy at the time of synovectomy. These findings 
suggest that aspirin may be unique in being an irreversible inhibitor 
of R.A. synovial PG synthetase whereas other aspirin-like drugs such 
as indomethacin, naproxen and ibuprofen are reversible inhibitors.
Such a difference in the modes of action of aspirin and indo­
methacin has not been reported in any other system, though the report 
of Raz, Stern and Kenig-Wakshal (1973) is interesting in the light of
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the present results. These authors found that both aspirin and indo­
methacin were irreversible inhibitors of sheep seminal vesicle PG 
synthetase (using an acetone-pentane powder preparation). However, 
when fresh slices of seminal vesicular tissue were pre-incubated with 
either aspirin or indomethacin, enzyme activity in microsomes prepared 
from the aspirin-treated slices was markedly inhibited while the 
activity in microsomes from indomethacin-treated slices was unaffected. 
The authors concluded that indomethacin may fail to reach the enzyme 
in an intact cell and questioned whether inhibition of PG synthesis by 
indomethacin in vivo is mediated via direct inhibition of PG synthetase. 
To the present author a more likely explanation is that indomethacin is 
a reversible inhibitor of PG synthetase in fresh tissue or microsomes, 
but an irreversible inhibitor when the enzyme is prepared as an acetone- 
pentane powder and is denuded of its normal lipid environment. Aspirin 
would appear to be an irreversible inhibitor of either preparation.
The above explanation is supported by the findings that indo­
methacin is a competitive inhibitor of fresh microsomal preparations 
of sheep and bovine seminal vesicle PG synthetase (Hamberg, 1972), 
but an irreversible inhibitor on an acetone-dried powder preparation 
(Smith and Lands, 1971). These findings, together with the results 
presented in the present work suggest that if this phenomenon is a 
general one, then acetone-pentane powder preparations of PG synthetase 
may produce in vitro results which are not relevant to the activity of 
the enzyme in vivo in its natural micro-environment.
A further finding of interest was that PG synthetase activity 
was abolished in microsomal preparations from three patients receiving 
only 600 mg/day of aspirin. Although such a dose is capable of exert­
ing an analgesic effect in man it is well known that much larger doses 
are necessary to produce a clinical antirheumatic effect (Boardman and
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Hart, 1967). If a small dose of aspirin is able to abolish PG synthetase 
activity in the target tissue, and if one accepts the hypothesis that 
aspirin exerts its anti-inflammatory effects via inhibition of PG 
synthesis, then it is pertinent to ask why much larger doses are necess­
ary in the treatment of rheumatoid disease. In the present author's 
opinion these findings support the view of Smith, Ford-Hutchinson and 
Elliott (1975) that the anti-inflammatory efficacy of aspirin may have 
important components other than its well-documented inhibition of PG 
synthesis.
As discussed by Whitehouse (1974) the aspirin-like drugs are 
able to modulate several molecular or cellular events concerned in the 
initiation and maintenance of inflammatory responses. It may be an 
oversight therefore to consider the anti-inflammatory and antirheumatic 
actions of these drugs solely in terms of inhibition of PG synthesis. 
Further elucidation of other facets of their mode of action may well be 
assisted by the design of new anti-inflammatory agents which are not 
inhibitors of PG synthetase(s). The use of such compounds might also 
indicate to what extent the undesirable side-effects of the aspirin- 
like drugs are due to inhibition of PG synthesis in tissues other than 
the target tissue. The present author suspects that the design and 
synthesis of a new drug possessing a high degree of specificity for 








The results obtained in the previous two chapters demonstrate 
that a microsomal fraction prepared from human rheumatoid synovial 
tissue is capable of considerable PG biosynthesis in vitro, and that 
this synthesis may be abolished by low concentrations of the aspirin­
like drugs, i.e. concentrations likely to be achieved in the blood 
during anti-inflammatory therapy.
As emphasised by Willoughby and others (1973) a knowledge of 
the source of the prostaglandins found at an inflammatory site is 
essential to an understanding of the mode of action of the aspirin­
like drugs, though differing views exist on this point. The original 
papers of Vane (1971), Smith and Willis (1971) and Ferreira, Moncada 
and Vane (1971) initiated the hypothesis that prostaglandins are 
formed at the site of inflammation, and that the aspirin-like drugs 
act at the site to abolish PG formation. Furthermore, Piper and 
Vane (1971) suggested that tissues do not store prostaglandins, and 
that PG release could thus be equated with synthesis. This is in 
accord with the report of Jouvenaz and others (1970) that in tissues 
extracted in such a way as to prevent PG synthesis, levels of prosta­
glandins are virtually undetectable.
In contrast, Willoughby and others (1973) have elaborated the 
hypothesis that prostaglandins are largely activated at an inflammatory 
site by migrating leucocytes. The use of selective inhibitors of 
histamine, 5-HT and kininogen by this group has demonstrated a 
'prostaglandin phase' in carrageenan-induced inflammation, and this 
phase is dependent upon both an intact complement system and the 
migration of cells into the inflamed site. Such evidence has however 
been questioned by Brockiehurst and Dawson (1974), who point out that
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in this model the phase of acute inflammation is over before any sig­
nificant amount of PG is detected and suggest that prostaglandins may 
be a product of the reaction rather than a cause of the swelling.
The concurrent appearance of lysosomal enzymes and prostaglandins in 
the exudate suggests that dead or damaged cells are the source of both.
A third possibility, proposed by Glatt, Peskar and Brune (1974) 
from their studies in chickens, is that platelets are the major source 
of PG-like material released into the joint fluid by urate crystals.
An important physiological stimulus for platelet aggregation is 
adhesion to collagen; at an inflammatory site platelets may adhere to 
collagen of the subendothelium at points where the endothelium is 
either damaged or missing, resulting in aggregation of fresh platelets 
arriving at the site (Baumgartner,1974). When platelets undergo 
'second phase' aggregation (also known as the platelet release reaction), 
large amounts of prostaglandins, their cyclic endoperoxide precursors 
and the recently discovered thromboxanes are formed (Smith and Willis, 
1971; Willis, 1973; Hamberg, Svennson and Samuelsson, 1975). A recent 
finding of great interest (Moncada and others, 1975) is that micro­
somes prepared from rabbit or pig aortas are able to convert PGG2 or 
PGH2 to an unstable substance ('PGX') that inhibits human platelet 
aggregation. It is suggested that generation of PGX by vessel walls 
could be the biochemical mechanism underlying their unique ability to 
resist platelet adhesion.
The work presented in this chapter was carried out in order to 
determine PG synthetase levels in peripheral and synovial fluid 
leucocytes, and to compare the action of the aspirin-like drugs on the 
PG synthetase of leucocytes with the results obtained using R.A. 
synovial PG synthetase. Furthermore, as it is not possible to carry
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out serial estimations of enzyme activity in human synovium after 
drug therapy, or to prepare tissue slices for in vitro studies, it 
was also hoped that studies using peripheral leucocytes, both in vitro 
and in vivo, might confirm the finding in the previous chapter that 
aspirin and indomethacin differ in the nature of their action on PG 
synthetase.
5.2 Metabolism of  ^^ C-arachidonic acid by human leucocyte 
microsomes
(i) 'Total' leucocyte preparation
The microsomal fraction of a 'total' leucocyte preparation 
from a healthy volunteer, obtained as described in section 2.3, was. 
incubated with ^^C-arachidonic acid (lOOnCi) for 1 hour at 37°c, and 
the formed products, together with unchanged substrate, extracted 
with diethyl ether and separated using thin-layer chromatography 
(see sections 2.4 and 2.5). Fig 5.1 (a) shows that such a microsomal 
preparation is capable of extensive arachidonic acid metabolism in 
vitro. The three peaks seen with values of 0.24, 0.44 and 0.51 were 
coincident with authentic markers of PGF2=, PGE2 and PGD2 respectively 
and were tentatively identified as such. The addition of indomethacin 
(10 ^M) to an identical incubate virtually abolished the production 
of these three peaks of radioactivity, suggesting that these compounds 
are indeed products of PG synthetase. A peak running ahead of 
arachidonic acid with an R^ value of 0.87 was not abolished by the 
addition of indomethacin and is possibly a hydroxy-acid formed by the 
action of a lipoxygenase upon the  ^**C-arachidonic acid. Interest in 
this peak was not pursued but could presumably be investigated with 
the use of a lipoxygenase inhibitor such as eicosatetraynoic acid 
(TYA). Similar chromatographic separations were obtained when the 
other solvent systems described in section 2.6 were employed.
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Fig 5.1 Metabolism of  ^ C-arachidonic acid by a microsomal 
















A 'total' leucocyte preparation was used to prepare a microsomal
C-arachidonic acid (lOOnCi) at
(a)
fraction which was incubated with
37 c for 1 hour ( ------  ), Products running in the positions of
PGF2=, PGE2 and PGD2, shown below the scan, were abolished by the 
addition of indomethacin (10 ^M) to an identical incubate (....... ).
(b) Leucocyte preparation from person who had taken aspirin (600mg) 
30 mins before venepuncture.
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A microsomal fraction was also obtained from the total leuco­
cyte preparation of a healthy volunteer who had ingested aspirin 
(600mg) one hour before blood was taken. When incubated with 
i^C-arachidonic acid this preparation produced only a tiny amount of 
product running in the prostaglandin region of the plate,Pig 5.1(b), 
though the 'hydroxy-acid' peak running ahead of the substrate was 
still present. This finding provided an indication that aspirin 
could irreversibly inhibit peripheral leucocyte PG synthetase in 
agreement with the results obtained in the previous chapter using 
R.A. synovial PG synthetase. Further effort was directed towards 
determining which cells were the principal source of PG synthetase in 
such 'total' leucocyte preparations.
(ii) Platelets
Peripheral blood was obtained from several healthy volunteers 
and a platelet microsomal fraction prepared from each sample as 
described in section 2.3. When incubated with  ^**C-arachidonic acid 
(lOOnCi) ,at 37°c for 1 hour these preparations produced extensive 
metabolism of the added substrate, a typical thin-layer separation of 
the incubation products being shown in Fig. 5.2(a). The principal 
product, representing 37% conversion of the substrate, was tentatively 
identified as ^**C-PGE2. Smaller peaks, corresponding to authentic 
markers of PGF2# and PGD%, represented 11% and 15% substrate conversion
respectively. For eight subjects the mean conversion of substrate 
to C-PGE2 was 31.5%, representing a production of 4,220 pmol/mg/hour, 
though the range was large (700-10,500 pmol/mg/hour). These values 
are at least an order of magnitude higher than those found for R.A. 
synovial microsomes in section 4.5 (mean values 171-256 pmol E 2 
produced /mg/hour). However, in three volunteers who had taken 
aspirin (600 mg) one hour before blood samples were taken (see 
section 5.8 for details) the mean production of ^^C-PGEz in vitro
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Fig. 5.2 Metabolism of ^‘*C-arachidonic acid by microsomes

















Microsomal fractions from normal human platelets or polymorphonuclear 
leucocytes were prepared as described in section 2.3 and incubated




37 c fo  1 hour. The positions of authentic markers are shown below
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by their platelet microsomes was 191 pmol/mg/hour, range 157-226 
pmol/mg/hour), again confirming that administration of aspirin in 
vivo largely abolished subsequent microsomal PG synthetase activity 
in vitro.
No qualitative or quantitative differences were found between 
platelet microsomes obtained from patients with rheumatoid arthritis 
and those prepared from healthy volunteers. Microsomes from eight 
patients receiving indomethacin therapy (175-225 mg/day) produced a 
mean substrate conversion to *^C-PGE2 of 37.3%, representing 3,920 
pmol/mg/hour, range 920-9,750 pmol/mg/hour. However in four patients 
receiving aspirin therapy (2.4-3.6 g/day) the mean conversion of 
substrate to ^**C-PGE2 was only 1.4%, representing a mean production 
of only 78 pmol/mg/hour.
(iii) PMN's
Polymorphonuclear leucocytes were prepared from the peripheral 
blood of six healthy volunteers and a microsomal fraction from each 
prepared as described in section 2.3. Fig 5.2(b) shows the thin-layer 
separation of the products of an incubate containing PMN microsomes 
and ^^C-arachidonic acid. The mean conversion of the substrate to the 
radioactive product running in the position of authentic PGE2 was 
5.1%, representing a mean production of ^^C-PGE2 of 255 pmol/mg/hour,. 
range 96-510 pmol/mg/hour.
PMN microsomes from six patients with R.A. who were receiving 
indomethacin therapy (175-225mg/day) produced a mean substrate 
conversion to the product identified as ^^C-PGE2 of 25.1%. However 
when the figure for production of PGE2 was calculated on the basis of 
microsomal protein content, the mean value (371 pmol/mg/hour) was 
not significantly different from that found with the preparations
142
from the healthy volunteers. PMN microsomes from three patients with 
R.A. who were receiving aspirin therapy (2.4-3.6 g/day) showed a 
mean of only 1.7% conversion of ^^C-arachidonic acid to ^**C-PGE2, a 
mean production of only 28 pmol/mg/hour, range 21-35 pmol/mg/hour.
(iv) Lymphocytes
Lymphocytes were prepared from the peripheral blood of seven 
healthy volunteers and a microsomal fraction obtained from each as 
described in section 2.3 . Incubation of these microsomal fractions 
with  ^^ C-arachidonic acid produced no detectable prostaglandin syn­
thesis in any sample, even when, in two cases, 50ml of whole blood 
was used for the cell preparation. This finding is in agreement with 
the report of Ferraris and De Rubertis (1974) that lymphocytes in 
culture produce only tiny amounts of prostaglandins in response to 
stimulation by either antigens or mitogens. Unfortunately no studies 
were possible on lymphocytes prepared from patients with rheumatoid 
arthritis though the finding of an active preparation would be sur­
prising in view of the findings cited above.
(v) Synovial fluid leucocytes
Fig. 5.3 shows the scan obtained when the microsomal fraction 
of a 'total' leucocyte preparation from the synovial fluid of a 
patient with R.A. was incubated with ^^C-arachidonic acid (lOO nCi) 
at 37°c for 1 hour, (0.24 mg protein per incubation). Although 
sharp peaks of activity were seen in the positions of PGFz^, PGE2 
and PGD2 these represented only 0.7%, 2.9% and 1.3% substrate 
conversion respectively. Addition of indomethacin (10 ®M) to an 
identical incubation abolished these peaks, providing good evidence 
that they were produced by the action of PG synthetase on the 
labelled substrate. Production of prostaglandins by several other 
synovial fluid leucocyte microsome preparations, both with and
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Fig 5.3 Metabolism of ^^C-arachidonic acid by microsomes 







F o ° c E2 Dv AA
A microsomal fraction prepared from rheumatoid synovial fluid
^ a r a c h i d o n i c  acid (lOOnCi) in 
O.IM tris-acetate buffer, pH 8.0, at 37°c for 1 hour. The
leucocytes was incubated with 
{ 
positions of authentic markers are shown below the scan. 
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than 3%.
ersion of ^^C-arachidonic acid to ^^C-PGE2 was less
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without hyaluronidase pre-incubation, was barely detectable, suggesting 
that synovial fluid leucocytes are not a good source of PG synthetase. 
This is perhaps a little surprising in view of the finding of Higgs, 
McCall and Youlten (1975) that the levels of PG synthetase found in 
PMN's undergoing phagocytosis are increased severalfold over the levels 
in resting cells.
Taken together, the-results presented above suggest that 
platelets contain by far the greatest biosynthetic potential for PG 
synthesis and preliminary in vivo results with aspirin and indomethacin 
confirm the findings discussed in the previous chapter that aspirin may 
be unique in being an irreversible inhibitor of PG synthetase. Further 
efforts therefore were directed towards the study of the interaction
between aspirin or indomethacin and human platelets as a 'model' cell
for the study of PG synthetase.
5.3 Chemical conversion of PGE2
Before proceeding with further studies it was considered 
desirable to confirm that the principal product of arachidonic acid 
metabolism produced by human platelet microsomes under the incubation 
conditions described was in fact PGE2. Fig. 5.4 shows that the 
radioactive product tentatively identified as ^^C-PGE2 behaved exactly 
as expected, producing virtually identical scans to ^**C-PGE2 isolated 
from R.A. synovial microsome incubations in Fig. 3.2. Thus treatment 
of the isolated product with sodium borohydride produced equal amounts 
of activity running in the positions of PGF2= and PGF2&, and sodium 
hydroxide treatment produced a single peak of activity running in the 
position of PGB2. This, together with chromatographic identification 
in three different systems provides good evidence that the product is 
in fact PGE2. (This might be expected as the presence of GSH in
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Fig. 5.4 Chemical conversion of formed C-PGE2 with 












^'^C-PGE2 formed from the incubation of human platelet microsomes 
with ^^C-arachidonic acid was isolated by thin-layer chromatography 
and treated with either NaBHi» or NaOH. Re-chromatography of the 
extract showed conversion to an equal mixture of PGF2= and PGF2# 
upon NaBHit treatment (upper scan) and conversion to PGB2 with NaOH 
(lower scan).
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incubations is known to promote PGE synthesis at the expense of other 
prostaglandins).
5.4 Biochemistry of human platelet PG synthetase
Fig. 5.5 shows a kinetic plot, time course of PG production, 
and pH profile for human platelet PG synthetase when incubated in 
vitro with *^C-arachidonic acid. The enzyme has a pH optimum at pH 8.0 
and in this respect is indistinguishable from the synthetase prepared 
from human R.A. synovial tissue (see Fig. 3.6) although the peak is 
somewhat sharper for the platelet enzyme. As found for R.A. synovial 
PG synthetase the time course of PG production by human platelet 
microsomes is linear for the first 30 minutes of the incubation.
After this time the production of prostaglandins increases further but 
is no longer linearly related to time. An incubation time of 1 hour 
was chosen for all incubations except those used to construct a 
kinetic plot, for which an incubation time of 30 minutes was chosen.
When such a kinetic plot was constructed a marked difference
was found between the calculated K values and those measured for the
m
synovial enzyme. Thus the values for human platelet PG synthetase,
calculated on the basis of PGE2, PGF2= or PGD2 production were 2.4,
3.2 and 4.4yM respectively, compared with values for R.A. synovial
PG synthetase of approximately 12yM. However, as the microsomal
preparations used in these studies are grossly impure preparations of
the enzymes such results should perhaps be interpreted with caution.
As discussed in detail by Youdim and Woods (1975) even the K value
m
obtained using a highly purified enzyme in vitro may be inapplicable 
to the situation in vivo.
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Fig. 5.5 Kinetic plot, time course and
pH profile for human platelet 
PG synthetase
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Calculated Km values were 2.4yM for PGE2 formation, 3.2yM for 
PGF2*^ and 4.4yM for PGD2.
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5.5 Inhibition of human platelet PG synthetase by aspirin­
like drugs in vitro
When added to active microsomal preparations of human platelet
PG synthetase, both aspirin and indomethacin produced the expected 
dose-related inhibition (Fig. 5.6). Calculated from the dose of each 
drug required to produce 50% inhibition of PG biosynthesis, and 
expressed on a molar basis, indomethacin was approximately 150 times 
more potent than aspirin. The production of PGE2 and PGF2= was equally 
affected, and no evidence was found for 'selective' inhibition by 
either drug.
Of other aspirin-like drugs examined in this system, similar 
potencies were found to those measured using R.A. synovial tissue as 
the source of the enzyme. An exception was azopropazone which was 
twice as potent as aspirin as an inhibitor of R.A. synovial PG synthe­
tase in vitro, but only \  ^  as potent as aspirin on the enzyme
prepared from human platelets.
5.6 Pre-incubation of whole platelets with aspirin or indomethacin 
Aliquots of platelet-rich plasma were incubated with either
aspirin or indomethacin over the concentration range 10 - 10 ^M,
at 37° for 30 min. with shaking. The platelet pellet obtained by 
centrifugation at 2500g for 5 min. was resuspended in Tyrode's 
solution (5.0 ml), incubated at 37° for a further 10 min. and the 
platelet pellet again obtained by centrifugation. The preparation 
of the microsomal fraction and measurement of PG synthetase activity 
were then carried out as described in sections 2.3-2.5.
The results are presented in Fig. 5.7 and show a marked 
difference between the two drugs. Thus whilst exposure to aspirin at
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Fig. 5.6 Inhibition of human platelet microsomal PG 





















Human platelet microsomes were incubated with  ^^ C-arachidonic 
acid as described in sections 2.4 and 2.5. Production of 
PGE2 (closed symbols) and PGF2* (open symbols) was inhibited 
in a dose-related manner by the addition of aspirin
(0— 0  / O  O) or indomethacin ( B B , □ O ) . Points
represent the mean of duplicate estimation.
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Fig. 5.7 Inhibition of human platelet microsomal PG 
synthetase after pre-incubation of whole 
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Whole human platelets were pre-incubated with either aspirin 
or indomethacin at 37 c. for 30 min. over the concentration 
- 10 and the PG synthetase activity of therange 10
subsequent microsomal fraction from each incubation measured
as described in sections 2.4 and 2,5. Whereas aspirin ( © ---@ )
produced a dose-dependent inhibition, indomethacin ( B O )
had little or no effect. Points are shown with the standard 
error of the means for 4 estimations.
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a concentration of 10 **M was capable of producing 80-90% inhibition of 
PG synthetase, indomethacin had little or no effect, even a concentra­
tion of 10 producing less than 10% inhibition of subsequent micro­
somal PG synthetase activity. The apparent stimulation of PG 
synthesis by aspirin at 10 is not readily explained, though similar 
phenomena have been reported in other systems (Brocklehurst and Dawson, 
1974; Stone, Mather and Gibson, 1975). The most potent inhibitor of 
PG synthetase found in these studies, flurbiprofen, was found, like 
indomethacin to be incapable of permanently inhibiting microsomal PG 
synthetase by pre-incubation with whole platelets. The use of flurbi­
profen coupled to sepharose for the affinity chromatographic purifica­
tion of PG synthetase (Smith, 1975) implies that the interaction between 
the enzyme and flurbiprofen (or at least its amide derivative) must 
be reversible as an active fraction is recovered upon elution with 
a solution of flufenamic acid.
5.7 Pre-incubation of human platelet microsomes 
with aspirin or indomethacin
Human platelet microsomes were re-suspended in Tyrode's 
solution and aliquots incubated with either aspirin or indomethacin 
over the concentration range 10 - 10 ^M, at 37° for 30 min. with
shaking. The suspension was then layered onto tris-acetate buffer 
(O.IM, pH 7.4) containing sucrose (0.25M) and a microsomal pellet 
obtained by centrifugation at 10^g for 1 hr. The PG synthetase 
activity of each microsomal pellet was then measured as described in 
sections 2.4 and 2.5.
The results are shown in Fig. 5.8 and confirm the findings 
described above using whole platelets. Thus whilst aspirin produced 
a dose-related inhibition of PG synthetase activity of similar potency
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Fig. 5.8 Inhibition of human platelet microsomal PG synthetase 


























Human platelet microsomes were pre-incubated with either aspirin
(©---- @) or indomethacin ( E-~-H3 ) at 37°c for 30 min. over the
concentration range 10 - 10 and the PG synthetase activity
of the washed microsomes measured as described previously. Points 
are shown with the standard error of the means for 4 estimations.
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to that found when present in an incubation mixture containing platelet 
microsomes and ^^C-arachidonic acid, indomethacin was considerably 
less potent than aspirin in producing inhibition of PG synthetase by 
pre-incubation. As indomethacin is approximately 150 times more 
potent than aspirin as a PG synthetase inhibitor when present in an 
incubation mixture containing platelet microsomes and  ^^ C-arachidonic 
acid (Fig. 5.6), these findings strongly suggest, as found with R.A. 
synovial PG synthetase, that indomethacin is a reversible inhibitor 
of human platelet PG synthetase, whereas the inhibition produced by 
aspirin is irreversible.
5.8 The effect of aspirin and indomethacin in vivo
Three healthy male volunteers who had received no medication 
of any kind for at least two weeks beforehand were given indomethacin 
(50mg) orally, and blood samples obtained over the following 96 hr, 
including a pre-drug, basal sample. Three weeks later the procedure 
was repeated with the subjects taking aspirin (600 mg). Platelet- 
rich plasma was prepared from each sample, a platelet count performed, 
and the PG synthetase activity of the microsomal fraction measured as 
described above, using a constant number of platelets from each subject. 
Plasma levels of indomethacin were measured by the method of Hucker 
and others (1966), and salicylate by the method of 0ie and Frislid 
(1971).
Administration of aspirin (600 mg) to 3 volunteers produced a 
prompt fall in platelet microsomal PG synthetase activity in vitro 
to less than 15% of basal levels, and this blockade lasted for 
several days (Fig. 5.9, lower trace). As platelets are devoid of a 
nucleus and contain little or no DNA they are capable of very limited 
de novo enzyme synthesis (Steiner, 1970). The time course of the
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Fig. 5.9 Effect of orally administered aspirin or indomethacin 
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3 healthy volunteers each took indomethacin (SOmg) orally. 
Blood samples were taken at intervals over the following 
96 hours, platelets prepared from each sample and the PG 
synthetase activity of the microsomal fraction from each 
one measured as described previously. Three weeks later the 
procedure was repeated with the volunteers taking aspirin 
(600mg). Points are shown with the standard error of the 
mean.
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Fig. 5.10 Plasma levels of indomethacin and salicylate after 
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Indomethacin levels were measured using the method of Hucker 
and others (1966) and the method of 0ie and Frislid (1971) 
was used to determine total salicylate levels. Calibration 
lines for each measurement are shown in the insets.
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inhibition of platelet PG synthetase by aspirin is thus effectively a 
measure of platelet turnover.
By contrast ingestion of indomethacin (50 mg) produced no 
reduction of microsomal PG synthetase activity in two individuals, and 
in the third subject brought about a stimulation of activity which at 
24 hr. after the drug had been taken was more than twice the basal 
level. This accounts for the large standard errors shown in the 
upper trace of Fig. 5.9.
Fig. 5.10 shows the plasma levels of either indomethacin or 
total salicylate of the three volunteers in the above experiment, as 
determined by standard fluorimetric techniques. As expected, indo­
methacin produced maximum plasma concentrations one hour after oral 
ingestion and was largely cleared from the blood at five hours 
(Rothermich, 1966) . In contrast, the concentration of total salicylate 
in the plasma was more sustained after the single oral dose of 600 mg 
aspirin, lying in the range 20 - 40 Ug/ml at 8 hr. after taking the 
drug, and was still detectable at 48 hr. in one subject. It should 
be noted however that although the half-life of plasma salicylate in 
man is of the order of 6 hours, aspirin is rapidly de-acetylated in 
plasma and has a half life of only 20-30 minutes (Levy, 1963). 
Significant concentrations of aspirin are unlikely to be present in 
the blood more than 2 hours after a single oral dose (Lester, Lolli 
and Greenberg, 1946).
The possibility that the prolonged inhibition of platelet PG 
synthetase seen after administration of aspirin in vivo could be due 
to salicylic acid, or one of its metabolites, was investigated by 
testing the potency of these compounds as inhibitors of platelet PG 
synthetase in vitro. Fig. 5.11 shows that although aspirin 
produced the expected dose-related inhibition of platelet PG synthetase.
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Fig. 5.11 Inhibition of human platelet PG synthetase in vitro 
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Human platelet microsomes (0.14mg protein/incubation) were 
incubated in 0.25M sucrose/O.lM tris-acetate buffer. pH 8.0, 
with ^^C-arachidonic acid (lOOnCi) for 1 hour at 37 c. 
Production of  ^ ^ ---- ^  ^  ^
( a a , O
'C-PGEz ( 
-O ), and C-PGDa
O—  O ) /
( A  A
'C-PGFa=
A  A  ) was
inhibited in a dose-related manner by aspirin (closed symbols) 
though salicylic acid (open symbols) was virtually inactive 
in this respect.
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salicylic acid was inactive in this respect. Similarly, as found 
with the enzyme prepared from R.A. synovial tissue, the four dihydroxy- 
benzoic acids were also inactive. It can reasonably be concluded 
therefore that aspirin exerts its prolonged inhibition of platelet 
PG synthetase by an irreversible action on the enzyme. As discussed 
in the following chapter, much evidence now exists to suggest that 
this may be brought about by acétylation of the cyclo-oxygenase 
component of the enzyme.
f
5.9 The effect of Cu and Zn on human platelet PG synthetase
The effect of copper ions on platelet PG synthetase was
studied in order to confirm the findings in section 4.4 using the 
enzyme from R.A. synovial tissue.
When copper ions (as cupric acetate) were added to human 
platelet synovial microsomes, incubated with ^^C-arachidonic acid 
in vitro, over the concentration range 10 ^M-10 ^M, the results 
obtained were almost identical to those obtained previously and are 
shown in Fig. 5.12, upper trace. Whereas the production of PGE2 
was inhibited in a dose-related manner, PGF2= was markedly stimulated 
at a copper concentration of 3 x 10 ^M. By contrast, the addition 
of zinc ions(as zinc acetate) produced no stimulation of PGF2= 
synthesis and inhibition of both PGE2 and PGF2= only at high concen­
trations (Big. 5.12, lower trace). The effect of copper on the enzyme 
would thus appear to be more specific than a purely chemical one.
5.10 Discussion
The results presented in this chapter were all obtained using 
PG synthetase prepared from human peripheral or synovial fluid 
leucocytes. Previous work had shown both platelets (Smith and Willis,
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Fig. 5.12 The effect of copper and zinc on human platelet 
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Human platelet microsomes were incubated with ^^C-arachidonic 
acid (lOOnCi) and either copper or zinc acetate added to give 
a concentration range from 10 -  10 ^M. Production of ^^C-PGEg
inhibited in a dose—related manner by both copper and zinc 
( 0  @  ),. However, only copper produced a stimulation of
C-PGF20C synthesis ( O O ) at a concentration of 3 x 10~**^*
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1971) and PMN's (Higgs and Youlten, 1972) to be capable of considerable 
PG synthesis in response to appropriate stimuli. When microsomal 
fractions were prepared from human peripheral platelets, PMN's and 
lymphocytes in the present study, by far the greatest levels of PG 
synthetase activity were found in the platelets. Much lower levels 
were found in PMN cells and no activity could be demonstrated in the 
microsomes prepared from human peripheral lymphocytes. Further studies 
were therefore carried out both in vivo and in vitro on the interaction 
between the aspirin-like drugs and PG synthetase, with particular 
attention being given to aspirin and indomethacin, in order to 
confirm the previous findings obtained using R.A. synovial PG synthetase.
Basic biochemical parameters of human platelet PG synthetase 
were found to be similar to those described for R.A. synovial PG 
synthetase, though the different K values and somewhat different 
patterns of products obtained upon incubation with ^^C-arachidonic 
acid in vitro suggest that the activity of synovial microsomes is not 
due to platelet contamination.
When either whole platelets or platelet microsomes were pre- 
incubated with aspirin or indomethacin, a marked difference between 
the two drugs was found in respect of their inhibition of subsequent 
PG synthetase activity in vitro. Thus, whereas aspirin was able to 
inhibit the enzyme after a period of pre-incubation prior to washing 
of the cells or microsomes, indomethacin was a potent inhibitor of 
PG synthetase activity only when present in incubation mixtures, and 
had little effect when present in pre-incubation solutions. These 
findings are in complete agreement with the results presented in 
Chapter 4, and suggest that the phenomena may be a general one, at 
least in human cells and tissues.
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The finding that administration of aspirin in vivo produces 
a long-lasting inhibition of human platelet PG synthetase may explain 
the report that whilst the effect of aspirin in inhibiting both 
platelet prostaglandin production and platelet aggregation lasts for 
several days, the effect of indomethacin is short-lived (Kocsis and 
others, 1973) and can be demonstrated only for as long as an 
adequate plasma concentration is maintained. A recent report (Jafari 
and others (1976) confirms the finding in the present study that 
aspirin produces an inhibition of platelet PG synthetase for the 
entire life span of the platelet, and suggests that aspirin may also 
acetylate the developing megakaryocyte prior to platelet release 
into the circulation.
As discussed in the following chapter the finding that low 
concentrations of aspirin are able to irreversibly acetylate a platelet 
particular fraction protein provides strong evidence that this may 
be its mode of action at the molecular level in inhibiting PG 
synthetase. Consideration of the structures of other aspirin-like 
drugs, however, suggests that this is unlikely to be a general 
property of this group of compounds, as most possess no labile function­
al group. The results presented have suggested that indomethacin 
probably does not function as a benzoylating agent in an analogous 
manner to aspirin, though it would clearly be of interest to investi­




STUDIES WITH / ACETYL-^H / ASPIRIN
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6.1 Introduction
The results obtained in the previous two chapters indicate 
that whereas indomethacin and some of the other aspirin-like drugs 
are reversible inhibitors of PG synthetase from R.A. synovial tissue 
and peripheral leucocytes, aspirin itself is an irreversible inhibitor 
of the enzyme. This action could be brought about by acétylation of 
the enzyme, possibly at the substrate or cofactor site, as it has 
previously been shown that aspirin acetylates proteins and other 
biological substrates. Thus, aspirin at a concentration of 0.5mM 
acetylates human serum albumin at a single site leading to the for­
mation of e-N-acetyl lysine residues (Hawkins and others, 1969). At 
high concentrations (2.0 - 20mM) aspirin acetylates haemoglobin at 
several sites within the molecule, perhaps through the formation of 
E-N-acetyl lysines (De Furia and others, 1974). The drug is also 
able to acetylate RNA, hormones and various other serum proteins 
(Pinckard, Hawkins and Farr, 1968) through the mechanisms of the 
reactions are not well characterised.
The use of [_ acetyl-l-^^C_/ aspirin and /_ acetyl-^H__/ aspirin 
(Al-Mondhiry, Marcus and Spaet, 1970; Rosenberg and others, 1971) 
showed that aspirin acetylates platelet protein, though quantitation 
was difficult due to the low specific activities of the labelled 
aspirin used, and characterisation of the labelled protein was not 
possible as only whole platelets, or TCA precipitates of whole 
platelets were analysed. It seemed, therefore, that if the inhibition 
of PG synthetase by aspirin depended upon the drug's ability to 
acetylate the enzyme, it should be possible to demonstrate the 
incorporation of labelled acetyl groups into the microsomal prepara­
tions of the enzyme described previously in this work. At about 
this time Roth and Majerus (1975) reported that incubation of human
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platelets with /_ acetyl-^H_/ aspirin produced a rapid, saturable, 
irreversible acétylation of a platelet particulate fraction protein 
whose molecular weight was estimated at 85,000. The correlation 
between these findings and previous physiological observations of the 
effect of aspirin on platelets led the authors to conclude that 
aspirin may exert its anti-platelet effect by acetylating a residue 
within an active site of the cyclo-oxygenase component of PG synthetase.
It was decided, therefore, to synthesise /_ acetyl-^H_/ aspirin 
of high specific activity, firstly to confirm the findings described 
above, in view of their relevance to the results obtained in the 
present work, and secondly to extend the results by studying the 
interaction between [_ acetyl-^H_/ aspirin and R.A. synovial PG 
synthetase.
6.2 Methods
Preparation of / a c e t y l - / aspirin.
Salicylic acid (2.5 mg) was dissolved in pyridine (2.0 ml, 
redistilled) and treated with ^H-acetic anhydride (25 mCi, specific 
activity 3500 mCi/mmol., Radiochemical Centre, Amersham) at 37°c for 
3 hr. The solvent was evaporated under nitrogen and the product 
purified by thin-layer chromatography (silica gel G, 0.25mm, methanol 
washed; solvent system cyclohexane-chloroform-acetic acid, 80:20:10). 
After radioscanning, the band corresponding to authentic aspirin, 
run in parallel, was transferred to a small sinter, eluted with 
redistilled ethanol (10 ml) and stored at -20°c. Chromatographic 
properties and absorption spectra of the purified product showed it 
to be identical to authentic aspirin (Fig 6.1). Yield of /_ acetyl-^H_/ 
aspirin 10.8mCi (86% of theoretical).
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Fig, 6.1 Absorption spectrum of synthesised 












[_ acetyl-^H_./ aspirin was synthesised as described in 
section 6.2 and its absorption spectrum measured in 
absolute ethanol (lOSyCi, ll.Oyg, in 1.0ml). The two 
curves show the spectrum with a fresh preparation ( A- 
and after 3 months storage in ethanol at -20 c ( A ----
-A ),
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Incubation of PG synthetase with / a c e t y l - / aspirin 
Platelet or synovial microsomes, prepared as described 
previously (section 2.3), were incubated with /_ a c e t y l - _/ aspirin 
(60yM) in O.IM tris-acetate buffer, pH 7.4, at 37° for 30 min. The 
suspension was then layered onto tris-acetate buffer (O.lM, pH 7.4) 
containing sucrose (0.25M) and a pellet obtained by centrifugation 
at lO^g for 1 hr.
Polyacrylamide gel electrophoresis of acetylated PG synthetase 
To the pellet obtained as described above was added 200yl 
of O.IM phosphate buffer, pH 7.1, containing 0.2% sodium dodecyl 
sulphate (S.D.S.), and 50yl of a solution of 20% S.D.S. and 0.5M 
mercaptoethanol in O.IM phosphate buffer, pH 7.1. The mixture was 
boiled for 10 mins., and aliquots (50-100yl) run on 5% polyacrylamide 
gels in O.IM phosphate buffer, pH 7.1 essentially as described by 
Weber and Osborn (1969). Electrophoresis was carried out using a 
constant current of 7 mA/gel, giving a running time for a 9cm gel 
of about 6 hr. Gels were run until a marker dye (lOyl of a 0.05% 
solution of bromophenol blue) had reached the bottom of the gel. The 
gels were sliced into 3 mm sections, digested by incubating for 48hr. 
at 56°C with hydrogen peroxide solution (20vol, 0.8 ml), liquid 
scintillant added ('Unisolve') and the samples counted for radio­
activity. Quench corrections were made using an external standard 
ratio method, the efficiencies being in the range 26-31%. Gels run 
in parallel, containing either microsomal preparations or protein 
markers of known molecular weight, were stained with Coomassie 
brilliant blue dye.
6.3 Results
When human platelet microsomes were incubated with / acetyl-^H /
167
aspirin of high specific activity, and the solubilised products 
subjected to polyacrylamide gel electrophoresis, a single peak of 
radioactivity labelled protein was seen (Fig 6.2). By reference to 
the calibration curve obtained from a series of proteins of known 
molecular weight (shown in the inset) the molecular weight of this 
labelled protein was found to be 81,000 in agreement with the figure 
reported by Roth and Majerus (1975) of 85,000. Calculation of the 
amount of label incorporated into the protein gave a figure of 2,000- 
3,000 acetyl groups per platelet, also in agreement with the above 
report. Calculation also indicates that the microsomal preparation 
used is, as might be expected, a highly impure form of PG synthetase; 
on the assumption that aspirin and the 85,000 molecular weight protein 
react on an equimolar basis, the microsomal preparation contains only
0.05% of this protein. Even if one hundred acetyl groups attach to 
one protein molecule the preparation only contains 5% of the protein, 
based on the total protein content of the microsomes.
When attempts were made to repeat the above experiment, but 
using R.A. synovial microsomes, much less satisfactory results were 
obtained. As with the platelet microsomes a labelled peak with a 
molecular weight of 81,000 was found (Fig. 6.3); however the amount 
of radioactivity incorporated into the peak was much less than was 
found in the platelet preparation; if the labelled peak is the 
cyclo-oxygenase component of PG synthetase (or at least a sub-unit of 
it) then this result is in accord with the findings in previous 
chapters that the level of PG synthetase is much higher in platelet 
microsomes than in R.A. synovial microsomes.
A further difference between the two preparations was seen 
when the polyacrylamide gels were stained with Coomassie brilliant 
blue; whereas the platelet preparation gave numerous clearly defined
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Fig. 6.2 Polyacrylamide/S.D.S. gel electrophoresis of 
solubilised human platelet microsomes after



















Human platelet microsomes were incubated with /_ acetyl-^H_/ aspirin 
(60yM) in 0.1 M tris-acetate buffer, pH 7.4, at 37°c for 30 min.
The washed microsomes were solubilised with S.D.S./mercaptethanol 
and an aliquot containing IVOyg protein electrophoresed on 5% 
polyacrylamide gel. The radioactivity in each gel slice was 
measured by liquid scintillation counting and the peak of activity 
calculated to have a molecular weight of 81,000.
Standard protein markers used were: BSA, bovine serum albumin;
PHOS-A, phosphorylase-A; PK, pyruvate kinase; OVA, ovalbumin;
LDH, lactic dehydrogenase; CHY, chymotrypsinogen; HB, haemoglobin.
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Fig. 6,3 Polyacrylamide / S.D.S. gel electrophoresis of 
solubilised R.A. synovial microsomes after 









R.A. synovial microsomes were incubated with [_ acetyl- H_/ aspirin 
(60yM) in O.IM tris-acetate buffer, pH 7.4, at 37°c for 30 min.
The washed microsomes were solubilised with S.D.S./mercaptoethanol 
and an aliquot containing 310|ig protein electrophorsed on 5% 
polyacrylamide gel. The radioactivity in each gel slice was 
measured by liquid scintillation counting and the peak of activity 
found to have a molecular weight of 81,000.
Note the enlarged scale on the ordinate compared with Fig. 6.2.
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bands on staining, the synovial preparation produced a diffuse stain 
throughout the length of the gel and no bands were seen at all. The 
possibility that the gels containing solubilised synovial microsomes 
were either overloaded or streaking, due to the rather impure nature 
of the synovial preparation, was investigated by adding several protein 
markers of known molecular weight to synovial preparations and sub­
jecting to gel electrophoresis followed by staining. The finding that 
the protein markers ran in the correct positions as sharp bands 
suggested that the synovial preparation was in fact suitable for gel 
electrophoresis. Attempts to produce a lipid-free preparation of 
acetylated microsomes, using either petroleum ether or acetone/pentane 
mixtures, followed by gel electrophoresis, were uniformly unsuccessful.
Studies had originally been planned to investigate the possible 
interaction of other aspirin-like drugs with the aspirin-microsome 
system; the finding that the potencies of the aspirin-like drugs as 
competitive inhibitors of the acétylation reaction correlated well 
with their potencies as inhibitors of PG synthetase would have provided 
good (albeit circumstancial) evidence that the labelled peak was indeed 
the cyclo-oxygenase component of the enzyme. An initial attempt was 
made to study this possible effect using indomethacin but no results 
were obtained, both due to the inconsistency of control incubations 
and also the very low levels of activity present once the control 
acétylation was inhibited. As the radioactively labelled aspirin 
used was synthesised from the highest specific activity reagent 
commercially available it seems unlikely that the technique described 
will yield good results, unless the enzyme preparation being studied 
contains a high level of PG synthetase activity.
Consideration was given to the possibility of subjecting 
cells labelled with / a c e t y l - / aspirin to autoradiography in order
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to locate the site of the PG synthetase within the cell. However, 
calculation showed that even in the platelet, which contains a high 
level of the enzyme, on the basis of 2000-3000 acetyl groups incor­
porated per platelet, autoradiography of a single labelled cell would 
yield approximately one disintegration per day due to ^H-acetyl groups.
A further complication would be that proteins within the cytoplasm 
may become labelled with ^H-acetyl groups (Roth and Majerus, 1975).
The results obtained using [_ acetyl-^H_/ aspirin were therefore 
disappointing and suggest that although the use of labelled aspirin as 
a tool for detecting sites of PG synthesis is extremely attractive, the 
practicalities of such experiments may be fraught with difficulties.
6.4 Discussion
The use of f_ acetyl-^H__/ aspirin has provided the first results 
of the way in which aspirin interacts with PG synthetase at the molecular 
level. The initial report of Roth and Majerus (1975) showed that aspirin 
acted as an acetylating agent, as might have been suspected from previous 
work; acetyl-labelled aspirin produced incorporation of activity into a 
particulate fraction protein whereas ring-labelled aspirin did not.. A 
later paper (Roth, Stanford and Majerus, 1975) showed that this interaction 
between aspirin and PG synthetase was not confined to platelets but also 
occurred with the enzyme prepared from ovine or bovine seminal vesicles.
The finding that all three preparations of the enzyme gave a labelled 
peak of molecular weight 85,000 suggests that the technique is unlikely 
to reveal isoenzymes of significantly different molecular weights.
The results obtained in the present work fully support the findings 
described above; R.A. synovial microsomal PG synthetase produced a 
labelled peak with an estimated molecular weight of 81,000. Future 
studies will probably show that the phenomenon is a general one.
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though it would clearly be of interest to find a preparation of PG 
synthetase which did not interact with aspirin in this way.
The very low levels of radioactivity incorporated into the 
enzyme in the present study, and in the previous reports described, 
suggests that lack of sensitivity may be a limiting factor in the 
use of l_ a c e t y l - __/ aspirin as a probe for detecting sites of PG 
synthesis. Seminal vesicular glands and platelets are known to 
contain high levels of PG synthetase and R.A. synovial tissue contains 
the same order of magnitude of activity as rabbit renal medulla, 
known to be a good source of the enzyme (Christ and van Dorp, 1972).
It may be extremely difficult therefore to demonstrate the incorpor­
ation of radioactivity into preparations containing low levels of 
the enzyme.
The finding that the radioactively-labelled protein peak seen 
in the present work has a molecular weight of 81,000 is of interest 
in the light of the report of Miyamoto and others (1976). These 
authors showed that a purified 'prostaglandin endoperoxide synthetase',
i.e. cyclo-oxygenase, prepared from bovine vesicular glands, has a 
molecular weight of 300,000-350,000, estimated using gel filtration 
on Sephadex G-200. It is tempting to speculate that the labelled 
peak found on gel electrophoresis may be a quarter subunit of the 





The work presented in this thesis centres around the proposal 
put forward by Vane in 1971 that the aspirin-like drugs exert their 
pharmacological properties by inhibiting the production of prosta­
glandins. A development of the original proposal was that PG 
synthetase exists within an organism in multiple molecular forms, each 
isoenzyme possessing a characteristic pharmacological 'profile' with 
respect to inhibition by the aspirin-like drugs (Vane, 1972). As most 
studies of PG synthetase have been carried out on the enzyme prepared 
from highly active animal tissues the relevance of studying the 
interaction between the aspirin-like drugs used in clinical practice 
and the enzyme prepared from human inflammatory tissue is self-evident.
Evidence for the existence of PG synthetase isoenzymes 
hinges largely upon the report of Flower and Vane (1972) that para­
cetamol is a much more potent inhibitor of brain PG synthetase than of 
the enzyme prepared from peripheral tissues such as spleen. The 
findings with this one, possibly atypical, drug have led to speculation 
that an ideal aspirin-like drug might be developed. Such a drug would 
be a potent inhibitor of the PG synthetase of inflammatory tissue, yet 
virtually inactive as an inhibitor of the enzyme found in other organs 
such as stomach or kidney, in which aspirin-like drugs may produce 
adverse side-effects via inhibition of PG synthesis.
The present author is highly sceptical that such a drug may be 
developed, for a recent report (Pong and Levine, 1976) has shown the 
PG synthetase prepared from seven different rabbit tissues to be 
inhibited identically by indomethacin, aspirin or flufenamic acid. 
Unfortunately these authors did not examine the potency of paracetamol 
as an inhibitor of the various preparations. If paracetamol is inac­
tive as an inhibitor of PG synthetase in peripheral tissues, (as found 
in the present work), it is difficult to explain the drug's analgesic
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activity in terms of inhibition of PG synthesis, though its lack of 
anti-inflammatory activity may be explained on this basis.
During the course of the present study no evidence was found 
that PG synthetase prepared from human inflammatory tissue differed 
radically, either biochemically or pharmacologically, from the well- 
studied systems prepared from animal tissues. It is possible that 
such differences as have been reported (Blackwell, Flower and Vane,
1975) may be a reflection of the relatively crude enzyme preparations 
employed and incubation conditions in vitro differing drastically from 
those existing in vivo.
A finding of great interest in the present work was that PG 
synthetase activity was abolished in the microsomal preparations from 
the synovial tissue of three patients receiving only 'analgesic'
(600 mg/day) doses of aspirin. If such a dose is cible to inactivate 
the enzyme in the target tissue, and if aspirin exerts its anti­
inflammatory properties through inhibition of PG synthetase, it is 
relevant to ask why much larger doses are necessary to demonstrate anti­
inflammatory activity in clinical practice. This argument has been 
expounded in detail by others (Smith, 1975; Smith, Ford-Hutchinson 
and Elliott, 1975); perhaps further evidence of this nature may help 
to displace prostaglandins from their current 'monopolistic' position 
in order that other facets of the mode of action of aspirin-like drugs 
may be objectively investigated.
In this respect the recent report of B.onta and others (1977) 
is of interest. These authors report that both aspirin and dexa- 
methasone are effective in suppressing carrageenin-induced oedema in 
both normal and essential fatty acid-deficient (EFAD) rats, even 
though, in the latter, the role of an activated PG system can be ruled
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out due to lack of endogenous PG precursors. The results suggest that 
the anti-inflammatory effect of these drugs involves at least one 
mechanism which is independent of PG synthesis inhibition, possibili­
ties including inhibition of leucocyte migration, inhibition of 
phosphodiesterase and formation of copper complexes. The EFAD rat 
may thus be a useful tool for investigating mechanisms which in 
normal animals may be masked by interference with PG production. The 
present author is convinced that future work will show the aspirin­
like drugs to have multiple interactions in the inflammatory process 
(Whitehouse, 1968).
Theories are not overthrown by criticism, but by better, 
theories, and it will be of interest to follow the development of 
new anti-inflammatory drugs which are not inhibitors of PG synthetase. 
Reports of anti-inflammatory peptides prepared from either bee venom 
(Billingham and others, 1973) or human plasma (Smith and others, 1974) 
have shown that these compounds do not interfere with the PG system, 
but may act by preventing the release of leucotactic factors when 
the complement cascade is activated by the alternate, i.e. non-iromune, 
pathway.
One of the most interesting reports to appear recently is that 
of Boyle and others (1976). These authors find that whilst the copper 
complexes of clopirac, niflumic acid and aspirin possess the same anti­
inflammatory potency as their parent compounds, as judged by suppre­
ssion of carrageenin-induced oedema in the rat paw, they are consid­
erably less ulcerogenic. This in itself is interesting, but the 
surprising finding is that these copper complexes are much less potent 
inhibitors of PG synthetase in vitro than their parent compounds.
Just why this is the case, and why indomethacin, ketoprofen and naproxen 
do not behave in this way are questions which remain to be answered.
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It would indeed be ironical if the inhibition of PG synthetase 
in vitro were to become a screening test for ulcerogenicity rather than 
anti-inflammatory activity! That this is not merely academic specu­
lation is shown by the finding that a new anti-inflammatory drug 
(LRCL 3794) currently under investigation has been found to be a very 
weak inhibitor of PG synthetase in vitro (W. Dawson, personal communi­
cation) . Similarly, the drug designated Abbott-29590 has been reported 
to be inactive as a PG synthetase inhibitor in vitro and to produce no 
gastric lesions in fasted rats at doses up to 526 mg/kg. (Carter and 
others, 1974). A low incidence of gastro-intestinal side effects 
produced by these compounds at the clinical trial stage would indeed 
be a finding of the greatest significance, and may herald a new class 
of aspirin-like drugs whose toxicity is (hopefully) far from aspirin­
like. Perhaps future antirheumatic drugs will not be subject to the 
jibe concerning present conventional medications that they are
"chemically a ragbag and therapeutically rather a disaster area".
O
A future challenge for the pharmacologist will be the develop­
ment of a screening test to detect the kind of antirheumatic activity 
shown by drugs such as penicillamine, chloroquine and gold salts.
Such compounds, with a slow onset of action, have in the past been 
discovered by chance and their mode of action is poorly understood. 
Perhaps in such compounds lies the possibility of a drug which may 
actually slow or halt the disease process, though the formidable toxicity 
of the drugs mentioned above suggests that it may be difficult to 
divorce their antirheumatic properties from their unwanted side- 
effects. The same argument may hold true for the development of 
future immunosuppressive drugs.
When the potencies of the commonly used aspirin-like drugs as 
inhibitors of R.A. synovial PG synthetase in vitro were compared with
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their known therapeutic potencies in vivo, the in vitro measurement 
was found to give a much greater potency, relative to aspirin, than 
is known for therapeutic activity. Whether this is an indication 
that inhibition of PG synthesis is not the sole, or even the most 
important factor governing therapeutic potency remains to be seen. 
Certainly one must interpret results obtained from in vitro studies 
with caution, as a drug studied in vitro does not have to overcome 
problems of absorption, distribution, metabolism and excretion before 
reaching its side of action, as is the case in vivo. Conversely some 
drugs may acquire anti-inflammatory activity only after metabolism 
in vivo, though as discussed previously the case for salicylic acid 
behaving in this way is not convincing.
Until more information is available concerning the precise 
working of the enzyme in vivo, such as the nature of cofactors, their 
concentrations and availability to the enzyme, substrate concentration(s) 
and availability, and the presence of 'natural' inhibitors, one must 
concede that an in vitro system is somewhat artificial and results 
obtained from it may only be extrapolated to the situation in vivo with 
caution.
An interesting finding to emerge from the present work, at 
least from a biochemical point of view, is that aspirin is an irreversible 
inhibitor of human synovial and platelet PG synthetase, both in vitro 
and in vivo, and that aspirin may be unique in this respect. One might 
therefore expect the time course of PG synthetase inhibition in vivo 
to be more prolonged with aspirin than one might predict from its 
relatively short half-life in the blood, and this is certainly true for 
platelets where no de novo enzyme synthesis is possible. The situation 
in tissue such as synovium however is much more complex as little is 
known of the turnover rates of PG synthetase in either synovial cells
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or invading leucocytes. If, for example, the turnover rate of the 
enzyme in synovial cells is high, then the action of an irreversible 
inhibitor of the enzyme in vivo may be difficult to distinguish from 
that of a reversible inhibitor.
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